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Abstract 
A key goal in regenerative therapy is to improve outcomes following the devastating 
consequences of spinal cord injury. Yearly, between 250,000 to 500,000 people suffer 
permanent injury to the spinal cord. The cost to the individual, their families and society is 
substantial. Modest success in clinical trials has offered hope. However, there remain a 
number of challenges still to be met in respect of a combinatorial approach that offers safe 
delivery of grafts, to promote recovery and regeneration in the injured spinal cord. 
In this context astrocytes have shown promise as a cell transplant population. This project 
aimed to develop strategies to engineer astrocytes to improve their repair capacity as a cell 
transplant population for regenerative applications. Specifically, methods were attempted 
using applied magnetic fields to i) enhance magnetic nanoparticle mediated gene delivery 
in primary-derived cortical astrocytes, and ii) achieve high levels of magnetic particle 
loading and long term retention in cells by tailoring particle magnetite content, improving 
utility for non-invasive imaging applications. Further, high cell loss during surgical 
delivery of transplant cells has prompted the need to develop protective cell delivery 
systems for neural cells. Use of a 3-dimensional collagen hydrogel was investigated for 
this purpose, and the capacity to image particle labelled intra-gel astrocytes evaluated.  
The findings show that a tailored combination of magnetic field parameters increased 
transfection efficiency, and enhanced transgene expression in astrocytes. Second, 
astrocytes showed rapid, highly efficient but safe accumulation and long term retention of 
high magnetite content particles. Third, collagen hydrogels offered a protective 
environment conducive to cell transplant delivery. Finally, within the hydrogel, magnetic 
particle labelled astrocytes retained their utility for cell tracking by MRI over an extended 
time frame.  
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 2 
1.1 Overview of spinal cord injury  
There are at present, approximately 2.5 million people globally affected by spinal cord 
injury (SCI). Up to 200,000 people are affected each year, with an incidence rate of 16 per 
million in Western Europe, of which 40,000 occur in the UK. Of these numbers globally, 
approximately 82% are male (Fitzharris et al., 2014; Lee et al., 2014). The major causes of 
SCI are motor accidents, falls (work or sport-related), or the result of violent attacks [Lee 
et al., 2014; World Health Organisation, 2013(WHO)]. The severity of the injury 
determines the long-term outcome. Incomplete injury, where the spinal cord has sustained 
moderate bruising (contusion) or pressure (compression), has a greater chance of recovery. 
Complete injury refers to full or partial severance of the spinal cord, and results in loss of 
sensory and motor function (paralysis) below the level of injury. Classification of the 
severity of SCI is scored according to the American Spinal Injury Association (ASIA), 
with function evaluated on a score of A –E [A refers to a complete loss of sensory/motor 
function below sacral level 4/5; E refers to normal levels of function (Table 1.2)]. 
Coincident with paralysis are a range of secondary pathologies, such as the inability to 
breathe unaided, the loss of urinary and bowel control, the inability to control body 
temperature, the loss of sexual function and the onset of continual chronic pain in the 
paralysed limbs [National Institute of Neurological Disorders and Stroke, 2016 (NINDS)]. 
The cost of ongoing treatment in the US alone is approximately $3 billion each year with 
the cost of treatment, in the US, averaging $105 – 400,000 over a patient’s lifetime 
(NINDS, 2016). Not every country provides excellent health care provision, or health care 
that is free at the point of use; irrespective the overall cost of health care, assisted living 
and assistive aids is mostly met by the patient and their family. Even where access to 
excellent health care is guaranteed, the mortality rate is much higher for those living with a 
SCI (WHO, 2013). The severity of this type of injury, coupled with the unlikely probability 
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of subsequent regeneration and neurological recovery, places a substantial emotional and 
financial burden on the patient and their families, with an ever increasing socio-economic 
cost. 
  
 4 
1.1.1 What is SCI? 
SCI is classified by type (contusion, compression or crush); location and extent (complete 
or incomplete), with the majority of SCI occurring in the cervical and thoracic regions and 
therefore, these are the focus of SCI models (Siebert et al, 2015) (Figure 1.1). 
 
Figure 1.1 Characterisation of the different regions of the spinal column and the 
areas of the body affected by spinal cord injury to that region The spinal column is 
made up of a continuous length of vertebrae that surround and protect the spinal cord.  
Severe impact to the spine risks damage to the cord, with the possibility of permanent 
paralysis below the level of injury. Severe damage to the spinal cord at the thoracic level 
results in paraplegia (trunk and lower limbs), with damage at the cervical level resulting 
in tetra- or quadriplegia (upper and lower body) (Figure adapted from www.spinal-
research.org).  
Cervical region 
- Head and neck 
- Diaphragm 
- Arms 
- Hands 
Thoracic region 
- Chest muscles 
- Abdominal muscles 
Lumbar region 
- Leg muscles 
Sacral region 
- Bowel 
- Bladder 
- Sexual function 
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Axonal rupture in SCI tends to be located at the nodes of Ranvier, as these are the weakest 
point in the spinal cord due to non-myelination of the axon (Maxwell, 1996). Rapid 
extracellular Ca2+ influx activates phospholipase A2 which is a Ca
2+-dependent enzyme 
involved in modulation of inflammation and “host defence” (Murakami & Kudo, 2002). 
This triggers re-sealing of the cut end of the axon (Yawo & Kuno 1985). Ca2+ also 
determines whether the damaged end develops into a functional growth cone or a non-
functioning end bulb (Kamber et al., 2009). Different responses occur at either end of the 
severed axon. While the distal end degenerates, chromatolysis (disintegration of the Nissl 
bodies) occurs at the proximal end, with the nucleus moving to the periphery of the neuron 
cell body (Kandel et al., 1991).  Injury to the spinal cord initiates an immediate graded 
neuroinflammatory response from neutrophils, macrophages and microglia; a response that 
continues over a number of months. It is this response that triggers reactive astrogliosis. 
Reactive astrocytes become hypertrophic and upregulate glial fibrillary acidic protein 
(GFAP) expression, leading to extensive proliferation and overlapping of the astrocyte 
matrix, resulting in formation of a glial scar (Fawcett & Asher, 1999). 
This glial scar forms a barrier which effectively seals the, by now, hypoxic injury site, 
preventing widespread inflammation, cell necrosis and neurite outgrowth into the 
surrounding healthy tissue. Moreover, dependent on the severity of the SCI, fibroblast 
infiltration can result in a dense fibrous scar that has a greater inhibitory effect on 
regeneration than the glial scar itself, due to its density and proclivity in binding “growth 
inhibitory molecules” (Macaya & Spector, 2012). Loss of oligodendrocytes following 
injury results in neuron demyelination, resulting in lack of myelin support for regenerating 
axons and a release of growth inhibitors from the degrading myelin (Hannila & Filbin, 
2008; Mukhopadhyay et al., 1994). The high level of chondroitin sulfate proteoglycans 
(CSPGs) within the injury site, also act as inhibitors for axonal regrowth by activating the 
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RHO-Rock inhibitory signalling cascade, which causes growth cone collapse and 
subsequent retraction, effectively halting neuronal regeneration (Siebert et al., 2015). Over 
time the lesion site develops into a fluid-filled cyst called a syrinx, and together with the 
tightly meshed astrocytic scar, prevents axonal ingrowth, limiting regenerative capacity 
(Norenberg et al., 2004; Goetz & Mummanemi, 2015). This remains the biggest 
challenge in spinal cord repair. Even if axonal ingrowth beyond the scar tissue were 
possible, the void within provides no trophic or structural support for regenerating axons. 
Indeed, degeneration continues beyond the initial response to injury, with infiltration of 
Schwann cells (SCs) into the injured spinal cord over the following 6-12 months, causing 
pain and spasticity alongside the paralysis (Macaya & Spector, 2012).  
Beyond inflammation and the astroglial scar lie further difficulties. Descending axonal 
tracts are dependent on activity from corticospinal motor circuits for their initial 
development. Following SCI, the severing of these pathways result in loss of voluntary 
motor skills, thus, the potential for regeneration is limited as the bi-directional circuits that 
corticospinal pathways depend on, are now no longer active. Further, prolonged motor 
inactivation results in subsequent axonal withdrawal (Martin, 2016). The incomplete 
nature of the majority of SC injuries can, however, result in some sparing of these 
pathways (Raineteau & Schwab, 2001). It is increasingly postulated that reorganisation of 
these pathways (i.e. synaptic plasticity) may be the underlying cause behind the 
‘spontaneous functional recovery’ (Renault-Mihara et al., 2008) seen in the immediate 
timeframe following SCI (Nakagawa et al., 2015), and recovery seen following cell 
transplant, where regeneration of severed pathways was absent (Yamamoto et al., 2009). 
Nevertheless, full functional recovery is rare, with the glial scar, the syrinx void, the 
high prevalence of axonal growth inhibitors and the subsequent infiltration of 
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peripheral neural cells, all contributing to the non-regenerative environment of the 
injured spinal cord. 
Initial interventions to alleviate the severity of SCI involve decompressive surgery to 
relieve pressure on the spinal cord from internal haemorrhaging and leaking of 
cerebrospinal fluid. Vasopressors and intravenous crystalloids are administered to increase 
blood pressure, thus ensuring an adequate blood supply. Intravenous delivery of 
corticosteroids act as anti-inflammatory agents, working to reduce inflammatory factors 
and Ca2+ influx, and facilitating increased blood flow to the spinal cord (Ahuja et al., 
2016). The most commonly used anti-inflammatory is methylprednisolone (MPRED), 
which also acts to promote survival of endogenous tissue through decrease of oxidative 
stress (Ahuja et al., 2016; Silva et al., 2014). This particular corticosteroid has been shown 
in numerous clinical trials to improve outcomes if administered within 8 h of injury (see 
Bracken, 2012 for review). However, the use of MPRED has proved controversial due to 
its serious side effects, most notable of which is sepsis, with high infection rates reported 
primarily in the wound site due to avascular necrosis, but also in the respiratory and 
urinary tracts (Matsumoto et al., 2001; Suberviola et al., 2008). “Worsening neurological 
function” (Hurlbert, 2000), and alteration to the immune response have also been reported 
with high doses of MPRED (Galandiuk et al., 1993).Therefore stringent guidelines have 
been devised on the rate and dose of delivery (Silva et al., 2014), although its use is still 
considered as standard care for initial intervention in SCI (Pandya et al., 2010). In order to 
develop a safe, effective pharmacological agent, other drugs have been subjected to clinical 
trials, for example monosialotetrahexosylganglioside (GM-1; formulated under the brand 
name Sygen®).  Use of this drug reported a small improvement in bowel and bladder 
function, and increased safety in its use (Geisler at el., 2001), although the level of 
improvement reported with the use of GM-1 was not sufficient to continue clinical trials. 
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The authors argued that greater benefit would have been seen had GM-1 been administered 
within an earlier timeframe. As it was MPRED was administered within 8 h of injury (as 
standard intervention), with GM-1 administered approximately 55 h later (Hawryluk et al., 
2008). However, findings prior to the Geisler study raised concerns regarding the drugs 
immunogenic potential and its associated link with Guillain-Barré syndrome (Bradley, 
1990; Lacomblez et al., 1989; Nagai et al., 1976; Yuki et al., 1991), resulting in its 
eventual withdrawal from market pending Phase III trials. Hence, as yet, no drug offers 
similar clinical benefit as MPRED. The side effects associated with its use though, have 
raised the suggestion that a delivery system utilising nanoparticles (Cerqueira et al., 2013) 
may facilitate a targeted, slower rate of delivery to the injury site, thus circumventing the 
side effects related to the high therapeutic dose of MPRED (Silva et al., 2014).  
Following the initial medical intervention, once the patient is stabilised, the main priority is 
mobilisation. This involves aggressive rehabilitation therapy to, at the very least, 
strengthen muscles (Behrman & Harkema, 2000), but has also been shown to exert 
beneficial effects on functional recovery (Sandrow-Feinberg & Houle, 2015). In this 
respect, it is hypothesised that manual manipulation i.e. through aggressive rehabilitation 
therapy, and/or neural stimulation of motor circuits (Song et al., 2016), may induce 
synaptic plasticity in the spared pathways, resulting in localised sprouting and new 
connections (Oudega & Perez, 2012); any level of functional recovery however, is very 
much dependent on the location and the severity of the injury (Fink & Cafferty, 2016 for 
review).  
Rehabilitation training will almost certainly involve the teaching of communication skills, 
together with fine motor skills and coping strategies for bladder/bowel toileting, and 
management of spasticity and chronic pain (Ahuja et al., 2016; NINDS, 2016). While 
these interventions are critical for the management of SCI, in that they are aimed at 
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limiting the initial damage and increasing quality of life, in the majority of SC 
injuries, they unfortunately lack the potential to promote regenerative processes in 
the injured cord.  
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1.2 The hope from emerging cell therapy 
Research into overturning the outcome of SCI goes back over a century (Thompson, 1890), 
with many aspects of the injury ‘cascade’ targeted in pursuit of repair. The role of the 
astrocytic scar has long been in dispute as to its ‘neuro-preventative’ or neuroprotective 
role in SCI. The barrier formed by the glial scar, their release of CSPGs to halt neuronal 
regeneration and the resultant void within the injury site (Goetz & Mummanemi, 2015; 
Norenberg at el., 2004; Siebert et al., 2015) proposed the glial scar as an inhibitory force 
preventing axonal regeneration (Liuzzi & Lasek, 1987). While this is indeed so, what has 
traditionally been perceived as a negative event is beginning to be understood as a major 
neuroprotective feature within SCI to prevent widespread injury (Sofroniew, 2015). For 
example, using a transgenic mouse model that expressed GFAP-herpes simplex virus- 
thymidine kinase transgene, following moderate crush or stab injury to the spinal cord, 
anti-viral agent ganciclovir was administered to ablate reactive “transgene-expressing” 
astrocytes, thus preventing formation of the glial scar. Injury was followed by blood-brain-
barrier failure, demyelination, tissue damage, cell death and subsequent motor impairment. 
By contrast, where ganciclovir was not administered, the subsequent formation of a glial 
scar following similar injuries, resulted in low levels of SCI and only temporary motor and 
functional impairment (Faulkner et al., 2004). Following the same protocol, a further study 
from this group caused a severe crush injury in the same transgenic mouse model, and 
compared the resulting consequences between mice where ganciclovir was administered to 
ablate reactive astrocytes and prevent scar formation, and control transgenic mice where a 
glial scar was allowed to form. The findings showed that, following severe SCI, there was 
no difference to the level of tissue loss and cell death (Myer et al., 2006). Taken together, 
the findings of these studies advocate the neuroprotective role of the glial scar, but suggest 
this protection is limited by the severity of the injury in that, with moderate SCI, reactive 
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astrocytes and the subsequent formation of the glial scar played a major neuroprotective 
role. However, in the severe SCI mice, there was little further tissue damage in the absence 
of  reactive astrocytes, than that occasioned in the control mice where a scar was allowed 
to form, suggesting that where injury is severe, little can effectively be done to limit the 
damage (Faulkner et al., 2004; Myer et al., 2006). In support of these findings, recent in 
vivo studies using differing transgenic strategies, either prevented or attenuated astrocyte 
reactivity following induced severe thoracic (T10) crush injury, or 5 weeks after such 
injury, ablated the scar tissue. Subsequent delivery of hydrogels loaded with axon-specific 
growth factors neurotrophin-3 (NT-3 - proven to be beneficial to regeneration of injured 
spinal cord axons) and brain-derived neurotrophic factor (BDNF - shown to promote 
regeneration of spinal cord tracts) to the lesion site, stimulated robust axonal growth across 
the glial scar, but only in mice where a scar was allowed to form. Where scar formation 
had been modified, initial axonal dieback was significantly increased compared with 
control wild-type mice, and despite delivery of NT-3/BDNF – loaded hydrogels, there was 
no axonal regrowth at all. Moreover, prevention and attenuation of reactive astrocytes 
increased the level of CSPGs in the lesion site, with the increase associated with influx of 
non-GFAP+ve cells. The study reported that contrary to being perceived as a barrier to 
regeneration, reactive astrocytes and the subsequent presence of the glial scar are proactive 
in neuroprotection through inhibition of overall CSPG expression, and continued 
expression of molecules supportive to axonal growth (Anderson et al., 2016). These 
findings reinforce the neuroprotective role of the astrocytic response and, more importantly 
the continuing protective role of astrocytes within the lesion site (discussed further in 
1.3.3). Thus, it is proposed that the target for regeneration is not the inhibition of the 
astrocytic response within the injured spinal cord, but rather in facilitating an environment 
within the void that is conducive to regeneration. In this respect, a key point to note in 
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transplant strategies is that cell transplant does not infer the capacity to replace 
damaged cells, but rather, to facilitate a regenerative environment through the 
neuroprotective and immunomodulatory mechanisms inherent within the transplant 
(Li & Leung, 2015). Further, it is postulated that these mechanisms may also confer a more 
advantageous environment for synaptic plasticity in spared pathways.  
In a bid to promote this, research has targeted the lesion site. A diverse number of 
strategies have shown promise, including use of chondroitinase ABC to neutralise the 
inhibitory effects of CSPGs, and antibody IN-1 to neutralise Nogo. Anticancer drugs have 
been found to aid in stimulating axonal regeneration, as have specific molecular signalling 
targets, transcription factors and neurotrophic factor supplements (Siebert et al., 2015 for 
review). In an endeavour to promote neuronal regeneration, functionalised scaffolds 
containing proteins that neutralise axon inhibitors have also seen modest success in axonal 
regrowth, and subsequent motor locomotion (Li et al., 2016). These strategies hold 
promise. However the probability of one type of strategy being sufficient for regeneration 
is unlikely, the greater likelihood being that of a combinatorial approach, of which this 
would play a part. For example, genetic engineering of cell transplants to deliver 
therapeutic biomolecules or growth factors to an injured spinal cord, and utilising a 
scaffold to act as a carrier for delivery of such a cell transplant. 
To address this challenge, cell replacement therapies have become a key strategy (Willerth 
& Sakiyama-Elbert, 2008). The difficulty here is in choosing the cell population that offers 
the most potential for regeneration within the injured spinal cord. The criteria for such a 
therapy are i) cell integration into the lesion site that ii) encourages axonal ingrowth, and 
iii) offers both trophic and structural support to the regenerating neurons. In this respect, a 
number of cell types have been tested in animal studies and shown modest success (Table 
1.1).*  
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* This table refers to the main cell types used, and is an illustrative, and by no means 
exhaustive, list. 
Of the animal studies, of note is the intravenous delivery of bone marrow-derived 
multipotent progenitor cells (BMmPCs) to rodents with thoracic contusion SCI (De Paul et 
al., 2015). Interestingly, the cells did not home to the injury site but instead, targeted the 
spleen. The authors concluded that the recovery observed in these animals was not due to 
cell ‘replacement’, but rather to the neuroprotective and immunomodulatory benefits 
induced by the transplant population, with recovery associated with marked sparing of the 
tissue in the SC (De Paul et al., 2015). These findings could suggest a greater role for cell 
transplant strategies than has been initially perceived.  
Not all cell transplant populations have been found to be advantageous to regeneration 
though. Transplant of undifferentiated NSCs in the injured spinal cord have revealed that 
the lesion site is non-conducive to stem cell expression (Cao et al., 2010; Teng et al., 
2009); a limiting factor in neuronal repair. More recent studies have found that NSC 
transplants migrate from the lesion site and begin to proliferate in an uncontrolled manner 
throughout the spinal cord, highlighting an ever-increasing concern for prospective 
tumorigenesis with this cell type (Steward et al., 2014). Indeed, for translational 
application, the use of undifferentiated stem cells is being increasingly deemed unfit for 
purpose, as the developmental signals that would drive typical stem cell differentiation are 
absent in the adult CNS (Dunnett & Rosser, 2014). 
 1.2.1 Cell therapies in clinical trials 
Certain cell therapies have been utilised in clinical trials, such as Schwann cells (SchCs - 
Saberi et al., 2008); olfactory ensheathing cells (OECs - Granger et al., 2012; Tabakow et 
al., 2014); mesenchymal stem cells (MSCs - Dai et al., 2013) and bone marrow cells 
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(BMCs - Syková et al., 2006) with others, such as oligodendrocyte precursor/progenitor 
cells (OPCs - Li & Leung, 2015) currently recruiting for phase I/II clinical trials (Asterias 
Biotherapeutics, Inc., 2016).  Variable success rates have been reported. SchCs have been 
regarded as safe for transplant, but their inability to migrate beyond the lesion site has 
resulted in low levels of success (Pearse et al., 2004; Xu & Onifer, 2009). The majority of 
animal studies found that utilising SchCs in a combinatorial approach offered higher 
levels of regeneration and improvement in functional recovery (Pearse et al., 2004; 2007; 
Takami et al., 2002). Of their use in clinical trials in patients with chronic thoracic or 
cervical SCI (ASIA grade A-B), a 2-year follow up study reported no toxicity with SchC 
transplant; “subtle” improvement in light touch/pinprick, but no gain in ASIA score. While 
some patients reported bladder and sphincter sensation, with two patients reporting a level 
of faecal control, SchC transplant was found to be ineffective in functional recovery and 
for 3 of the 33 patients, actually worsened the symptoms (Saberi et al., 2008; 2011).  
In recent years, clinical studies transplanting OECs have reported promising results, with 
restoration of fore-hind leg co-ordination in dogs with severe SCI (Granger et al., 2012). 
OEC transplant to a patient with complete transected spinal cord resulted in restoration of 
“trunk stability”, touch sensitivity, visceral sensation and improved blood flow to the lower 
limbs. Of major consequence, a level of voluntary lower body movement was recovered, 
with evidence of long tract restoration (Tabakow et al., 2014). This is the first reported 
clinical evidence of long tract restoration; all other studies of functional recovery have 
reported only short tract axonal sprouting, interestingly even with OECs (Granger at el., 
2012).   
A number of mechanisms are suggested for OECs success in SCI. One is their migratory 
capacity. It is thought that they migrate alongside growing axons and therefore, as they 
have been shown to ameliorate the astrocytic response and subsequent CSPG expression 
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(Takami et al., 2002); OECs modulate the non-permissiveness of the spinal cord lesion (Xu 
& Onifer., 2009). This ‘mechanism’ could offer plausible explanation for long tract 
restoration. Results such as these, while highly promising, are moderated by the low 
overall success rate, with a number of earlier studies reporting no benefit at all, with 
considerable doubts surrounding claims of success (Hawryluk et al., 2008). Indeed, of the 
more recent studies, Tabakow et al. state that the nature of the spinal cord transection 
facilitated, to a large extent, the success of the repair (Tabakow et al., 2014), with Granger 
et al. finding that low efficacy of surgical techniques was a major factor in prevention of 
repair and subsequent recovery, resulting in only a 50% success rate (personal 
communication – N. Granger); a finding echoed in a number of studies utilising OECs 
(Guest et al., 2011; Pearse et al., 2004).  
Bone marrow-derived MSCs have also shown promise in clinical trials, with a number of 
studies reporting modest recovery in sub- acute and acute SCI, but not in chronic injuries 
(Hawryluk et al., 2008 for review).  Although, a recent clinical study has reported 
significant motor and sensory improvement in patients with chronic cervical SCI. 
Urodynamic improvement was also observed, in that bladder hyperreflexia improved, 
although voluntary control and bladder perception showed no improvement (hyperreflexic 
bladder refers to an overactive bladder that holds less urine). Moreover, some level of 
respiratory muscle strength recovery has also been reported in these patients (Dai et al., 
2013). Importantly, at 6 month follow-up there was no evidence of tumour formation or 
adverse side effects at the lesion site, suggesting, at least in the short term, the safety of 
these cells. Despite these promising reports, measures of improvement were only seen in 
50% of the treatment group, and the measures did not translate into functional benefit for 
these patients.  
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Clinical studies utilising bone marrow-containing nucleated cells have also shown 
improvement in motor and sensory function, although this was mostly seen in patients with 
sub-acute SCI where cell transplant was conducted within 1 month post-SCI. Of the 
patients with chronic SCI, cell transplant was conducted between 2 and 18 months 
following injury. Of this latter group (12 patients), modest improvement was seen in 1 
patient (Syková et al., 2006). It is unclear, considering the difference in severity of SCI 
between the two groups, whether earlier intervention is more conducive to recovery, or 
whether the earlier intervention (within 1 month) ‘masked’ spontaneous recovery. Further, 
the majority of the ‘improvement’ reported in this study related to electrophysiological 
recordings of motor and somatosensory potentials, which do not necessarily confer 
functional recovery. Notwithstanding, increases in ASIA classification changed for a 
number of patients from A to B, with one patient recording a classification change from B 
to D (Table 1.2 for ASIA classification). 
Table 1.2 American Spinal Injury Association (ASIA) Classification Criteria for SCI 
Class Classification Prognosis criteria 
A - Complete No motor or sensory function in 
sacral segment (S4-5) 
SENSORY - 28 key sensory points 
(light touch & pin prick) 
0 – absent 
1 – present but impaired 
2 - normal 
B - Incomplete Sensory function below injury 
and in S4-5 but no motor function 
MOTOR – 10 key muscles 
Scale of 0 – 5; 0 = total paralysis and 5 = 
active movement; full range of motion 
C - Incomplete Motor function below injury; 
>50% key muscle groups have 
muscle grade < 3 
COMPLETE INJURY PROGNOSIS 
No voluntary anal contraction 
S4-5 sensory score is zero 
No anal sensation 
D - Incomplete Motor function below injury; 50% 
key muscle groups have muscle 
grade > 3 
 
 
E - Normal Normal sensory and motor 
function 
 
Criteria adapted from ASIA 
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OPCs in animal studies showed evidence of differentiation into mature oligodendrocytes, 
and migration and enhanced remyelination, all of which appeared to facilitate a 
neuroprotective effect on motor neurons. This would suggest a plausible mechanism 
underpinning the improvement in locomotor function seen with transplant of these cells 
(Keirstead et al., 2005; Sharp et al., 2010; Xie et al., 2016). However, one of the major 
considerations with the use of OPCs is that of “autologous availability”, with extensive 
immunosuppressive drugs required following donor transplant (Li & Leung, 2015). To 
circumvent this, iPSC-derived OPCs have been utilised in cell transplant studies. Initial 
findings reported decreased cavitation and increased axonal remyelination following SC 
contusion, and myelin initiation when transplanted into myelin-deficient mice. (h)ESC-
derived OPCs have also been suggested as a clinical - but not autologous - alternative, 
having also proved beneficial in animal studies (Li & Leung, 2015 for review). A major, 
albeit now regarded as controversial study, utilising a low dose of (h)ESC-derived OPCs 
was the Geron trial. Financial instability was the reason given for its cancellation, although 
of the four patients who underwent cell therapy, no benefits were reported (Wilcox et al., 
2012 for review). Notwithstanding these findings, a second clinical study is currently 
recruiting for phase I (cervical SCI) and phase II (spinal injury & spinal cord trauma) 
clinical trials investigating the safety of “escalating OPC dose” (Asterias Biotherapeutics, 
Inc., 2016). 
One particular cell that has proved highly successful in animal models but that has, until 
relatively recently been mostly overlooked, is the astrocyte. This neural cell is highly 
specific to neuroprotection in both healthy and injured spinal cord, with a growing body of 
evidence supporting astrocyte involvement in axonal regeneration. Far from being the main 
inhibitory factor in the injured spinal cord, there is now a wider realisation of their 
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involvement in neuroprotection and “spontaneous functional recovery” (Renault-Mihara et 
al., 2008).  
For example, following SCI, astrocyte-induced cell division cycle 2 (Cdc2) and vimentin 
activity facilitated neuronal outgrowth in co-culture (Toy & Namgung, 2013). Similar 
neuron regrowth was observed from Cdc2-vimentin activity in astrocytes in vivo (Seo et 
al., 2013). β3-Integrin has also been shown to play a role in axonal regeneration, with the 
linked mechanism of Cdc2, vimentin and integrin, mediating communication between 
astrocytes and regenerating axons (Toy & Namgung, 2013). Thus, utilising astrocytes as a 
transplant population may be beneficial in mitigating regeneration in the spinal cord. In 
this context, it has also been posited that ingrowth of astrocytes into the injury site may be 
a mechanism for functional regeneration (Joosten et al., 2004; Macaya et al., 2013). So, it 
could be postulated, that as well as having a major role in the healthy spinal cord for 
neuroprotection and homeostasis, astrocytes may offer the promise of regeneration and 
consequent functional recovery to the injured spinal cord; as such, they are now emerging 
as a major candidate as a transplant population for SCI.  In this respect, it has to be made 
clear from the outset that cell transplants are not intended as a direct replacement of 
damaged astrocytes, but rather to confer the neuroprotective and neuro-immunomodulatory 
benefits inherent to endogenous astrocytes (Li & Leung, 2015). 
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1.3 What are astrocytes? 
Within the central nervous system (CNS), glial cells provide physical and trophic support 
for neuronal cells. Of these supporting cells, astrocytes are the most predominant and their 
contribution to continued CNS function is of critical importance. Astrocytes are a highly 
heterogeneous cell population displaying morphological, functional, molecular and 
chemical differences with distinct roles dependent on the brain region they inhabit 
(Freitas-Andrade & Naus, 2016). Astrocytes and neurons form a structural and 
communicative network in the brain with a ratio of one astrocyte to eight neurons, five 
blood vessels and in excess of 100,000 synapses (see Chu et al., 2014 for review), 
facilitating extensive signalling ‘cross-talk’ with neurons, which influences the functional 
characteristics of both (Fellin & Carmignoto, 2004; Van den Bosch & Robberecht, 2008). 
For example, through end-feet contact, astrocytes mediate between neurons and the basal 
lamina of blood vessels, modulating neuronal activity and cerebral blood flow. This 
neuron-astrocyte-bloodstream relationship facilitates the key role astrocytes play in 
regulating the barriers between brain, blood and cerebrospinal fluid and in turn, CNS 
metabolic homeostasis (Abbot et al., 2006; Maragakis & Rothstein, 2006). This involves 
the glutamate-glutamine cycle (Danbolt, 2001), and the glucose-lactate shuttle which 
transports glucose (amongst other substances) into the brain, converting it to lactate to 
meet the energy demands of the neuron (Magistretti & Pellerin, 1999). Astrocytes also 
regulate the intra- and extracellular ion concentrations of the by-products of these 
metabolic functions (Kofuji & Newman, 2004) (Figure 1.2). 
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Figure 1.2 The metabolic relationship between astrocytes and neurons in the adult 
brain A schematic of the glutamate-glutamine cycle and the glucose-lactate shuttle.  When 
glutamate is released from neurons, the excess glutamate is taken up from the synaptic 
cleft by the plasma membrane glutamate transporters expressed on astrocytes. Conversion 
of glutamate to glutamine is undertaken by astrocytes before returning it back via the 
presynaptic terminals of the neuron. Astrocytes also convert glucose taken up from the 
vasculature into lactate, which is then taken up by the neurons and converted into pyruvate 
for energy metabolism. Astrocytes regulate the intra- and extracellular ion concentrations 
of the by-products of these metabolic functions via their synapses and end-feet. 
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1.3.1 Astrocytes – origin and development in the CNS  
Astrocytes have differing lineage, dependent on their subtype and relationship with other 
neural cell types. Mammalian astrocytes and neurons (together with other main CNS cells) 
originate from the same precursor cell, radial glia (Malatesta et al., 2008). Astrocytic 
differentiation (astrogliogenesis) is marked by the onset of astrocyte-specific markers, the 
main ones being GFAP (widely used for identification); brain lipid binding protein 
(BLBP); S-100 and M1 antigen (Barry & McDermott, 2005). Two further astrocyte 
subtypes are derived from these glial-restricted precursor cells. Exposure to different 
signalling molecules, bone morphogenetic protein-4BMP, or ciliary neurotrophic factorCNTF, 
facilitates differentiation into two specific astrocyte sub-populations, now regarded as of 
key importance to cell transplant populations due to their regenerative (-BMP), or 
inhibitory (-CNTF) effect in SCI (Davies et 2011; Liu et al., 2015). During differentiation, 
the continued expression of neuronal markers by radial glia-derived astrocytes facilitates 
neuronal growth and migration in the developing brain and spinal cord (Joosten & 
Gribnau, 1989). 
Comparative studies of human, primate and rodent astrocytes highlight differences and 
similarities in astrocyte subtype, morphology, activation state, ion channel pharmacology 
and role in intercellular communication, related to the differing level of complexity 
required for CNS function across species (Oberheim et al., 2006). Notwithstanding these 
differences, astrocyte morphology across species is broadly characterised as protoplasmic 
(predominant within grey matter) or fibrous (principally found in white matter). However, 
in light of biomedical applications involving astrocytes based on rodent experimental 
models, as is the case here, it is needful to address the difference in astrocyte morphology 
between human and rodent cortical astrocytes in vivo and those observed in rodent models 
in vitro. 
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It is important to note that the origin and development of astrocytes in rodent brain differs 
from that of human. Neuroepithelial stem cells in the rodent brain generate neuron-
restricted precursor cells, and from rodent spinal cord, glial-restricted precursor cells 
(Barry & McDermott, 2005; Hirano & Goldman, 1988; Mayer-Proschel et al., 1997). 
Human cortical astrocytes, both protoplasmic and fibrous, are larger and have an extensive 
process network not seen in rodent cortex.  Moreover, the uniform nature of rodent 
astrocytes in vivo, while similar to the uniformity and even distribution observed in human 
hippocampal regions (Ogata & Kosaka, 2002), differs notably from the subtype 
distribution observed in human cortex. Interlaminar astrocytes, observed in both primate 
and human cortex, extend long glial processes through cortical layers II and IV, from 
somas contained within cortical layer I (Columbo & Reisin, 2004; Columbo et al., 2002; 
2005). Protoplasmic astrocytes are found in layers II to VI, with fibrous astrocytes 
localised to white matter. A further subtype, specific to human cortex layers V and VI, are 
polarised astrocytes, characterised by long varicose processes (Oberheim et al., 2009). This 
variation differs greatly from morphologies observed in monolayers of primary rodent 
astrocytes cultured on glass, whereby cortical astrocyte subtypes are characterised by their 
morphology (flattened, unbranched membraneous cells with truncated processes, or small 
soma and highly branched) and classified by phenotype – type 1 and type 2, respectively 
(Pickard et al., 2011). 
1.3.2 Astrocytes are a major player in the homeostatic function of the healthy CNS 
The homeostatic role of astrocytes in the mature CNS is intrinsic to continued neuronal 
function. Homeostatic membrane channels, sodium (Na+), potassium (K+) and calcium 
(Ca2+) differ dependent on subtype and location, in vivo or as a cell culture. In vitro studies 
have shown only 30% of astrocytes in culture express Na+ current, with cultured astrocytes 
showing no expression of Ca2+ current unless co-cultured with neurons (Schipke & 
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Ketenmann, 2004). By comparison, Ca2+ shows significant increase in vivo in the presence 
of glutamate and purinergic receptor agonists, and rapidly propagates in the presence of 
glutamate release (Oberheim et al., 2009). This is an important consideration when 
proposing clinical applications of experimental models, highlighting the gulf between 2-
dimensional culture and the 3-dimensional, functional environment of the CNS. 
Astrocytes form a neuronal trophic support network within the CNS facilitating the 
astrocyte-neuronal signalling complex; their physical coupling isolating synapses (Schipke 
& Kettenmann, 2004). Electrical coupling is facilitated by an extensive astrocyte-neuronal 
gap junction communication network. This highly interactive network is instigated by 
astrocytes. Their high expression of gap junction protein molecules, connexin -43 and -30, 
establish astrocyte-neuronal communication, the subsequent regulation of which is tightly 
controlled, in turn, by neurons (Fellin & Carmingnoto, 2004; Rouach et al., 2004). Of 
importance to translational application, in vitro studies of co-culture with neurons have 
shown similar extensive physical and electrical coupling typically observed in vivo (Nagy 
& Rash, 2000; Rouach et al., 2004). 
The astrocyte matrix also enables neuroprotection. Astrocytes are fundamental to 
homeostasis of glutamate and γ-aminobutyric acid (GABA) neurotransmission within the 
CNS (Yu et al., 1983). Their high expression of glutamate transporters (GLAST) and 
GABA receptors for neurotransmitters and modulators are crucial to synaptic transmission, 
enabling uptake and transport of excess glutamate, GABA and glycine (amongst others) 
from the synaptic cleft, and thus preventing neurotoxicity from overexpression of these 
Ca2+  dependent processes (Danbolt, 2001; Sattler & Tymianski, 2001). Astrocytic 
synthesis and release of neurotrophic and growth factors also facilitate neuronal survival 
and function. 
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It has been widely held that astrocytes possess negligible regenerative properties following 
maturation. However, recent evidence is highlighting a level of regenerative capability in 
healthy adult astrocytes. The use of specific transcription factors have proved successful in 
promoting neurogenesis of murine and human astrocytes. In the adult mouse brain, SOX2 
generated proliferative neuroblasts from adult and aged astrocytes, with the addition of 
BDNF and Noggin to SOX2 promoting neuroblast development into functional neurons 
(Niu et al., 2013). The individual addition of OCT4, SOX2 or NANOG to cultured human 
cortical astrocytes induced cells expressing neural precursor markers, with the resulting 
NSCs giving rise to astrocytes, neurons and oligodendrocytes. Further, transplantation of 
these NSCs into mouse lateral ventricles generated neuronal and glial phenotypes, with 
some migration into the cortical area (Corti et al., 2012). The generation of neuronal 
precursors from foetal human astrocytes, when exposed to medium supplemented with 
basic fibroblast growth factor (BFGF) has also been reported, with maturation into neurons 
occurring following subsequent BFGF withdrawal (Aziza & Krynska, 2013). Although 
modest, the regenerative potential of mature astrocytes is beginning to be realised. 
1.3.3 Astrocytes are intrinsic to neuroprotection in SCI 
In the injured spinal cord, coincident with glial scar formation, reactive astrocytes release a 
plethora of neurotrophic factors to promote neuronal survival, and signalling molecules 
that mediate both neuroprotective and neurotoxic effects (Freitas-Andrade & Naus, 2016). 
Interleukin-1 β and tumour necrosis factor-α (astrocyte derived cytokines) are released into 
the area of insult, promoting neurotoxicity to phagocytose necrotic tissue, with Interleukin-
6 and transforming growth factor-β (also astrocyte derived cytokines) promoting 
neuroprotection (John et al., 2003; Liberto et al., 2004). CSPGs are produced by reactive 
astrocytes, with the influx of macrophages and microglia into the injury site further 
increasing CSPG expression (Viapiano & Matthews, 2006). OPCs, triggered by 
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demyelination of the severed axon, also increase CSPG expression following injury (Asher 
et al., 2002). To limit tissue damage, reactive astrocytes also take up from the synapse the 
glutamate and ions released from dying neurons, and remove the metabolic by products 
(Chen & Swanson, 2003; Sofroniew et al., 2001).  
1.3.4 Astrocytes play a major role as a transplant population for SCI 
The co-dependency of the astrocyte-neuron relationship suggests the continuation of 
astrocytes’ role as critical to repair and restored function within the injured spinal cord. In 
this regard, there are a number of properties that propose them as ideal candidates.  Unlike 
transplantation of undifferentiated NSCs into the lesion site, the transplantation of 
astrocytes appears to mitigate the astroglial response to injury. In this context, it has been 
postulated that the reduction of proliferation and the consequent reduction of glial scar 
density, facilitates axonal regeneration (Wang et al., 1995). Interestingly, regeneration 
appears dependent on astrocytes’ developmental stage at the point of transplantation. 
Astrocyte precursor cells (glial-restricted) transplanted into rat spinal cord, reduced glial 
scarring and induced low levels of improvement to the surrounding tissue. Autonomic 
function was enhanced, as observed by penis pressure tests, although no effect on 
functional erectile recovery was observed (Nout et al., 2011). By contrast, differentiating 
these cells into astrocytes prior to transplantation, enabled extensive regeneration and 
repair to axons and neurons, with restoration of mobility function as assessed by grid-walk 
foot placement (Noble et al., 2011).  
It has also been observed that regeneration appears to be dependent on a specific 
population of differentiated astrocytes. The two signalling molecules (BMP or CNTF) that 
facilitated differentiation of these cells during mammalian development, have been found 
to confer different regenerative properties to the mature sub-populations when used for cell 
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transplant (Davies et al., 2011; Liu et al., 2015). Use of BMP-4 resulted in an astrocyte sub-
population that facilitated extensive regeneration and functional recovery, whereas use of 
CNTF resulted in the similarly low levels of regeneration observed with precursor cells 
(Davies et al., 2011; Liu et al., 2015; Noble et al., 2011). 
Their therapeutic benefits following SCI have prompted a number of astrocyte transplant 
studies which have subsequently provided a broad knowledge base for the further 
development of this cell to translational application (Table 1.3). 
*Astrocyte transplant studies not in the context of SCI are not included. 
 
Table 1.3 Astrocyte Cell Transplant Studies in Rodent SCI Models 
Transplant 
population 
characteristics 
Injury model Outcome Study 
SC embryonic 
astrocytes 
Crush injury - rat Limited inflammatory 
response; axonal regrowth 
 
Kliot et al 
1990 
Embryonic whole 
SC (graft) or SC 
embryonic 
astrocytes (EmA) 
Cervical aspiration (C3) 
- rat 
Improved hind limb 
placement with graft; 
worsening of hind limb 
placement with EmA 
 
Bernstein & 
Goldberg 
1991 
Type 1 astrocyte 
culture 
EB SC lesion - rat Promoted host OL 
integration into the lesion 
site resulting in increased 
OL remyelination 
 
Franklin et al 
1991 
Neonatal cortical Hemi-sected lumbar 
(L3) - rat 
Astrocyte migration; 
reduction in glial scar; 
nerve fibre regrowth 
 
Wang et al 
1995 
    
Embryonic whole 
SC  
Thoracic transection 
(T8-9) - rat 
Integration of host axons 
with transplant; 
regeneration and recovery 
of foot placement and 
weight-supported stepping 
Coumans et 
al 2001 
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Human adult 
astrocytes 
Non-injured SC (T9) - 
mice 
Migration and integration 
into the host SC tissue; 
absence of tumour 
formation 
 
Ridet et al 
2003 
Neonatal cortical 
astrocytes 
Thoracic hemi-section 
(T7-9) 
No migration from implant 
into host tissue led to 
significant corticospinal 
axon fibre ingrowth; 
resulted in modest 
(temporary) locomotor 
recovery 
 
Joosten et al 
2004 
GRP cells SC contusion - rat Differentiated into 
astrocytes & OL in vivo; 
reduction of glial scar; 
reduction of CSPGs; altered 
axon stumps to growth 
cones 
 
Hill et  2004 
NRP + GRP Thoracic contusion 
(T8-9) - rat 
In vivo differentiation into 
neurons and astrocytes; 
accelerated recovery from 
bladder areflexia vs 
control; improved 
hypersensitivity to heat; 
greater recovery of hind 
limb function; no 
difference in locomotor 
grid walk function vs 
control 
 
Mitsui et al 
2005 
Primary adult rat 
cortical astrocytes 
Thoracic transection 
(T8) - rat 
Cells genetically modified 
to express gfp – cells 
migrated from injection 
site & integrated with host 
tissue 
 
Pencalet et 
al 2006 
Embryonic GRP 
cells 
 
 
 
Pre-differentiated 
astrocytes from 
embryonic GRP 
cells 
Cervical transection 
(C1-2 or C3-4) - rat 
No suppression of glial scar 
formation; no axonal 
growth; no locomotor 
recovery 
 
Promotion of axonal 
growth into and beyond 
the lesion; improved 
locomotor function 
Davies et al 
2006 
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GRP-derived 
astrocytes (+BMP 
or CNTF) 
Cervical transection 
(C1-2 or C3-4) - rat 
Astrocytes+CNTF – no 
axonal regeneration or 
functional recovery; onset 
of neuropathic pain 
Astrocytes+BMP – 
promoted axonal 
regeneration and 
functional recovery; no 
pain syndrome exhibited 
 
Davies et al 
2008 
Embryonic (h)GPC-
derived astrocytes 
(+BMP or CNTF)  
Cervical transection 
(C3-4) 
Astrocytes+CNTF – failure 
of axonal growth, neuronal 
survival and behavioural 
recovery 
Astrocytes+BMP – 
promoted axonal growth; 
increased neuronal 
survival; significant 
recovery of voluntary foot 
placement 
 
Davies et al 
2011 
iPSC-derived 
astrocytes 
Thoracic contusion 
(T9-10) - rat 
Despite process 
elongation, no integration 
with host cells was 
observed; no 
tumorigenesis; no 
locomotor recovery; 
increased sensitivity (pain) 
 
Hayashi et al 
2011 
(h)GRP vs (h)GRP-
derived astrocytes 
Thoracic contusion 
(T10) -rat 
Both cell transplants 
migrated into host tissue; 
(h)GRP differentiated into 
astrocytes in vivo; cyst & 
scar formation was 
reduced; axonal growth; no 
increased sensitivity (pain); 
no improvement in motor 
function recovery; (h)GRP-
derived astrocytes 
promoted normal recovery 
of sensory function  
 
Jin et al 2011 
GRP-derived 
astrocytes 
Thoracic contusion 
(T9) - rat 
Integration with host 
tissue; axonal 
regeneration; decreased 
injury size; improved 
locomotor function 
Fan et al 
2013 
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(h)GRP-derived 
astrocytes 
(+BMP/CNTF) 
Cervical transection 
(C4-5) - rat 
Both astrocyte-BMP and 
astrocyte-CNTF promoted 
regeneration of long 
ascending tracts into lesion  
site 
Haas & 
Fischer 2013 
 
 
GRP-derived 
astrocytes+BMP+ 
(hr)-decorin 
Thoracic contusion 
(T8)-rat 
Reduced SC inflammation; 
inhibited astrogliosis and 
glial scar formation; axonal 
regeneration; improved 
functional recovery 
 
Wu et al 
2013 
(h)iPSC-derived 
astrocyte 
progenitors 
Cervical laminectomy 
(C6) - rat 
Limited cell survival (<5%); 
In vivo differentiation to 
astrocytes; upregulation of 
mature astrocyte genetic 
markers 
 
Haidet-
Phillips et al 
2014 
GRP-derived 
astrocytes+BMP – 
periostin+/-  
Cervical transection 
(C1-2) 
GRP-A periostin+ cells 
reported axonal growth & 
motor functional recovery. 
GRP-A periostin- cells 
inhibited axonal growth 
  
Shih et al 
2014 
(h)iPSC-derived 
astrocytes+GLT 
Cervical contusion (C4) 
- rat 
In vivo differentiation into 
astrocytes; long term 
survival; increased 
expression of GLT 
transporters and functional 
GLT uptake; reduced lesion 
size; improved functional 
diaphragm denervation 
(aiding respiration) 
 
Li et al 2015a 
GRP-derived 
astrocytes+AAV8 
Cervical hemi-
contusion (C4) -rat 
GRP-derived 
astrocytes+AAV8 
overexpressed GLT 
transporters in SCI; 
significant increase in GLT 
transporter protein 
expression and subsequent 
GLT uptake; reduced lesion 
size; reduction in 
diaphragm dysfunction 
 
Li et al 2015b 
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SVZ-NPCs Cervical hemi-section 
(C2) - rat 
50% cell survival; in vivo 
differentiation into 
astrocyte phenotype; 
increased phrenic nerve 
output (improvement in 
respiratory recovery) 
 
Sandhu et al 
2015 
BMP–bone morphogenetic protein; C3–cervical region; CNTF–ciliary neurotrophic 
factor; CSPGs–chondroitin sulfate proteoglycans; EB–ethidum bromide; EmA– 
embryonic astrocytes; GLT–glutamate; GRP–glial restricted precursor; GRP-A–glial 
restricted precursor-derived astrocytes; (h)GPC–human glial restricted progenitors; hr– 
human recombinant; iPSC-induced pluripotent stem cell; L3–lumbar region; NRP–neuron 
restricted precursor cells; OL–oligodendrocytes; SC–spinal cord; SVZ-NPCs–sub-
ventricular zone neural progenitor cells; T9–thoracic region.  
 
As can be seen from the above studies, astrocytes as a transplant population have been 
showing consistently promising results in the repair of SCI for over a decade. The field has 
shown development from basic rodent cell transplant (Bernstein & Goldberg, 1991; 
Coumans et al., 2001; Davies et al., 2006; Franklin et al., 1991; Kliot et al., 1990; Wang 
et al., 1995) to that of a combinatorial approach, delivering functionalised and/or genetic 
engineered cells as a transplant to the injured spinal cord (Davies et al., 2008; 2011; Haas 
& Fischer, 2013; Joosten et al., 2004; Li et al., 2015a; 2015b; Shih et al., 2014; Wu et al., 
2013). They have been tested across a wide developmental range, from GRP cells (Davies 
et al., 2006; Hill et al., 2004; Jin et al., 2011; Mitsui et al., 2005; Sandhu et al., 2015) 
through to mature adult astrocytes (Pencalet et al., 2006; Ridet et al., 2003), with both rat 
and human origin proving beneficial to recovery (Davies et al., 2011; Haas & Fischer, 
2013; Haidet-Phillips et al., 2014; Jin et al., 2011; Li et al., 2015a; Ridet et al., 2003).  
It is interesting to note that differentiating precursor cells to astrocytes prior to transplant 
(Davies et al., 2006; 2008;2011; Fan et al., 2013; Haas & Fischer, 2013; Jin et al 2011; 
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Li et al., 2015b; Shih et al., 2014; Wu et al., 2013), appears to exert greater functional 
recovery and regeneration than allowing cells to differentiate in vivo (Hill et al., 2004; Jin 
et al., 2011; Li et al., 2015a; Sandhu et al., 2015). The benefit though of the latter 
approach appears to be in mitigating the non-permissiveness of the lesion environment 
(Hill et al., 2004; Jin et al., 2011). From this a combinatorial strategy could be postulated 
for the transplant of differentiated astrocytes alongside precursor/progenitor cells, to gain 
the benefits attributed to both when transplanted separately.  
While a number of cell types in both animal and clinical trials have reported improved 
sensory, motor and to some degree, functional recovery, unlike astrocytes relatively few 
cell types have reported any improvement to urodynamics. This has physical, 
psychological and social consequences. Erectile dysfunction related to SCI has been shown 
to be mediated by pharmacological intervention (Giuliano et al., 1999; Khorrami et al., 
2010; Lombardi et al., 2012). However, the major impact on ‘quality of life’, as reported 
consistently by SCI patients during clinical trials (Professor Steven Conlan; Swansea 
University - personal communication), has been the loss of urodynamic control (loss of 
bladder/bowel control). Hyperreflexia and areflexia impact kidney function, preventing 
adequate filtering of the blood with the potential consequences of kidney failure and 
dialysis. (Bladder areflexia refers to a flaccid bladder that overfills and leaks due to non-
contraction). Incontinence without proper management, can lead to breakdown of the 
surrounding skin tissue, resulting in pressure ulcers and infection. Loss of bowel control 
can lead to faecal impaction and/or sudden ejection of faecal matter from an overloaded 
bowel (UPMC, 2016).  
In this regard, NRP+GRP-derived astrocytes reported beneficial effect following cell 
transplant (Mitsui et al., 2005). In this study, both treatment and control groups acquired 
bladder areflexia immediately following SCI, however, the treatment group showed a 
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significantly accelerated and improved recovery compared with control (Mitsui et al., 
2005). Coupled with the extensive regeneration seen within the lesion site and the 
subsequent translation of this regeneration into functional recovery (i.e. sensory and motor 
function; improved and recovered locomotor function; improvement in respiratory 
recovery; improvement in urodynamics), astrocytes as a cell transplant appear to be 
offering high promise in regenerative treatment of SCI.  
Notwithstanding, it has to be recognised that a number of cell types that showed promise in 
animal studies have not translated favourably into the clinic. In the context of translatable 
application, the use of (h)iPSCs have been promoted as having high potential, although, 
there appears to be an inordinate number of complications surrounding their use 
(Nakamura & Okano, 2013; Ruff et al., 2012; Yamanaka, 2009). Indeed, of all the 
precursor cell types differentiated into astrocytes both prior to transplant and in vivo, the 
use of (h)iPSCs showed the least promise, with very low cell survival (<5%), no motor 
recovery and increased hypersensitivity (worsening of pain symptoms) (Haidet & Phillips., 
2014; Hayashi et al., 2011). Of interest, these cells appear to be more promising when 
used as part of a combinatorial approach, in that survival in vivo was significantly 
increased, although it may be that they are functioning only as a vehicle for transport of 
glutamate, and that the therapeutic benefits seen are due only to the presence of this 
neurotransmitter (Li et al., 2015a). Thus, at present, these findings do not promote them 
sufficiently as a transplant population.   
By contrast, human (h) adult astrocytes, embryonic (h)GPC-derived astrocytesBMP and 
(h)GRP-derived astrocytes report cell migration and integration into host tissue; axonal 
growth and regeneration into and beyond the lesion site; neuronal survival and recovered 
urodynamics. Coupled with improved “volitional” (Davies et al., 2011) functional 
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recovery, and reports of high levels of safety, astrocytes represent an ideal candidate for 
translational application into clinic. 
Autologous transplantation is a distinct possibility with this cell type, obviating the need 
for extensive immunosuppression (Ridet et al., 1999; 2003). Ridet et al., reported 
obtaining human adult cortical astrocytes and maintaining them in vitro for approximately 
10 months, prior to lenti-viral modification of the cells to express gfp. To “mimic an 
autologous human transplant”, the cells were transplanted into adult nude mice (Ridet et 
al., 2003). They reported cell survival and migration of the cell transplant, together with 
sustained expression of the gfp transgene. There was complete absence of tumorigenesis, 
suggesting the safety of these cells for clinical application. Ridet et al., argue the obvious 
biological advantage to autologous transplant, compared with the ethical and safety 
considerations concerning embryonic and cloned cells (Ridet et al., 2003).  
1.3.5 Cortical astrocytes as a cell transplant population in injured spinal cord 
In respect of clinical application, and with regard to the series of studies detailed within 
this research, a key point to note is the well-documented use, and potential feasibility of, 
cortical astrocytes (as opposed to SC astrocytes) as a transplant population in the injured 
SC, due to their subsequent survival and integration into host tissue, coupled with the 
consequent functional improvement observed in animal studies  (Joosten et al., 2004; 
Pencalet et al., 2006; Ridet et al., 2003; Wang et al., 1995). This in contrast to the use of 
embryonic SC astrocytes which showed significantly worse outcomes and ‘highly variable 
regeneration’ when transplanted into injured SC (Bernstein & Goldberg, 1991; Kliot et al., 
1990). While it is recognised that more recent studies have utilised (h)GRP-differentiated 
astrocytes as a transplant population, the ethical challenges remain, as does the challenge 
to move towards translational and/or autologous use.   
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Astrocytes ‘tile’ the entire CNS (Sofroniew et al., 2010), and are classified at present, not 
by region, but by phenotype (Type 1 or 2), and morphology [protoplasmic (located 
predominantly in grey matter) or fibrous (white matter)]. Putative regional heterogeneity 
has been suggested, based on differing neuronal characteristics when cultured with 
astrocytes from different regions, however, in respect of astrocyte molecular markers, 
while onset may differ, expression itself does not (Molofsky et al., 2012 for review). 
Moreover, irrespective of location astrocytes are similarly characterised (Kerstetter & 
Miller, 2012, and as elucidated previously – section 1.3); for example, cortical and SC 
astrocytes show no difference in Ca2+ conductance for intercellular communication 
(Scemes et al., 2000).  Fundamentally, astrocytes’ role in the CNS is to provide a structural 
and supportive environment for neuronal networks and axonal growth (Chu et al., 2014 for 
review). 
Hence, in respect of utilising cortical – as opposed to SC - astrocytes as a cell transplant in 
the injured spinal cord, the key points remain i) astrocytes throughout the CNS are 
similarly characterised; ii) their use as a transplant population in injured spinal cord has 
been well-documented; iii) for the purposes of translational/autologous use, cortical 
astrocytes can be feasibly derived and therefore, iv) circumvent ethical challenges.  
Importantly, the fundamental purpose of a cell transplant is not to replace damaged cells, 
but rather to confer the neuroprotective and neuro-immunomodulatory benefits of a cell 
transplant to facilitate a conducive environment for regeneration (Li & Leung., 2015). 
It is therefore postulated that astrocytes propose an excellent strategic approach to 
regeneration within the injured spinal cord; nonetheless there remains a major challenge 
still represented in pursuit of translational application (Ridet at al., 2003).   
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1.4 The need to develop better cell therapies 
While it is clear then, that astrocytes as a cell therapy are advantageous for regeneration 
within the injured spinal cord, in order to enhance their promise, there is a critical need to 
address the fundamental issues surrounding the development of a more select cell therapy. 
In the drive for improvement there are a number of approaches that could be considered, 
three of which are the focus of this research.  
1.4.1 The need for safe, effective genetic engineering of the cell transplant population  
The first approach considered is that of genetically engineering the cell transplant 
population. Varied therapeutic approaches have been utilised to deliver drugs/genes to the 
injured spinal cord. Strategies deployed to inhibit degenerative processes and promote 
neural repair are considered of greater efficacy when delivered within specific timeframes, 
i.e. the administration of corticosteroid within 8 h of injury (Bo et al., 2011 for review). 
However, a number of concerns have been expressed regarding the mode of delivery; its 
effectiveness and its safety.  
Drug delivery at SCI onset is either systemic or direct. Each method has limitations. 
Systemic delivery faces two main challenges in crossing the “blood-spinal cord barrier” 
(Kabu et al., 2015). Firstly, while this barrier is more permissible than the blood-brain 
barrier, pharmacokinetic studies have shown that the damage occasioned by SCI (and 
disease) alters its dynamic activity in gap-junction and receptor expression (Ge & Pachter, 
2006; Li et al., 2004; Whetstone et al., 2003). The second challenge with systemic delivery 
is that of retaining sufficient dose to be effective on arrival at the injury site. By contrast, 
direct administration is targeted, but entails a number of puncture wounds due to the 
overall volume required (an average of 8 sites were required for delivery in animal 
studies), inducing tissue damage and potentially further inflammation (Guest et al., 2011). 
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The use of slow release intrathecal catheters has been suggested to address this. However, 
they incur further problems such as infection, and the extended time frame required to 
deliver the dose (Jones et al., 2001). Moreover, and of clinical relevance, doses delivered 
in the lab are not tolerated in the clinic, presenting a major challenge to translational 
therapies (Kabu et al., 2015).  
It is increasingly clear that a combinatorial approach offers the most promise for recovery 
and regeneration in the injured spinal cord, with therapeutic molecules delivered alongside 
cell transplants seeing effective results (Coumans et al., 2001; Shih et al., 2014). However, 
the low effectiveness and rapid degradation of neurotrophins, growth factors or inhibitory 
molecules when delivered utilising standard approaches, represents an obstacle to the 
development of such an approach. This demonstrates a need to genetically engineer 
transplant populations, to augment cells to facilitate delivery of therapeutic molecules.  
There are two main strategies for transducing genes to astrocytes (and indeed, most cell 
therapies). The less common strategies are non-viral approaches to genetic engineering, 
such as Lipofectamine (Tinsley et al., 2004). For example, to upregulate BDNF and glial 
cell-line derived neurotrophic factor (GDNF), Lipofectamine was used to introduce a 
vector containing the cDNA for Pitx3 to primary-derived astrocytes; Pitx3 protein being a 
transcription factor critical to dopamine neuron development (Yang et al., 2008). 
Following introduction of these cells into a dopamine neuron injury model, the study found 
the significant upregulation of GDNF and BDNF attenuated dopamine neuron injury (Yang 
et al., 2008). Although these particular results are promising, the low transfection 
efficiency (10-15%) and transient expression (24 h) associated with this approach has 
discouraged development (de Lima et al., 2005). Other non-viral approaches, such as 
electroporation, where DNA is introduced into the cells using an electrical pulse to disrupt 
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the cell membrane, are also disadvantageous due to the high cell death occasioned with 
such a forceful strategy (de Lima et al., 2005). 
The more common strategy has been the use of viral vectors – notably lentiviral (LV); 
retroviral (RV) and adeno-associated viral vectors (AAV) (Merienne et al., 2013). A large 
proportion of earlier studies utilising RV (Selkirk et al., 2002) or LV vectors (Ericson et 
al., 2002; Filous et al., 2010; Pencalet et al., 2006; Ridet et al., 2003), genetically 
engineered astrocytes to express a reporter protein (green fluorescent protein – gfp). These 
studies proved its safety and efficacy in gene transfer, and its capacity to facilitate tracking 
of a cell transplant population. Moreover, use of viral methods for transgene expression in 
astrocytes in neurological disease has proved highly beneficial. For example, using a 
recombinant AAV, primary adult human astrocytes were transduced to carry (h)β-
glucuronidase cDNA – an enzyme whose deficiency in the developing CNS leads to 
growth and mental retardation (Serguera et al., 2001). Transplant of the genetically 
engineered cells to mouse striatum, resulted in long term survival and expression of the 
enzyme (Serguera et al., 2001). Use of an AAV-5 vector for delivery of GDNF transgene-
expressing neurons into the brain of Parkinson’s disease animal models, reported serious 
side effects due to mis-targeting and entry to the unaffected part of the brain (Drinkut et 
al., 2011). However, use of this vector for GDNF transgene expression in astrocytes, 
facilitated efficient and specific targeting to the affected area only (Drinkut et al., 2011). 
A number of studies have investigated the development of a combinatorial approach of 
genetically engineering astrocytes as a vehicle for delivery within the injured spinal cord. 
One particular study, utilising a retroviral approach, engineered astrocytes to express a 
novel, multiple neurotrophin -‘D15A’, which possesses the combined benefits of NT-3 and 
BDNF. Following transplant into a contusion SCI, apart from the reduced lesion size and 
low expression of CSPG, an increased level of spared white matter was observed, 
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suggesting a neuroprotective effect with this cell transplant. Functional recovery showed 
significant improvement, and as evidenced with other astrocyte transplants, 
hypersensitivity did not increase (Fan et al., 2013).  
Loss of glutamate transporters in the injured spinal cord results in high levels of excess 
glutamate, leading to disrupted glutamate homeostasis. This has been found to have a 
highly negative effect on phrenic nerve function in cervical SCI (i.e. it impacts on 
respiratory recovery) (Li et al., 2015a). To ameliorate “diaphragm dysfunction” (Li et al., 
2015b), (h)iPSC-derived astrocytes (Li et al., 2015a) and GRP-derived astrocytes (Li et al., 
2015b) were genetically engineered using LV and AAV-8, respectively, to overexpress 
glutamate transporters. Following transplant into a cervical hemi-contusion (C4) animal 
model, glutamate protein expression and uptake was significantly increased, with a 
significant reduction seen in denervation and “diaphragm dysfunction”, resulting in a level 
of improvement in muscle action potentials within the diaphragm (Li et al., 2015a; 2015b). 
Although promising, viral-mediated strategies have their limitations. While they are highly 
efficient in targeting the lesion site, and show high and sustained expression, they are 
restricted to small plasmid size, making them inefficient carriers of larger therapeutic 
molecules. RV has little efficiency in post-mitotic cells, with both RV and LV showing 
random integration (de Lima et al., 2005). By contrast, AAVs are more precise and target-
selective and therefore, represent the safest option in vivo. They are however, the least 
efficient of the viral vectors (Lentz et al., 2012). Of major concern is the level of safety 
associated with these approaches. They can represent an unpredictable immune response in 
vivo, and have been linked with insertional mutagenesis and oncogene activation (Blits & 
Bunge, 2006; Ryan & Federoff, 2007). Moreover, the inability to monitor or control their 
level of expression within the lesion site, suggests a high potential for tumorigenesis 
(Costantini et al., 2000; de Lima et al., 2005; Siebert et al., 2015).  
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Thus, there has arisen a critical need for a safe, effective mode of delivery that has to 
fulfil a number of criteria: i) it can be accurately targeted to the site of injury without 
incurring tissue damage or increased inflammation; ii) the delivery vector should be 
capable of retaining sufficient dose to be clinically effective and have the capacity to 
remain at the injury site long enough for efficient delivery, and iii) be biocompatible and 
biodegradable to ensure no toxicity to the host tissue. In this respect, magnetic nano-
particles (MNPs) - used extensively in clinical application for contrast under magnetic 
resonance imaging (MRI) - have emerged as excellent delivery vectors for transgene 
expression in cell transplant populations (Cerqueira et al., 2013). Moreover, and discussed 
more extensively in Chapter 5, MNPs have been suggested as a “safer and more efficient” 
approach, due to their biodegradability, capacity to target the lesion site and to facilitate 
slow and sustainable release of therapeutic drugs/genes (Hans & Lowman, 2002; Silva et 
al., 2014). Until recently, the limiting factor with this approach was their low transgene 
efficiency when compared with the high transfection efficiencies reported with the use of 
viral vectors.  Nucleofection, RV and LV routinely achieve transfection efficiencies of 60-
90% in astrocyte cultures, with 100% seen with certain viral vectors (see Pickard & Chari, 
2010 for review). However – and discussed further in Chapter 5 – the deployment of 
magnetic fields in conjunction with MNPs, is proving highly advantageous in overcoming 
the barriers to MNP-mediated gene transfer. 
1.4.2 The critical need to develop a means of non-invasively detecting and tracking 
transplant populations, fundamental to translational applications  
The second approach requiring development is for non-invasive tracking of the cells for 
transplantation, in order to correlate their distribution in host tissue with any observed 
functional neurological recovery. Cell tracking of transplant populations in host tissue, 
have shown heavy reliance on dyes such as Hoechst 33342, fast blue (Joosten et al., 2004) 
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or fluorescent dyes (Frampton et al., 2011; O’Shaughnessy et al., 2003). Other methods 
include DNA identification of Y-chromosome probes (Pearse et al., 2007); retrograde 
tracing (i.e. Fluoro-Gold – Kushchayev et al., 2016), radiolabelling or reporter protein 
expression (Bulte et al., 2001; Filous et al., 2010; Kircher et al., 2011). Each of these 
strategies have a number of limitations in respect of imaging, toxicity and rapid decay of 
the label (Hossain et al., 2014; Mertens et al., 2014; Pearse et al., 2007). The biggest 
obstacle with these methods is that the end point of each of these strategies still remains 
histological analysis, a major barrier to translational use.  
Thus, there is a requirement for a non-invasive approach to in-vivo detection and 
tracking of a cell transplant population. This approach requires a high level of safety, both 
to the transplant population and to the endogenous cells. It must offer a high imaging 
contrast that is not subject to rapid degradation, and yet remain both biocompatible and 
biodegradable to offer potential for clinical application. In this respect, superparamagnetic 
(nano) particles have shown themselves to be a highly effective contrast agent for non-
invasive MRI, and have been used as such for the tracking of cell suspensions. For 
example, NSC-derived OPCs showed efficient labelling of magnetodendrimers (magnetic 
tags); sufficient to be tracked using MRI in intracerebral regions of rodent neonatal brains 
(Bulte et al., 2001). MSCs loaded with silica-coated magnetic particles were suspended in 
a dense collagen gel and injected into an ex vivo cartilage slice prior to imaging under MRI 
(Harrison et al., 2016). Adipose-derived stem cells showed uptake of oleic-acid modified 
MNPs which were seen to be localised to vesicles within the cytoplasm. Following 
injection of these labelled cells into murine subcutaneous tissue, they could be visualised 
under MRI for up to 9 days (Cen et al., 2009). However, the biggest challenge that still 
remains is ensuring a sufficient high initial loading of particles into the cell transplant to 
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promote high imaging sensitivity over an extended time frame, as loss of signal is the 
major limitation in clinical application (Bernsen et al., 2015). 
1.4.3 The low survival rate of cell transplant populations necessitates a protected cell 
transplant delivery system  
The third area for development entails addressing the low efficacy of surgical techniques in 
cell delivery. A number of approaches are used in delivery of the cell transplant population 
to the site of injury. However limitations to the transplant’s subsequent effectiveness in the 
injury site have been reported. The main consideration is the initial major surgery required 
to expose the spinal cord. Percutaneous surgery has been suggested as a less invasive 
alternative, although the adjunct here is that, in comparison to animals, human SCI would 
require a number of needle penetrations to cover the entire length of the lesion, increasing 
the invasive nature of this approach (Granger et al., 2012). Further to this is the highly 
invasive nature of implanted pumps or catheters, all of which have the potential to increase 
the inflammatory response in the lesion site. There is a high risk of infection with 
implanted devices, which also carry the threat of failure or breakdown (Jones et al., 2001). 
Moreover, delivery of growth factors or protein inhibitors alongside cell transplants is 
unable to be successfully monitored to ensure safety and prevent tumorigenesis (Siebert et 
al., 2015). Delivery of cell transplant populations via fine bore needles, the more common 
route, involves either a series of injections, or one large dose to ensure the high cell 
numbers required are delivered, resulting in a high incidence of “injection injury” (Guest et 
al., 2011). In this context, the autonomic pulsing nature of the spinal cord around the 
infiltrating needle can result in cavitation, triggering a further neural response and 
increased neuronal degradation (Guest et al., 2011). Potentially the major factor underlying 
the low success rate in clinic and laboratory is the use of fine bore needles. These place 
shearing stresses on the cell membrane during delivery, with the majority of cell death 
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reported as occurring at the time of transplant (Hill et al., 2007; Pearse et al., 2007). To 
allow for this, a high cell density is used. To reduce ‘injection injury’, one large dose is 
delivered. However, this higher volume impacts on the pressure that can be sustained by 
the spinal cord lesion, causing injury due to overexpansion of an already highly damaged 
area (Dai et al., 2013; Guest et al., 2011). Circumventing this problem would require 
slower release, however, it has been reported that a therapeutic dose of cells would require 
a delivery rate of 1 µl over approximately 2 hours; an unsustainable timeframe for clinical 
application (Guest et al., 2011).  
A lesion site is an irregular 3-dimensional space (Siebert et al., 2015). A second major 
factor fundamental to the lack of efficacy in surgical techniques, is the delivery of a 
transplant cell population in a 2-dimensional construct i.e. cell suspension. The cells, 
following injectable delivery, flow in an uncontrolled manner into the cavity and, in the 
absence of a structure, settle disproportionately. This heterogeneous distribution of dead, 
dying and surviving cells leads to high proportions of cell clumping. The high level of cell 
mortality occasioned by delivery and subsequent clumping of surviving cells leads to 
further infiltration by macrophages, increasing the already hostile environment and, in turn, 
lowering survival of the remaining cells (Pearse et al., 2007). It is being increasingly 
realised that the technical difficulties associated with surgical delivery of transplant 
cells would be attenuated by the use of a 3-dimensional protective cell construct (i.e. 
Siebert et al., 2015; Vater et al., 2010).   
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1.5 Emerging technologies offer the hope for development of better cell 
therapies 
To meet these challenges, two technological approaches have emerged that offer promise 
for cell therapies to realise their full potential in SCI.  
The first approach is that of utilising MPs. These have i) been proved as a safe, efficient 
delivery vector for the genetic engineering of a cell transplant population, and ii) through 
particle labelling of the cell transplant, have shown themselves as an ideal contrast agent 
for non-invasive tracking under MRI.  
The second approach is the delivery of the engineered cell transplant population within a 3-
dimensional hydrogel construct. This would offer a protected cell delivery system, which 
would circumvent the low efficacy of surgical techniques seen with transplant of 2-
dimensional cell suspension to the spinal cord. It is the further development of these two 
approaches that is addressed within this project.  
1.5.1 Magnetic platforms as potential tools in basic and clinical neurobiology 
The disadvantages inherent within non-viral and viral-mediated delivery systems i.e. their 
immunogenic response; insertional mutagenesis; potential oncogene activation and their 
questionable safety (Ryan & Federoff, 2007), have brought to the fore the need to develop 
a non-viral mediated strategy that provides for safe, efficient gene delivery to, and 
cell:particle labelling of, a cell transplant applicable to clinical applications. In this regard, 
magnetic assistive technologies offer considerable promise. 
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Magnetic (nano) particles are ideal candidates for delivery of therapeutic bio-molecules 
to the spinal cord 
Magnetic (nano) particles (MPs) propose themselves as ideal candidates for delivery of 
therapeutic drugs/genes to the injured spinal cord on a number of counts. One, they possess 
superparamagnetic (SP) properties, meaning they are only magnetic when in the presence 
of a magnetic field gradient. Superparamagnetism in these particles is facilitated by the 
iron oxide - magnetite or maghemite - crystallites which make up their composition 
(Hofmann-Amtenbrink et al., 2010). These SP properties allow MPs to be administered and 
targeted to the site of interest via an external magnet. Two, they can be functionalised to 
deliver a therapeutic molecule. Three, for tracking purposes, they have proved themselves 
as a safe, effective contrast agent under MRI, and as such, are used extensively in clinic.  
MPs are typically formulated with a magnetite core, and overlaid with a positively charged 
surface coating that can be functionalised through attachment of a variety of biomolecules 
(Mykhaylyk et al., 2007). Conjugated fluorophores enable microscopy visualisation, with 
the magnetite loading acting as a contrast agent for non-invasive tracking under MRI.  
Astrocytes show efficient MP uptake  
Astrocytes show efficient uptake of various types of particles (Hohnholt et al., 2013). 
However, certain particle formulations have induced a level of toxicity in these cells. For 
example, silver nanoparticles show a concentration-dependent toxicity (Haase et al., 
2012), as do other metallic oxide particles i.e. titanium dioxide, zinc oxide and magnesium 
oxide (Lai et al., 2008). By contrast, use of iron oxide MPs have shown themselves to have 
a high safety profile (Geppert et al., 2012; Hohnholt et al., 2013; Hohnholt & Dringen., 
2013). Although, particle addition to astrocytes has been shown to be dependent on the 
cell’s developmental age, where addition to immature astrocytes, or to astrocytes that have 
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not attached to the culture substrate, has prevented cell adherence and subsequently, cell 
growth (Au et al., 2007). Further to this, particle uptake in astrocytes appears to be 
temperature, concentration and time–dependent, with increased uptake of higher iron oxide 
particles over time (24 h vs. 4 h), being markedly reduced at lower temperatures (4° C), 
showing the uptake mechanisms of this cell to be energy-dependent (Pickard et al., 2011). 
Astrocytes also show higher and increased uptake of positively charged MPs (Harush-
Frenkel et al., 2007; Sun et al., 2013), with uptake of negatively charged particles linked to 
toxicity (Sun et al., 2013). There are a number of probable explanations for this. One is the 
attraction of the positively charged MP to the relative negative charge of the cell (Ito et al., 
2005). Another explanation offered is that particle charge has a preference for specific 
endocytotic mechanisms (Harush-Frenkel et al., 2007). This then has implications to 
particle size, as endocytotic mechanisms are also known to be size-dependent (Oh et al., 
2009; Rejman et al., 2004; Zhu et al., 2013).  
Of particle retention in astrocytes, particle accumulation has been shown to be intact up to 
21 days post-particle exposure (Hossain et al., 2014; Pickard et al., 2011), with a putative 
link between surface coating and a cell’s capacity for particle retention being reported. It 
was found that dextran-coated particles ‘leaked’ from healthy MSCs, significantly 
truncating the timeframe for tracking. However, changing the surface coating to, in this 
instance, aminopropyltriethoxysilane, facilitated longer term particle retention (Hossain et 
al., 2014).  
Magnetic assistive technology to enhance cell:particle interaction 
In order to be of functional use in clinical applications, sufficient particle uptake in a cell 
transplant population is critical to therapeutic gene delivery, and subsequent tracking of the 
cell (Bernsen et al., 2015). However, the major obstacle for particle, and by definition 
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particle:plasmid uptake is thought to be the cell’s endocytotic capability (Fernandes & 
Chari, 2015). To overcome this obstacle, an innovative strategy has been the deployment 
of static magnetic fields beneath cell monolayers to promote the sedimentation of 
particle:pDNA complexes onto cells, thereby enhancing complex interaction with, and 
subsequent uptake by, the cell (Laurentt et al., 2011). This process of magnetically assisted 
gene delivery is referred to as ‘magnetofection’ (Plank et al., 2011). ‘Magnetolabelling’ 
refers to the use of this strategy to enhance MP-labelling of cells for tracking purposes. 
Such an understanding can aid the development of both robust experimental protocols, and 
state-of-the-art devices, to optimise the use of magnetic assistive technology with 
astrocytes. 
Indeed, use of magnetic fields deployed beneath astrocyte cultures has significantly 
increased particle uptake in these cells. For example, it has been widely reported that 
astrocytes show greater uptake of positive compared with negatively charged MPs 
(Harush-Frenkel et al., 2007; Ito et al., 2005; Sun et al., 2013). Yet, application of a 
magnetic field enhanced particle accumulation of both positive and negatively charged 
particles (Sun et al., 2013). It has also been reported that particle uptake in astrocytes is 
temperature-dependent, with reduced uptake at 4° C vs. 37° C (Pickard et al., 2011). 
However, deployment of a magnetic field beneath the cells circumvents this limitation, 
with increased particle uptake even at this low temperature, suggesting this strategy plays a 
role in enhancing endocytotic mechanisms (Lamkowsky et al., 2012).  
Magnetic field arrays have been further developed to increase their capacity for 
magnetofection and magnetolabelling purposes. Oscillating, rotating, pulsing and 
directional-alternating magnetic field arrays have been investigated for enhanced 
efficiency in magnetofection (Baryshev et al., 2011; Dahmani et al., 2013; Fouriki et al., 
2010; Kamau et al., 2006; McBain et al., 2008; Subramanian et al., 2013). One particular 
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array - oscillating magnetic fields - which impart a lateral motion to the MPs, has been 
postulated to increase cell particle contact across the whole cell population (Pickard & 
Chari, 2010).  Exposure of cells to oscillating fields has shown significant enhancement of 
transgene expression in a number of cell types, including in astrocytes (McBain et al., 
2008; Pickard & Chari, 2010). In this respect, investigation of a range of oscillating 
frequencies found enhanced magnetofection in astrocytes to be frequency-dependent 
(Pickard & Chari, 2010).  
Knowledge gaps 
In addressing this first approach, that of utilising MPs for genetic engineering and labelling 
of astrocytes, there appears to be a number of knowledge gaps. 
1).    It is becoming widely acknowledged that a combinatorial approach to SCI offers the 
most promise. Therefore with regard to genetically engineering astrocytes as a cell 
transplant population, transgene expression in astrocytes (and cell lines) has been reported 
as being frequency-dependent. However, extrapolating the benefits of magnetic oscillating 
fields to their fullest extent raises further questions:  
i) How does the amplitude of oscillation affect transgene expression in this cell? 
i) How does repeat application of a gene affect transgene expression in this cell? 
2).    The major limitation with the use of MPs as a contrast agent under MRI is the loss of 
imaging signal, requiring high MP-loading into the cell transplant to confer utility for 
tracking (Bernsen et al., 2015). To address this, use of high magnetite-loaded MPs may 
offer the potential for the high sensitivity required for MRI over an extended timeframe. 
Astrocytes show efficient uptake of MPs, and show a high resistance to iron, being 
complicit in iron homeostasis in the brain (Moos, 2002; Moos et al., 2007; Hohnholt & 
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Dringen, 2013). This raises a number of questions regarding cell tracking and the factors 
that govern this in this particular cell type. 
i) How will astrocytes deal with such high magnetite-loaded particles required 
for clinical application?   
ii) Further to this, how will astrocytes deal with magnetolabelling strategies that 
enhance uptake of such particles?  
iii) Astrocytes are a highly proliferative neural cell, what are the factors 
governing their conferred utility for tracking? 
iv) With regard to the use of magnetolabelling strategies and their putative role in 
enhancing cellular trafficking of particles, how will this affect particle 
retention in astrocytes?  
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1.5.2 3-dimensional hydrogels as potential constructs for delivery of cell transplant 
populations  
The second approach, of delivering an engineered, trackable cell transplant population 
within a 3-dimensional construct, has the potential to offset the lack of efficacy of surgical 
techniques seen with delivery of cell suspension transplants to the injured spinal cord. 
Substrate differentially affects cellular function and morphology 
The use of 3-dimensional constructs are an emerging field for therapeutic cell 
transplantation, with the now widely accepted understanding that cells removed from their 
in vivo environment display atypical morphologies and functional behaviour when cultured 
on flat substrates (Hu et al., 2014; Moshayedi et al., 2010). For example, on a 2-
dimensional substrate, postnatal astrocytes mostly possess a rounded morphology with a 
small subpopulation of bipolar cells. However, when cultured within the 3-dimensional 
environment of a hydrogel, these cells developed into a population of equal proportions of 
round, stellate and perivascular morphologies (Balasubramanian et al., 2016).  Adult 
astrocytes show similar comparison between 2-dimensional culture and 3-dimensional in 
vivo environment. They display a flattened, membraneous morphology with truncated 
processes and a highly proliferative reactive behaviour when plated on a hard substrate, in 
clear contrast to their highly ramified morphology, and their typically quiescent state in 
vivo.  
Of importance to clinical application, functional homeostatic behaviour of astrocytes has 
been observed to be affected dependent on the substrate on which they are grown (Lee et 
al., 2008; Miron-Mendoza et al., 2013). For example, astrocytes and brain endothelial cells 
were co-cultured on a 2-dimensional substrate and within a 3-dimensional hydrogel. TGF 
β1, which is a transforming growth factor responsible for cell growth and development, 
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was added to the co-cultures to stimulate reactive astrogliosis, i.e. to mimic an injured 
spinal cord.  Modulation of brain endothelial cells was much greater in the hydrogel than in 
the 2-dimensional culture, suggesting a putative explanation for the increased permeability 
of the blood-brain barrier observed in SCI. The study highlights the differing results that 
would have been reported, had this experiment only been conducted on a flat substrate 
(Hawkins et al., 2015). Thus, they present a strong argument that 2-dimensional cell 
cultures may not fully represent their in vivo counterparts (Hawkins et al., 2015).  
3-dimensional constructs are beneficial to clinical application 
So what are these 3-dimensional constructs and what are their benefits to clinical 
application?  Hydrogels are a highly hydrated network of cross-linked polymers with their 
hydrophilic properties facilitating high water content (Frampton et al., 2011). Their protein 
composition self assembles in vitro into a highly fibrous structure that closely 
approximates an in vivo environment (Trappmann & Chen, 2013). They have shown 
themselves to be implantable and mouldable for ease of delivery to various lesion shapes 
(Hejcl et al., 2008; Perale et al., 2008), and show no effect on cell viability (Frampton et 
al., 2011).  Indeed, the specific tuneable properties of hydrogels facilitate a cell’s typical in 
vivo behaviour (Trappmann & Chen, 2013). Development of 3-dimensional constructs 
such as hydrogels, show promise to the combinatorial approach required for successful 
regeneration in SCI. They offer the potential to incorporate therapeutic molecules or 
growth factors, structure to support ingrowing axons, and delivery of cell transplant 
populations to offer trophic support and recovery of a homeostatic environment. 
Collagen as an ideal carrier for cell transplant 
The formulation of carrier for delivery of the therapeutic cell transplant is critical to 
translational application. A hydrogel implant has to be biocompatible and biodegradable, 
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and yet offer a sufficient time scale for tissue formation, for example, to allow ingrowth of 
host axons. A number of polymers, synthetic and natural (biologically-derived) have been 
used for the formulation of hydrogels. Biologically-derived polymers have been classified 
as superior due to their biocompatibility and the existence of these proteins within the 
ECM (Alovskaya et al., 2007); therefore these will be the focus.  
Various formulations of biologically-derived polymers have been used as tissue engineered 
grafts, scaffolds and in vitro models, with hydrogels emerging as a key component for 
clinical application. However, a number of limitations have been reported with the use of 
certain gel formulations.  
Agarose and methylcellulose hydrogels have shown cell growth, nerve guidance and 
successful delivery of neurotrophic factors (Perale et al., 2011 for review). However, their 
major limitation is their lack of bioactivity and biodegradability (Tate et al., 2001; Wells et 
al., 1997). Adhesion of cells is prevented within the negatively charged environment of 
alginate gels. Negatively charged hyaluronan hydrogels do not pose the same problem, 
having been shown to support viability of encapsulated SCs, although the gel formulation 
has impeded their success as an implant (Tian et al., 2005). Chitosan has been linked with 
increasing the inflammatory response of a SCI, as its properties activate macrophages and 
microglia within the lesion site (Crompton et al., 2006). Matrigel™, a commercially 
available hydrogel formulation, does not appear to have the limitations seen with other 
hydrogels. However, tissue loss has been associated with its use, requiring addition of 
MPRED to aid in regeneration of infiltrating axons (Chen et al., 1996). The use of 
MPRED, as discussed above, has serious side effects associated with its use, raising 
concern regarding its use within an implant.  
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Collagen type IV is the major protein and component of the ECM, and is the most prolific 
collagen within the brain. However, it is collagen I – found in more than 90% of the body - 
that is more commonly used in SCI, both for in vitro and in vivo work (Hawkins et al., 
2015; Di Lullo et al., 2002). This preference is mainly due to the structural properties of 
each of the collagen types. Collagen IV is a non-fibrillar protein which forms the basal 
lamina and thus, is found in basement membrane. Following SCI, because of the disruption 
caused to the endothelial cells, it shows increased accumulation at the lesion site 
(Assuncao-Silva et al., 2015; Stitchel et al., 1999). Collagen I is a fibrillary protein and 
therefore, has the properties necessary to form a structural and supportive fibril construct 
for the purposes of a ‘scaffold’ or ‘bridge’ within the lesion site (Han et al., 2010; Kaneko 
et al., 2015; Li et al., 2015; 2016; Nam et al., 2010). For the purposes of the series of 
experiments reported here, unless otherwise stated, it is collagen type I that is referred to.  
Collagen implants used as carriers for neurotrophic or growth factors - ‘functionalised 
scaffolds’ - have been shown to promote neurological recovery and spinal cord 
regeneration. For example, addition of BDNF to a collagen gel implant into a T7-10 crush 
SCI, showed a slower and more extended release rate than BDNF injection alone. 
Moreover, this translated into functional improvement over a 6-week period (Liang et al., 
2010). Similar levels of recovery and regeneration have been reported with addition of 
BDNF and 151IgG, which is an antibody that neutralises epidermal growth factor receptor 
(EGFR). EGFR is a precursor of myelin inhibitory factors and CSPG upregulation, 
therefore targeting EGFR effectively halts these “regeneration inhibitors” (Han et al., 
2010). Implant into a complete thoracic (T7-10) transected spinal cord prevented glial 
scarring and promoted regeneration of neurons and electrical synapse transmission (Han et 
al., 2010).  Moreover, reports of locomotor recovery and regeneration have been reported 
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with implant of unfunctionalised gels, which act as a bridging tissue in thoracic transection 
SCI (Kaneko et al., 2015).  
Collagen I has been used extensively as a 3-dimensional hydrogel in a number of in vitro 
studies with astrocytes (e.g. Al Ahmad et al., 2010; East et al., 2009; 2010; 2012; Hawkins 
et al., 2015; Seyedhassantehrani et al., 2016; Winter et al., 2016). In comparison to other 
formulations, collagen offers a homogeneous, consistent composition (Hawkins et al., 
2015) made up of a porous, fibrillary network that offers structure to encapsulated cells 
(Alovskaya et al., 2007; Macaya & Spector, 2012). These gels possess tuneable 
characteristics, for example, pore size is concentration-dependent, allowing for ingrowth of 
neurites (Willits & Skornia, 2004). Applying tension to the gel can induce alignment of the 
encapsulated cells, with “mechanical elongation” producing longer length “stretch-growth” 
of astrocytic processes cultured on top of collagen gels; both mechanisms facilitating 
guidance for axonal growth (East et al., 2010; Katiyar et al., 2016).   
Collagen gels are biodegradable and yet retain sufficient function within the lesion site for 
ingrowth of sprouting axons. For example, collagen degradation time is approximately 3 - 
4 weeks, yet can be extended up to 6 months with the addition of additives (Kaneko et al., 
2015; Macaya & Spector, 2012). Rodent axonal sprouting within collagen implants has 
been observed as early as 3-4 weeks post implant (Hill et al., 2001; Yoshii et al., 2004), 
proposing these gels as functional implants for the regenerating spinal cord. In the context 
of axonal ingrowth, again collagen has been shown to provide a permissive environment, 
as endogenous proteases released from the tips of neuronal growth cones possess the 
ability to degrade collagen, thus facilitating axonal regeneration through the implant (Seeds 
et al., 1997). Of further importance to the use of these hydrogels as a carrier for astrocytes 
as a cell transplant, collagen type I has been shown to inhibit glial proliferation of the 
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encapsulated astrocytes, and inhibit endogenous astrocyte response in host tissue 
(Eccleston et al., 1989).  
Considering the large body of evidence regarding the regenerative benefits of astrocytes as 
a transplant population in the injured spinal cord, there are relatively few studies utilising 
astrocytes as a cell transplant population within a hydrogel, as an implant into a SCI. One 
such study transplanted neonatal astrocytes encapsulated within a collagen hydrogel, into a 
bilateral transection of the dorsal half of the spinal cord at the thoracic level (T7-9) 
(Joosten et al., 2004). The study reported survival and localisation of the astrocytes to the 
implant, and significantly increased ingrowth of neurofilament positive fibres and cortico-
spinal axons. Of consequence to the beneficial influence of astrocytes, the axonal and fibre 
ingrowth was closely associated with the transplanted cells. Moreover, regeneration within 
the lesion site translated into functional recovery, with modest improvement of locomotor 
recovery and fore-hind limb co-ordination (Joosten et al., 2004). What is interesting is that 
cell tracking was facilitated with fast blue dye and subsequent histological analysis.  
Knowledge gaps 
Taken together, these findings highly promote the benefits conferred by 3-dimensional 
hydrogels to bridging the gap between bench and clinic. However, as this is an emerging 
field, and as astrocytes have until relatively recently been overlooked, there are a number 
of major knowledge gaps. 
1).    While the combination of astrocytes and hydrogels as an implant is still relatively 
unexplored, it is clear that use of a 3-dimensional substrate offers greater knowledge 
applicable to an in vivo environment than cultures grown on 2-dimensional substrates. 
Moreover, the use of a combinatorial approach offers greater promise to SCI than separate 
procedures. Of major consequence to cell transplant is the survival of the cells to be able to 
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offer any regenerative purpose. In this respect, hydrogels may offer the potential for a 
protective cell delivery system as a carrier for cell transplants. This raises a number of 
questions: 
i) How will a 3-dimensional environment affect astrocyte characteristics, 
compared with cultures grown on a 2-dimensional flat substrate? 
ii) How will a collagen hydrogel offer potential as a carrier of a cell transplant, in 
terms of addressing the challenges presented by lack of efficacy in surgical 
technique? 
2).    The tracking of cell transplants utilising MPs as a contrast agent, has proved 
successful with cell suspensions. However, as astrocytes are a highly proliferative neural 
cell, this may present specific challenges. 
i) How will this affect the utility for tracking with this cell when grown within a 
3-dimensional construct?  
ii) Moreover, how will the capacity to track a MP-labelled cell transplant be 
affected when grown within a hydrogel construct?  
In further developing these two main approaches, 1) utilising magnetic particles for 
magnetofection and magnetolabelling of astrocytes, and 2) the delivery of an engineered 
cell transplant within a 3-dimensional construct, the knowledge gaps that have arisen have 
informed the main aims of this research. 
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Chapter 2  
Materials and Methods 
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2.1 Materials 
All tissue culture-grade plastics were from Greiner bio one Ltd (Stonehouse, UK). Media, 
media supplements (including foetal bovine serum [FBS-Ref. 11573397]) and reagents, 
excepting where stated, were from Fisher Scientific (Loughborough, UK) and Sigma-
Aldrich (Dorset, UK).   
Reagents used in the transfection experiments were pmax:GFP plasmid which was from 
Amaxa Biosciences (Cologne, Germany) and prepared using Endofree® Plasmid Maxiprep 
Kit which was from Qiagen (UK). The NeuroMag and NeuroMag Fluo particles used for 
transfection were obtained from Oz Biosciences (Marseilles, France).  The magnetic 
particles used for cell labelling experiments were prepared by the Boris Polyak Laboratory, 
Drexel University, Philadelphia using published procedures (MacDonald et al., 2012).   
For immunocytochemistry, the primary antibody used was polyclonal rabbit anti-glial 
fibrillary acidic protein (GFAP; Z0334), which was from DakoCytomation (Ely, UK). The 
secondary antibodies, fluorescein isothiocyanate (FITC) and Cy3-conjugated AffiniPure 
donkey anti-rabbit, IgG, were both sourced from Jackson Laboratories (Pennsylvania, 
USA). Normal donkey serum was from Stratech Scientific (Suffolk, UK) and Vectashield 
mounting medium containing DAPI (4',6-diamidino-2-phenylindole) was from Vector 
Laboratories (Peterborough, UK).   
For the 3-dimensional collagen hydrogel experiments collagen type I, rat tail, high 
concentrate (H/C; Corning - No. 354249; 100 mg) was sourced from VWR (Lutterworth, 
UK).  Agarose type VII: low gelling temperature (A4018), was from Sigma-Aldrich 
(Dorset, UK). Hoechst 33342 (used as a nuclear counterstain as it emits blue fluorescence 
when bound to double stranded DNA) was from ThermoFisher Scientific (Loughborough, 
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UK).  The CELLview™ glass bottom dish (No. 627 899) was from Grenier bio-one 
(Stonehouse, UK). 
Reagents for safety assays were CellTiter 96 Aqueous One Solution Reagent MTS [3-(4,5-
Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, 
inner salt] assay from Promega UK (Southampton, UK) and Click-iT® Plus EdU Alexa 
Fluor® 488 Flow Cytometry Assay Kit from Life Technologies (Paisley, Scotland, UK).  
For the live-dead studies propidium iodide (penetrates compromised membranes of dead 
cells) was from Fisher Scientific (Loughborough, UK) and calcein AM [fluoresces when 
metabolised in live cells (80011-10)] was sourced from VWR (Lutterworth, UK). 
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2.2 Preparation of mixed glial culture and isolation of cortical astrocytes 
The care and use of animals used in the production of cell cultures was in accordance with 
the Animals (Scientific Procedures) Act of 1986 (UK), and with approval by the local 
ethics committee. 
2.2.1 Preparation of mixed glial culture 
Mixed glial cultures [microglia; OPCs; astrocytes] were derived from disaggregated cortex 
of Sprague-Dawley rat pups (postnatal day 1-3) with dissection procedure conducted 
following established protocols (Cole & de Vellis, 2001).  Cell suspension was diluted with 
D10 medium  (Dulbecco’s modified Eagle’s medium plus 2 mM glutaMAX-I, 1 mM 
sodium pyruvate, 50 U/mL penicillin, 50 µg/mL streptomycin, and 10% FBS) and 
routinely seeded at a cell density of ≻ 0.75 x 106 viable cells/mL into poly-D-lysine [PDL 
(10 µg/mL working solution – 7.5 mL/flask]-coated T75 flasks.  Cultures were maintained 
in D10 medium with a 100% D10 medium change at 24 h, and a 50% D10 refresh every 2-
3 days.  All cultures were incubated at 37° C in 5% CO2/95% humidified air 
2.2.2 Isolation of astrocytes from mixed glial culture  
At day 7-8, sequential shaking of the culture flasks facilitated the isolation of a high purity 
astrocyte culture for sub-culturing.  Briefly, the flasks were shaken for 2 h and the medium 
(containing largely microglia and OPCs) discarded. The flasks were then rinsed with 
phosphate buffered saline (PBS), then fresh D10 medium (10 mL) was added before being 
incubated at 37° C (5% CO2/95% humidified air) for 2 h to re-gas (restore physiological 
pH and a 5% CO2 flask headspace). To remove all OPCs and microglia, this step was 
repeated sequentially over the following 2-3 days, with the flasks shaken for 22 h each day 
followed by a 100% medium change and 2 h to re-gas.  Visualisation of ≤ 10 OPCs per 
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microscopic field (100 x magnification) was considered indicative of sufficient astrocyte 
purity for subculturing. 
2.2.3 Sub-culturing of astrocytes 
Following the sequential shakes, the astrocyte monolayer was washed with PBS to remove 
traces of medium, as FBS inhibits trypsin.  TrypLETM (a dissociation reagent; 2.5 
mL/flask) was added to the cell culture and the flask placed on an orbital shaker for ca. 5 
min @ 100 rpm. Dissociated cells were centrifuged (1000 rpm; 4 min) and cell counts 
were performed by mixing 10 µl of cell suspension with 10 µl of 0.4% trypan blue (an 
exclusion dye that selectively stains dead cells blue), and adding 10 µl of the cell mixture 
into one chamber of the haemocytometer.  Viable cells appeared bright and round.  Cells 
were seeded at 1-2 x 105 cells/mL D10 in PDL-coated T75 flasks.  Since OPCs adhere 
more slowly and less avidly than astrocytes, a 100% medium change performed ca. 1 h 
post-seeding helped to further reduce any OPC contamination.  
Subsequent passages of the astrocyte flasks were conducted while cultures were 
subconfluent (ca. 2-3 d post-plating), up to a maximum of two passages per culture. For all 
2-dimensional monolayer experiments cells were seeded at 2.7 x 105/mL D10 either on 
PDL-coated coverslips in a 24-well plate (0.3 mL/well), directly on a PDL-coated 6-well 
plate (0.9 mL/well) or on a PDL-coated 96-well plate (0.07 mL/well) for use in MTS 
assays.  
In preparation for hydrogel studies, cells were seeded at 2.7 x 105/mL D10 either directly 
on a PDL-coated 6-well plate (0.9 mL/well) or in PDL-coated T175 flasks (20 mL/flask). 
Cultures were maintained in D10 medium (incubated at 37° C in 5% CO2/95% humidified 
air) with a 50% medium refresh every 2-3 days. 
 64 
2.3 Oscillating magnetic array for MP-labelling of and MNP-mediated gene 
transfer to astrocyte monolayers 
All magnetofection protocols were conducted using the magnefect-nano oscillating 
magnetic array device (nanoTherics Ltd., Stoke-on-Trent, UK).  The device utilises high 
gradient neodymium iron boron (NdFeB) magnets with lateral oscillation capability having 
both programmable frequency (F = 1 – 4 Hz) and amplitude (100 – 1000 µm), with a field 
strength at the magnet face of 421 ± 20 mT (24-magnet array) and 303 ± 5 mT (96-magnet 
array) (Pickard & Chari, 2010).  The interchangeable 24-well and 96-well magnetic arrays 
facilitated the use of different size culture plates but having similar experimental 
configurations. (Figure 2.1) 
Unless otherwise stated, each experiment utilising magnetofection consisted of three 
conditions; no magnetic field (NF), static magnetic field (F0) or oscillating magnetic field 
with specific frequency and amplitude of displacement.  Within the experiments, the cells 
were subjected to 30 min application of either the static or the oscillating magnetic field. 
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Figure 2.1: Schematic diagram of magnefect-nano oscillating magnetic array device 
(NanoTherics, UK) The magnefect-nano oscillating magnetic array device utilises static 
or oscillating magnetic fields with a programmable combination of frequency and 
amplitude. Interchangeable arrays of 24 and 96 magnets enabled similar experimental 
configurations to be used for both 24- and 96-well plates.  Frequency and amplitude used 
in transfection experiments was F0 or F1 Hz and 100-1000 µm, with F0 or F1 Hz and 200 
µm amplitude used for the labelling experiments. 
  
NanoTherics Oscillating Magnetic Plate 
F0; F1 Hz – 100 – 1000 µm – 30 min 
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2.4 MP – labelling (magnetolabelling) of astrocyte monolayers 
2.4.1 Particle characterisation 
Four types of magnetic particles (MPs) of differing magnetite content were used for uptake 
experiments and were evaluated for their labelling efficiency (percentage of cells labelled) 
and extent of accumulation in astrocytes. All four types were prepared using published 
procedures by the Boris Polyak Laboratory, Drexel University, Philadelphia, (MacDonald 
et al., 2012) with extensive characterisation having been undertaken previously (Adams et 
al.,  2015; Johnson et al., 2010; MacDonald et al., 2012).   
The superparamagnetic MPs were composed of a matrix of magnetite, poly (lactic acid; 
PLA) and poly (vinyl alcohol; PVA) with a BODIPY® 564/570 fluorophore-PLA coating.  
Differences in magnetite loading in the three types of magnetite-loaded particles resulted in 
MPs with magnetite weight percent ratios of 1:3:7, from which the nomenclature MP-1x; 
MP-3x and MP-5x originated and to which they are hereinafter referred. This increase in 
magnetite loading altered their magnetic responsiveness and weight but not their size 
(hydrodynamic diameter range of 262-278 nm), their shape (as imaged under transmission 
electron microscopy [TEM]; see Figure 2.2) or their surface charge (-8.98 to -14.4 mV).  A 
non-magnetic control particle with no magnetite (having the nomenclature MP-0x) was 
also synthesised, its size, shape and surface charge similar to the magnetite-loaded particles 
(Table 2.1). Use of fourier transform infrared spectroscopy (FTIR) has previously 
confirmed the overall similarities in composition of these particles, irrespective of their 
differing magnetite loading (Adams et al., 2015). 
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Figure 2.2 Transmission electron micrographs of the MP-0x – MP-5x particles All 
four particles can be clearly visualised under TEM with the differing magnetite content of 
each particle (Non-Mag; MP-0x; MP-1x; MP-3x and MP-5x) a defining characteristic. 
Note also the similarity in shape and size of all four particles. Images courtesy of Boris 
Polyak Laboratory and adapted from Johnson et al., 2010 
 
The superparamagnetic nature of the particles allows for magnetic responsiveness only 
when particles are exposed to a magnetic field gradient. Therefore use of these particles in 
combination with the deployment of a magnetic field gradient (e.g. permanent NdFeB 
magnets used throughout this series of studies)  beneath the culture plate attracts the 
particles down to the cell monolayer, while the application of an oscillating field/gradient 
may cause particles to (i) move laterally with the movement of the magnets, enhancing the 
likelihood of contact with cells, and/or (ii) vibrate in situ when attached to cell membrane, 
potentially stimulating endocytotic mechanisms and enhancing cellular MP  uptake (Adams 
et al., 2013; Fouriki et al., 2010; McBain et al., 2008; Pickard et al., 2011).  
All MPs were stored at 4° C in a lyophilised state and re-suspended in 100 µl of sterile 
deionised water as required.  Once re-suspended, the MPs were kept at 4° C and protected 
from light until use.  For experiments, 1 µl of MPs per mL of D10 was used, a 
concentration that corresponded to 13 µg/mL dry weight for MP-0x, 15 µg/mL for MP-1x, 
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19 µg/mL for MP-3x and 26.5 µg/mL dry weight for MP-5x; each corresponding to an 
identical number of particles per mL (Adams et al., 2015).  
 
 
Table 2.1 Physical characterisation of magnetic particles Magnetic particles of differing 
magnetite content were used for all uptake experiments, and evaluated for their labelling 
efficiency, and extent of accumulation in astrocytes. There was little difference in physical 
characteristics between the particles. The increase in magnetite loading altered their 
magnetic responsiveness but not their size, shape or surface charge (data taken from 
Adams et al., 2015; MacDonald et al., 2012) 
 
2.4.2 Magnetolabelling of astrocytes utilising the magnefect-nano oscillating magnetic 
array device 
At 24-48 h post-plating (allowing for cell adherence and growth of processes), the MPs 
were added to the cells; diluted per weight ratio (see 2.4.1) in fresh D10 (1 µL/mL D10) in 
a final volume of 0.3 mL/well for 24-well plates. Following particle addition, the plates 
were immediately placed on the magnefect-nano device (see 2.3) for 30 minutes using 
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either a static magnetic field (F0) or an oscillating magnetic field having a frequency of F1 
Hz and an amplitude of 200 µm (F1; 200 µm).  The cells under the NF condition were 
incubated in the absence of a magnetic field. All magnetolabelling was carried out at 37° C 
in the 5% CO2/95% humidified air incubator. After 30 minutes, the cell plates were 
removed from the device and incubated at 37° C (5% CO2/95% humidified air). Controls 
consisted of unlabelled cells (no particles) which were subjected to the same 
magnetofection protocols. For all magnetolabelling experiments, at 24 h post-particle 
addition the cells were rinsed once with PBS to remove any extracellular particles and 
subsequently maintained in D10 medium, incubated at 37° C.  For long term experiments 
(21 days) cells were maintained in D10 medium with a 50% refresh every 2-3 days 
(incubated at 37° C).  
2.4.3 Magnetolabelling of astrocytes as monolayers in preparation for use in hydrogel 
constructs 
In preparation for the hydrogel experiments, as detailed above monolayer cultures were 
grown in T175 flasks (see 2.2.3).  MP-5x labelling of these cell monolayers was carried out 
24 -48 h post-plating with MP-5x particles added to the cells in fresh D10 (1 µl/mL D10) 
in a final volume of 20 mL/flask.  The cells were exposed to a static magnetic field (F0) for 
30 minutes.  As with well plates, controls consisted of unlabelled cells (no particles) and 
were subject to the same magnetofection protocol.  Following 24 h post-particle addition, 
cells were rinsed once with PBS to remove any particles not internalised by the cells.  
Control and MP-labelled cells were then enzymatically detached and used for hydrogel 
experiments.  
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2.5 Processing of astrocyte monolayers 
2.5.1 Particle inheritance by daughter cells of dividing astrocytes 
Particle inheritance by daughter cells of dividing labelled astrocytes was assessed using 
dynamic time-lapse microscopy. Time-lapse images were captured over at least 48 h.  
Cells were incubated at 37° C in D10 medium with 5% CO2.   
2.5.2 EdU as a measure of proliferation in cell monolayers 
A Click-iT® EdU (5-ethynyl-2´-deoxyuridine) cell proliferation assay was used as a 
measure of proliferation. Briefly, 10 µM EdU in a final volume of 0.3 mL D10 was added 
over the coverslip followed by incubation at 37° C for 18 h.  This incubation time was 
determined by the cell growth rate for astrocytes which is acknowledged to be between 14 
– 24 h (Pedram et al, 1998). The cells were then fixed in 4% PFA for 30 min at RT, 
followed by 2 washes with 3% bovine serum albumen (BSA).  Incubation for 20 min in 
0.3% Triton-X 100 in PBS (0.5 mL) permeabilised the cells facilitating access to the 
internalised cell DNA.  Following permeabilisation, the cells were washed twice in 3% 
BSA and the reagent cocktail for EdU detection was distributed over the cells (0.3 mL final 
volume/well; see Appendix 1).  Following incubation at RT for 30 min (protected from 
light), the cells were washed twice with 3% BSA.  In preparation for imaging and analysis, 
the coverslips were mounted on slides using mounting medium containing DAPI, with the 
coverslips sealed with nail varnish to prevent dehydration. Imaging took place 
immediately. 
2.5.3 Termination of monolayer experiments 
To terminate the monolayer experiments, at the indicated time (4 – 48 h post-particle 
addition for short-term experiments; 21 days for long-term), cells were rinsed twice with 
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PBS before being fixed with 4% PFA for 30 min at RT.  Following fixation cells were 
washed three times with PBS to remove fixative, and stored at 4° C prior to 
immunolabelling.  
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2.6 MNP-mediated gene transfer (magnetofection) to astrocyte 
monolayers 
2.6.1 Particle characterisation 
NeuroMag and NeuroMag Fluo transfection-grade magnetic particles are patented by Oz 
Biosciences and have a proprietary formulation involving iron oxide and polyethylenimine. 
Our laboratory has characterised the physicochemical properties of these particles. Briefly, 
the positively-charged (ζ-potential +40.3 mV) particles range in size from 140-200 nm 
with an average size of  160 nm for NeuroMag (Pickard & Chari, 2010) and 200 nm for 
NeuroMag Fluo (Fernandes & Chari, 2014).  The positive charge facilitates binding of 
nucleic acids, allowing the particles to serve as transfection vectors. NeuroMag-based 
protocols have resulted in high transfection efficiencies (ca. 60%) in astrocytes (Pickard & 
Chari, 2010), demonstrating their suitability for use here. Both NeuroMag and NeuroMag 
Fluo are biodegradable within cells over 96 h. NeuroMag Fluo are NeuroMag particles 
with a tetramethylrhodamine-conjugate that can be visualised under fluorescence 
microscopy (excitation peak 555 nm; emission maximum 580 nm); the covalent coupling 
of this label to the particles ensuring non-disruption during cellular internalisation (OZ 
BIOSCIENCES: Pers. Comm.).  These fluorophore-labelled particles were used to study 
the co-localisation of MP-labelling with transgene expression. 
2.6.2 Plasmid characteristics 
To assess transfection efficiency a plasmid encoding a reporter transgene was used 
(pmaxGFP; 3486bp; Figure 2.3) which encodes green fluorescent protein (gfp). Large scale 
plasmid DNA preparations (Maxipreps) were generated using the Endofree® Plasmid 
Maxiprep Kit following the manufacturer’s instructions.  Briefly, pmaxGFP transformed 
bacteria were cultured overnight at 37° C on agar containing Kanamycin (50 mg/mL). The 
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following day colonies were transferred to LB broth and incubated overnight (37° C, 180-
200 rpm on an orbital shaker) to prepare precultures. Minipreps were carried out in order to 
verify the presence of the pmaxGFP plasmid prior to carrying out maxipreps. For 
minipreps, the following protocol was used in accordance with Qiagen Qiaprep® Miniprep 
kit.  1 mL of the bacterial precultures was transferred into eppendorfs and centrifuged for 5 
min (1000 rpm).  The supernatant was removed and 250 µL of P1 added to the pellet 
followed by 250 µL of P2, the eppendorf gently inverted to mix the two solutions. 
Addition of Buffer N3 was followed by centrifugation for 10 min (13000 rpm). The 
resulting supernatant was poured into a filter column tube and centrifuged for 30-60 s. The 
supernatant in the tube was discarded and Buffer PB (0.5 mL) added on top of the filter 
and the contents centrifuged for 1 min (13000 rpm). The supernatant was again discarded 
and Buffer solution PE (750 µL) added and centrifuged for ca. 1 min. The column was 
then emptied and re-centrifuged to remove all traces of ethanol. The column containing the 
DNA was transferred to a fresh eppendorf and 50 µL of EB Buffer added to the centre of 
the filter and incubated at RT for ca. 1 min and then centrifuged for 1 min (12-13000 rpm) 
to retrieve the maximum yield of DNA. For Maxipreps, the remaining preculture was used 
to inoculate 400 mL of LB broth (containing Kanamycin) 
For Maxipreps, a similar protocol to minipreps was carried out. For resuspension and lysis 
of the bacterial pellet, Buffers P1 and P2 were added respectively. For neutralisation the 
lysis reaction Buffer P3 was added. This mixture was filtered to obtain a clear lysate to 
which Buffer ER (endotoxin removal) was added and incubated for 30 min. This mix was 
then added to a DNA purification column, washed (Buffer Q3) and eluted (Buffer QN). 
DNA was precipitated with the addition of isopropanol, the resulting DNA pellet washed 
with 70% ethanol and dissolved in Buffer TE.  This yielded high quality plasmid DNA 
without contaminating endotoxins from the E.coli host.  
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(P1; P2; Buffer N3; Buffer PB; Buffer PE; EB Buffer referred to above are all proprietary 
components of the Qiaprep® Miniprep Kit.   P1; P2; P3; ER; Q3; QN; TE referred to 
above are all proprietary components of the Endofree® Plasmid Maxiprep Kit) 
 
 
Figure 2.3 pmaxGFP plasmid map pmaxGFP plasmid encodes for green fluorescent 
protein (GFP) facilitating the scoring of transfected cells using fluorescence microscopy. 
Plasmid map image adapted from amaxa Nucleofactor® technology literature. 
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2.6.3 MNP-mediated gene transfer to astrocytes using the magnefect-nano oscillating 
magnetic array device 
The transfection protocol was performed in 24- and 96-well plates at 24-48 h post-plating 
to allow for cell adherence and growth of processes. In the use of lipofection for gene 
transfer, adverse effects on transfection efficiency were reported with the use of antibiotics 
in the medium (Asgharian et al., 2014), therefore 1 h prior to particle addition, all wells 
were refreshed with antibiotic-free D10 (24 well, 0.225 mL; 96 well, 0.054 mL).  
For each well of the 24-well plate, 60 ng of pmaxGFP plasmid was mixed with 0.21  µL 
NeuroMag or NeuroMag Fluo in a final volume of 75 µL DMEM, and for each well of the 
96-well plate, 12 ng of pmaxGFP was mixed with 0.042 µL NeuroMag or NeuroMag Fluo 
in a final volume of 15 µL DMEM. The plasmid:particle solution was triturated gently to 
mix and allowed to complex for 20 min. The complexes were then gently added dropwise 
to the cells while gently moving the plate in a circular manner to help disperse the complex 
over the cell monolayer. DMEM alone or DMEM plus plasmid were added to the control 
wells.  The plate was then placed on the magnefect-nano device (see 2.3) with 
cells:particles and controls exposed to an oscillating magnetic field (F = 1 Hz; at a 100 – 
1000 µm amplitude of displacement) for 30 min.  All magnetofection was conducted at 37° 
C within the 5% CO2/95% humidified air incubator. As the term suggests, plates 
containing cells under the no magnetic field (NF) condition were incubated in the absence 
of a magnetic field.  
After removal from the magnefect-nano device, the cells were incubated without a 
magnetic field for 30 min followed by a 100% medium change of antibiotic-free D10 to 
remove any extracellular particles.  The cells under the NF condition also received a 100% 
antibiotic-free medium change at this time point. All cells were incubated for a further 47 h 
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(48 h in total), as previous studies have bracketed this time point at which gfp expression is 
maximal in 2-dimensional cell monolayers (Guo et al., 1996; Pickard & Chari, 2010; 
Rubio et al., 2004).   
At 48 h, the cells in the 24-well plate were rinsed twice with PBS before fixing with 4% 
paraformaldehyde (PFA) for 30 min incubation at RT. Following fixation the cells were 
washed three times to remove any residual fixative and stored at 4 °C prior to 
immunolabelling. In contrast, the cells in the 96-well plate were immediately subjected to 
an MTS assay.  
Controls for the experimental plate and the MTS assay consisted of cells only and 
cells+plasmid, with further controls for the MTS assay consisting of blanks (no cells) 
containing medium; medium+plasmid; medium+plasmid+MNPs.  A key point to note here 
is that cells+MNPs and medium+MNPs were not classed as viable controls as 
unfunctionalised MNPs (without plasmid) are considerably smaller and have a 
substantially different charge to that of a functionalised MNP (in this case, 
NeuroMag+plasmid).  As unfunctionalised MNPs would not be used to engineer cells it 
was more pertinent to measure any potential toxicity of functionalised NeuroMag.   
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2.7  Collagen I hydrogel experiments 
Collagen I hydrogels were used as a substrate for 2-dimensional monolayer surface seeding 
and for 3-dimensional internal seeding of astrocytes (hereinafter referred to as 
‘supraconstruct’ and ‘intraconstruct’ hydrogels respectively).  Hydrogels were assembled 
using a published protocol (Phillips & Brown, 2011) producing a collagen substrate with a 
multi-layered and porous fibrillary collagen network (Figure 2.4).  
Supraconstruct – astrocytes seeded as monolayers on top of a collagen I hydrogel  
Intraconstruct – astrocytes seeded within a collagen I hydrogel 
 
 
Figure 2.4 Structural composition of collagen I hydrogel substrate Scanning electron 
micrographs show the structural composition of the hydrogels. Note the multi-layered 
construction of the gels (a; arrow) and the open fibrillary network (a & b; arrow head).  
Scale of images (a = 74.4 µm); (b = 7.5 µm) 
  
a b 
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2.7.1 Preparation of a Collagen I hydrogel for use in supraconstruct experiments. 
All preparation of hydrogels was conducted under aseptic conditions, keeping all 
components at 4° C until ready for use.  Collagen I, rat tail, high concentrate was used to 
assemble the hydrogels, diluted in 0.6% acetic acid to a 2 mg/mL concentration for use in 
both supra- and intraconstruct hydrogel experiments.  Each hydrogel had a final volume of 
0.5 mL.  The composition of the assembled hydrogel was 80% 2 mg/mL Collagen I; 10% 
Modified Eagle’s Medium (MEM) Alpha (10x) and 10% D10 medium for supraconstruct 
hydrogels; the latter constituent replaced with 10% cell suspension (at 1 x 106 cells/gel) in 
D10 for intraconstruct hydrogels. For both types of gel, prior to addition of D10 or cell 
suspension in D10, sodium hydroxide (NaOH; 1x) was used to obtain neutral pH.  
In preparation to forming supraconstruct hydrogels, coverslips were placed into the 24-well 
plates and kept hydrated in D10 which was aspirated off just prior to dispensing the 
hydrogel solution. Placement of coverslips in the well was to ensure the correct orientation 
of the hydrogels when removing them for imaging purposes.  The following technical 
procedures were adhered to during formation of the supraconstruct hydrogels - the 
hydrogel solution and the D10 were prepared in separate 50 mL falcon tubes to permit 
gentle addition of the different components, with a 10 mL pipette used when dispensing 
the hydrogel solution into the well plate to prevent shearing of the collagen fibres or 
addition of bubbles to the viscous collagen solution.  
The hydrogel solution was prepared by adding the MEM Alpha to the collagen, gently 
swirling the tube to mix.  To bring the solution to neutral pH, NaOH was added in a 
dropwise manner while gently swirling the tube, until the hydrogel solution turned red, the 
colour change indicating neutral pH.  This colour change is due to the phenol red contained 
within the MEM Alpha. Upon neutral pH, the hydrogel solution was immediately added to 
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the D10, again gently swirling to mix.  To form the hydrogel, a 10 mL pipette was used to 
dispense 0.5 mL of the hydrogel solution into each well of a 24- well plate (0.5 mL/gel).  
The hydrogels were incubated at RT for 15 min before incubating at 37° C (5% CO2/95% 
humidified air).  This 15 min step allowed for a gradual increase in temperature facilitating 
the setting process. After 1 h D10 medium was gently added over the top of the hydrogels 
to keep them hydrated (Figure 2.5). 
 
 
Figure 2.5 Schematic of Collagen I hydrogel construct MEM Alpha (10x) is added to 
the (a) 2 mg/mL Collagen I in a 50 mL falcon tube and the two liquids swirled gently to 
mix. Dropwise addition of (b) sodium hydroxide brings the hydrogel solution to neutral pH 
indicated by a colour change of the solution to red. Using a 10 mL pipette (c), the hydrogel 
solution is added gently to D10 medium before (d) dispensing 0.5 mL hydrogel solution per 
gel/well in a 24-well plate.  After 1 h incubation, D10 medium is added gently over the top 
of the hydrogel to prevent dehydration.  
  
 80 
2.7.2 Supraconstruct hydrogels with MP-labelled astrocytes 
After further 2 h incubation, cell monolayers at 2.7 x 105 cells/mL were seeded on top of 
the hydrogel, following one of two labelling approaches (Figure 2.6). 
 
 
Figure 2.6 Schematic outlining the two approaches used in MP-5x labelling of 
supraconstruct hydrogels Following (a) formation, astrocytes were seeded as a 
monolayer to form a supraconstruct hydrogel.  Cells were either (b) pre- labelled with 
MP-5x particles as a monolayer culture before (c) seeding onto the formed hydrogel, or 
(d) unlabelled (no particles) cells from monolayer cultures were (e) seeded onto the 
hydrogel, and after 24 h (f) were labelled ‘in-situ’ with MP-5x particles following the same 
protocol as for cell monolayers on coverslips.  
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One approach was to pre-label the cells with MP-5x particles as a monolayer culture (see 
2.4.2), enzymatically detach and seed these pre-labelled cells on top of the gel, forming an 
‘pre-labelled’ supraconstruct hydrogel. The second approach was to seed cells as a 
monolayer on top of the gel and, following 24 h to allow cell growth and adherence, label 
the cells with MP-5x particles in-situ, using a static magnetic field to draw the particles 
down to the cell monolayer, forming an ‘in-situ labelled’ supraconstruct hydrogel. In-situ 
labelling followed the same protocol as for cell monolayers on coverslips, as detailed 
above (see 2.4.2)  
Supraconstruct hydrogels were maintained in D10 medium, incubated at 37° C (5% 
CO2/95% humidified air), with a 50% D10 refresh every 2 days.  Samples were subject to 
different processes as detailed below (see 2.8.1). 
2.7.3 Preparation of a Collagen I hydrogel for use in intraconstruct experiments  
The hydrogel assembly for the intraconstruct hydrogels used the same protocol and the 
same concentration as used previously (see 2.7.1) with the 10% D10 medium replaced with 
10% cell suspension in D10 at 1 x 106 cells per hydrogel. Final volume of the assembled 
hydrogel was 0.5 mL as detailed previously (see 2.7.1). 
2.7.4 Intraconstruct hydrogels with MP-labelled astrocytes 
In addition to intraconstruct seeding of gels with unlabelled (no particles) cells, particle 
labelling of cells associated with an intraconstruct hydrogel required two different 
protocols; exogenous particle-labelling and in-situ particle labelling, both of which are 
detailed further within each experimental chapter.  Briefly, exogenous particle-labelling 
refers to cells pre-labelled (MP-5x) as monolayers in T175 flasks. These exogenously 
labelled cells were added as cell suspension when forming an intraconstruct hydrogel, as 
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detailed above (see 2.7.1; 2.7.3). In-situ particle labelling refers to addition of magnetic 
particles (MP-5x) to the cell suspension prior to association with the hydrogel solution.  In-
situ labelling allowed observation of endocytotic activity in intraconstruct hydrogels, i.e. 
intracellular particle uptake and trafficking. 
Following assembly of the intraconstruct hydrogels, incubation was carried out in two 
steps as for the supraconstruct gels as detailed above (see 2.7.1).  After 1 h post-construct,  
D10 (0.5 mL) was gently added over the hydrogels with a 100% refresh at 30 min intervals 
over 90 min to replenish protein/nutrients taken up by the internalised cells.  Following 3 h 
incubation, the hydrogels were transferred from a 24-well plate to a 12-well plate (detailed 
further within the experimental chapter), and maintained in D10 at 37° C (5% CO2/95% 
humidified air) with a 50% D10 refresh every 2 days.  Samples were subject to different 
processes as detailed below (see 2.8.2). 
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2.8 Processing of hydrogels 
At termination of the experiments hydrogels were fixed at different time points as 
indicated by the separate experiments. Unless otherwise stated, all hydrogels were rinsed 
briefly in PBS and fixed with 4% PFA for 3 h at RT, followed by three PBS washes (5 
min/wash) before being stored at 4° C prior to immunolabelling and imaging for analysis. 
2.8.1 Analysis of supraconstruct hydrogels 
Particle uptake  
For the particle uptake experiments, sample gels were fixed at different time point’s post-
particle addition (24 h – 14 DIV).  
Particle inheritance in daughter cells of dividing astrocytes 
Particle inheritance in supraconstruct hydrogels was assessed from dynamic time-lapse 
images as detailed above (see 2.5.1). 
Ultrastructural membrane features associated with endocytotic activity 
To investigate ultrastructural membrane features associated with endocytotic activity, MP-
5x particles were added to supraconstruct hydrogels following the same protocol as for cell 
monolayers (see 2.4.2) and fixed in glutaraldehyde at 24 h post-particle addition. To fully 
dehydrate the hydrogels for visualisation in a field emission scanning electron microscope 
(FESEM) they were prepared using the Osmium-Thiocarbohydrazide  step-wise procedure 
with the samples further dehydrated in a critical point dryer (detailed further within the 
experimental chapter). Following critical point drying, the samples were mounted onto 
carbon pads on aluminium stubs, with the sample edges sealed with silver conducting paint 
(Agar Scientific) to improve electron conductivity.  
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2.8.2 Analysis of intraconstruct hydrogels 
Particle uptake  
For the particle uptake experiments, sample gels were fixed at different time point’s post-
particle addition (24 h – 37 DIV).  
Intracellular features and endocytotic activity associated with particle uptake 
To investigate intracellular features and endocytotic activity associated with particle uptake 
in intraconstruct hydrogels, MPs were added to the astrocytes ‘in-situ’ (see 2.7.4).  At 15 
days the hydrogels were glutaraldehyde fixed and prepared for transmission electron 
microscopy (TEM). In brief, following glutaraldehyde fix and first Osmium step and 
washes, the hydrogels were taken through a series of dehydration steps and embedded in 
Spurr resin (detailed further within the experimental chapter).  Ultrathin sections (100 nm) 
of the resin-embedded hydrogel were cut using a Reichert Ultracut E Microtome with the 
sections collected on 200-mesh thin bar grids. The grids were stored in a grid box prior to 
imaging.    
MP-5x particles as a contrast agent  
To investigate the potential of the MP-5x particles as a contrast agent under magnetic 
resonance imaging (MRI), astrocytes were exogenously pre-labelled with MP-5x particles 
and at 24 h post-particle addition, were added to collagen solution to form an intraconstruct 
hydrogel.  Sample intraconstruct hydrogels were fixed with 4% PFA (see 2.8) following 24 
h, 14 days and 37 days incubation and were prepared for MRI imaging (detailed further 
within the experimental chapter). Controls, which were fixed at the same time points, 
consisted of intraconstruct hydrogels containing unlabelled cells (no particles). 
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EdU as a measure of proliferation  
Sample intraconstruct hydrogels were processed for EdU labelling at indicated time points 
(24 h; 7 DIV; 14 DIV) using a Click-iT® EdU (5-ethynyl-2´-deoxyuridine) cell 
proliferation assay as a measure of proliferative capacity of intraconstruct hydrogels over 
time.  Briefly, the same protocol was followed as detailed above (see 2.5.2) with increases 
to volumes and incubation timings (East et al., 2009).  Specifically, 10 µM of EdU in a 
final volume of 1 mL D10 was added over the hydrogel followed by incubation at 37° C 
for 18 h.  The hydrogels were then fixed in 4% PFA for 3 h at RT, followed by 4 washes 
with 3% bovine serum albumen (BSA).  To permeabilise the hydrogel, the concentration of 
Triton-X 100 was increased to 0.5% Triton-X 100 in PBS and the hydrogels incubated for 
40 min at RT.  Permeabilisation was followed by four washes in 3% BSA prior to the 
reagent cocktail being distributed over the hydrogel (1 mL/gel; see Appendix 1). The 
hydrogels were then incubated for 1 h, protected from light, at RT followed by 2 washes in 
3% BSA.  Nuclei were counterstained with Hoechst 33342 as detailed below (see 2.9.2) 
and imaged immediately.  
Viability  
To assess cellular viability, sample hydrogels (control and exogenous MP-labelled) were 
subjected to a live/dead assay at defined time points (24 h; 7 DIV; 14 DIV).  Hydrogels 
were incubated in a mixed solution of propidium iodide (5 µM), calcein (4 µM) and 
Hoechst 33342 (5 µg) in a final volume of 2 mL D10 medium per gel/well. Following 30 
min incubation at 37° C (5% CO2/95% humidified air), the hydrogels were fixed with 4% 
PFA for 3 h at RT, followed by 3 PBS washes and imaging for analysis. 
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2.9. Immunocytochemistry 
2.9.1 Immunolabelling of cells seeded as monolayers  
Following fixation and PBS washes, cell monolayers on coverslips were immunolabelled 
in preparation for imaging.  The blocking solution used throughout was 5% normal donkey 
serum (NDS) diluted in 0.3% Triton-X 100 in PBS.  The primary antibody (diluted in 
blocker solution) was polyclonal rabbit anti-GFAP (1:500), with the secondary antibody 
(diluted in blocker solution) being FITC- or Cy3-labelled donkey anti-rabbit IgG (1:200).  
The cells were blocked for 30 min at RT (0.2 mL/well), after which the primary antibody 
was added (0.2 mL/well) and the cells incubated overnight at 4° C.  Following overnight 
incubation the cells were washed twice in PBS at RT for 15 min per wash before being 
incubated in blocker solution (0.2 mL/well) for 30 min at RT. The secondary antibody was 
then added (0.2 mL/well) and the cells incubated, protected from light, at RT. Following 2-
3 h incubation, the cells were washed three times with PBS for 5 min per wash. Cells on 
coverslips were mounted on slides in mounting medium containing DAPI, and the 
coverslips were sealed with nail varnish prior to fluorescence microscopy. 
2.9.2 Immunolabelling of supraconstruct hydrogels 
Supraconstruct hydrogels were subject to the same immunolabelling protocol as detailed 
above for cell monolayers (see 2.9.1), with some alterations to the protocol. Namely, the 
volume of blocking solution, primary and secondary antibodies was increased to 0.5 
mL/gel.  Following immunolabelling, nuclei were counterstained with Hoechst 33342 
rather than DAPI mounting medium. Hydrogels were incubated in Hoechst 33342 at a 
concentration of 5 µg/mL PBS (0.5 mL/well) for 30 min at RT, protected from light, 
followed by three 5 min PBS washes (1 mL/well).  For imaging purposes, the hydrogel 
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was gently transferred from the coverslip to a glass slide ensuring that the correct 
orientation of the gel was maintained. The hydrogel was then imaged under an inverted 
fluorescence microscope. 
2.9.3 Immunolabelling of intraconstruct hydrogels 
For protein detection and labelling of cellular architecture in intraconstruct hydrogels the 
primary and secondary antibodies used, and their respective dilutions, were the same as 
those used for cell monolayers and supraconstruct hydrogels as detailed above (see 2.9.1), 
with some alterations to the protocol.  Specifically, all incubation times were doubled.  
Also, to facilitate permeabilisation of the hydrogel, the 5% NDS blocker solution was 
diluted in 0.5% Triton-X 100 in PBS; these alterations to the standard protocol were based 
on published procedures for immunolabelling of hydrogels (Phillips & Brown, 2011). 
Briefly, following fixation and PBS washes, the intraconstruct hydrogel was blocked for 1 
h at RT (0.75 mL/gel) followed by addition of the primary antibody (0.75 mL/gel) and 
incubation for 24 h at 4° C.  The hydrogel was then washed three times in PBS (2 mL/gel) 
for 15 min/wash at RT before addition of the blocker solution (0.75 mL/gel) and 
incubation at RT for 1 h. The secondary antibody (0.75 mL/gel) was added and the 
hydrogel incubated at RT, protected from light, for at least 4 h. Incubation was followed by 
three PBS washes (2 mL/gel) for 10 min per wash. To counterstain for nuclei, Hoechst 
33342 was added at a concentration of 5 µg/mL PBS at a final volume of 1 mL/gel, and 
incubated for 1 h at RT, protected from light. To remove residual stain, the hydrogels were 
washed three times in PBS for 10 min per wash (1 mL/gel) before being imaged.  
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2.10 Imaging  
2.10.1 Imaging of cell monolayers 
Fluorescence microscopy 
Analysis of each experimental condition was conducted using fluorescence images 
captured at 200-400 x magnification, from four random fields per coverslip/hydrogel.   
Three different microscopes were used to capture the fluorescence images. A Leica DM IL 
LED inverted microscope fitted with a DFC 420 C digital camera and a pE-300 W 
CoolLED fluorescence unit, was used to capture images from well-plates using the Leica 
Application Suite imaging software, version 3.3.1. Fluorescence images from cell 
monolayers on coverslips were captured using an AxioScope A1 microscope fitted with an 
AxioCam ICc1 digital camera, and utilising Axiovision imaging software by Carl Zeiss 
MicroImaging, GmbH (Germany). Fluorescence Z-stack images of supraconstruct 
hydrogels were captured using a Nikon Eclipse 80i microscope, fitted with a Hamamatsu 
ORCA camera utilising NIS-Elements imaging software, version Br3.2.  
All images were captured using fixed exposure settings to allow for consistency and 
accuracy in analysis of fluorescence intensity measures of gfp expression and particle 
accumulation in cells. 
Dynamic time-lapse microscopy  
Particle inheritance in daughter cells of dividing astrocytes cultured on coverslips was 
assessed from dynamic time-lapse images captured at a frequency of 1 frame/120 s over a 
period of at least 48 h.  Images were captured from the transmitted light (16 ms exposure) 
and BODIPY® 564/570 (420 ms exposure) fluorescence channels using an Axio Zoom 
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V16 microscope fitted with an AxioCam ICm1 camera  and utilising Blue Edition ZEN 
software, version 1.1.1.0.  
2.10.2 Imaging of supra- and intraconstruct hydrogels 
Z-stack microscopy  
Intraconstruct hydrogels were transferred into a CELLview™ glass-bottom petri dish for 
imaging. Quantification and subsequent analysis of culture characteristics, experimental 
outcomes and cellular assessments using intraconstruct hydrogels was assessed from four 
(RGB fluorescence and phase) z-stack images. These were captured at 100-200x 
magnification from four random fields of the hydrogel using a Zeiss Axio Observer.Z1 
microscope fitted with a Zeiss AxioCam MR R3 digital camera and a pE-300 CoolLED 
fluorescence unit and utilising the Blue Edition ZEN 2 software, version 2.0.   
Dynamic time-lapse microscopy  
Particle inheritance in daughter cells from in-situ MP-5x particle-labelled supraconstruct 
hydrogels were assessed from time-lapse images taken at a frequency of 1 frame/120 s 
over a period of at least 48 h. Images were captured from the transmitted light (23 ms 
exposure) and BODIPY® 564/570 (20 ms exposure) fluorescence channels using hardware 
and software as detailed above (see 2.10.1).  Particle inheritance from in-situ MP-5x 
particle-labelled intraconstruct hydrogels were assessed from images taken at a frequency 
of 1 frame/180 s with transmitted light exposure set at 97 ms and BODIPY® 564/570 set at 
500 ms exposure.  
Field emission scanning electron microscopy of supraconstruct hydrogels 
Observation of the cell ultrastructure on supraconstruct hydrogels was visualised using a 
Hitachi S4500 FESEM operating at an accelerating voltage of 5 kV. 
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Transmission electron microscopy of intraconstruct hydrogels 
Cell cytoskeletal and subcellular features were visualised from the ultrathin sections using 
a JEOL-100CX TEM operating at an accelerating voltage of 100 kV. 
Magnetic resonance imaging of intraconstruct hydrogels 
The MRI imaging of the intraconstruct hydrogels was conducted at the Centre for Pre-
Clinical Imaging (Liverpool, UK) using a Bruker 9.4 T Avance III HD instrument (Bruker, 
Coventry, UK) utilising a 40 mm transmit/receive quadrature volume coil. High resolution 
three-dimensional TurboRARE  T2 weighted and T2*  images were captured using a 25 x 
25 x 4 mm field of view with 8 slices in total taken of each hydrogel.  Each hydrogel took 
an acquisition time of 2 h 37 min with a calculated resolution of 256 x 256 x 41 pixels per 
hydrogel, with an echo time (TE) of 8 ms and a repetition time (TR) of 400 ms.  T2-
weighted images are a ‘true’ or ‘natural’ image of the sample, weighted to accentuate the 
local magnetic homogeneity effect to give a greater degree of contrast.  The T2* images 
have a greater degree of ‘observed’ resolution accuracy as they reflect the ‘true’ T2  image 
and account for any magnetic field inhomogeneities within the sample (H. Poptani; 
University of Liverpool – Pers. Communication.). 
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2.11 Histological analyses of culture properties  
Culture characterisation within each experimental condition was quantified by cell counts 
(the number of nuclei/image), culture purity (percentage of nuclei co-localised with 
GFAP+ expression) and incidence of pyknosis (as a percentage of healthy plus pyknotic 
nuclei), which was categorised by shrunken, fragmenting nuclei.  Astrocyte phenotype was 
classified as type 1 or type 2 based on their morphology. Type 1 astrocytes have flat, 
membranous unbranched morphology compared with the small soma and highly branched, 
more complex morphology seen with type 2.  
 2.11.1 Cell monolayer experiments 
All culture characteristics, experimental outcomes and cellular assessments in cell 
monolayer experiments were quantified from fluorescence images taken from four random 
fields per coverslip with at least 100 counterstained nuclei assessed from each experiment.  
Prior to counting, images were triple merged using Adobe Photoshop CS5 Extended, 
version 12 x32 with all quantification carried out using ImageJ image analysis software 
(NIH USA).  Using this approach to analyses enabled quantification of experimental 
outcomes while simultaneously assessing for cell health, for example cell adherence, 
atypical cell morphologies or prevalence of pyknosis. 
2.11.2 Supraconstruct hydrogels 
Observations of culture characteristics, experimental outcomes and cellular assessments 
from supraconstruct hydrogels were visualised from images taken from four random fields 
per hydrogel and as such, were used as proof-of-concept findings to validate experimental 
outcomes and to inform subsequent intraconstruct hydrogel protocols.   
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2.11.3 Intraconstruct hydrogels 
In intraconstruct hydrogels culture characteristics, experimental outcomes and cellular 
assessments were quantified from z-stack images taken from four random fields per 
hydrogel, one field captured through the centre of the gel with the other three fields 
captured from at least 1-2 mm in from the outer edge of the gel (Figure 2.7) with all 
counterstained nuclei counted per z-stack image/field of view.  To investigate homogeneity 
of cell distribution and cell growth throughout the hydrogel, the data obtained from the 
centre of the gel was compared with that obtained from the edge. Quantification was 
carried out using Blue Edition ZEN 2 software, version 2.0 and ImageJ.  
 
 
Figure 2.7 Schematic of z-stack imaging through an intraconstruct hydrogel  Culture 
characterisation and experimental outcomes were evaluated from z-stack images captured 
from four random fields of a hydrogel. To investigate homogeneity of cell distribution and 
growth, comparisons were made between data taken from the centre and data taken from 
the edge of the hydrogel (see arrows).  
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2.12 Analyses of magnetic (nano) particle uptake and transfection  
2.12.1 Analysis of MP-labelling of astrocytes in cell monolayers and intraconstruct 
hydrogels 
Labelling efficiency in astrocytes was quantified by the proportion of GFAP+ cells 
showing particle uptake. All data were expressed as a percentage of the total number of 
cells per field. The extent of particle accumulation per cell was evaluated using pixel 
intensity. Briefly, using ImageJ software pixel intensity readings were taken from each cell 
showing particle uptake. As with fluorescence intensity (see 2.12.2) readings were taken to 
correct for background fluorescence with the resulting value representing the extent of 
particle accumulation per cell (detailed further within the experimental chapter). The data 
for each condition was averaged to allow comparisons across experimental conditions.  
2.12.2 Analysis of MNP-mediated gene transfer to astrocytes in cell monolayers 
Transfection efficiency in astrocytes was classified as the proportion of GFAP/gfp+ cells 
and expressed as a percentage of the total cells. In the cell monolayer experiments, 
fluorescence intensity was used as a representative measure of gfp expression, with particle 
accumulation classified semi-quantitatively as low, moderate and high. Briefly, using 
ImageJ software, fluorescence images were converted to grayscale, inverted and calibrated 
using an optical density step tablet before fluorescent intensity readings were taken from 
each cell expressing gfp. Readings were taken to correct for background fluorescence, 
these values then subtracted from the mean fluorescence intensity value taken from the 
cells, with the resulting value representing a measure of the extent of gfp expression in a 
transfected cell. The data for particle accumulation vs. gfp expression was then correlated 
to allow for comparisons across experimental conditions.  
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2.13 Viability and proliferation assays for cell monolayers and 
intraconstruct hydrogels 
2.13.1 Cellular assessment 
Assessment of cell health within the experimental conditions was quantified through 
culture characterisation i.e. average cell count; culture purity and prevalence of pyknosis 
across conditions (see 2.11). 
 2.13.2 MTS Assay in cell monolayer transfection experiments 
At 48 h post-transfection, an MTS assay was conducted to measure mitochondrial 
dehydrogenase activity in the astrocyte monolayer, as an indicator of metabolic activity, 
and consequently as a safety assessment of the transfection protocols. Briefly, additional 
D10 medium was added to each well (cells; cells+plasmid; cells+plasmid+MNPs) to equal 
a final volume of 0.2 mL and 20 µL/well of MTS reagent added.  Following 3 h incubation 
at 37° C (5% CO2/95% humidified air) absorbance was measured at 490 nm (A490 - 
VICTOR2 Multi-label Counter, PerkinElmer).  The ‘blank’ (no cells) absorbance readings 
were subtracted from the appropriate test readings with the resulting values expressed as a 
percentage of cellular viability relative to the control incubations minus MNPs. 
2.13.3 EdU proliferation assay in cell monolayers and intraconstruct hydrogels 
Click-iT® EdU (5-ethynyl-2´-deoxyuridine) cell proliferation assay was used to assess the 
proliferative capacity of astrocytes in cell monolayers and within intraconstruct hydrogels, 
as detailed above (see 2.5.2 & 2.8.2 respectively).  For cell monolayers, fluorescence 
images were captured from four random fields of the coverslip, and for intraconstruct 
hydrogels, Z-stack images were captured from four random fields of the gel. Counts of 
nuclei co-expressing the EdU marker and nuclear counterstain (DAPI or Hoechst 33342) 
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were classified as proliferating cells (proliferation expressed as a percentage of the total 
cells counted).  For intraconstruct hydrogels, data were evaluated to provide a comparison 
of proliferative capacity at the hydrogel centre, with that seen at the edge. 
2.13.4 Cellular viability assay in intraconstruct hydrogels 
Alongside culture characterisation assessments, cell viability in hydrogels was assessed by 
live/dead assays as detailed above (see 2.8.2). Fluorescence z-stack imaging captured 
images from four random fields of the hydrogel, one from the centre and three from the 
edge.  Cellular viability was determined as the percentage of cells expressing calcein (live) 
from the total number of cells per field. The data obtained from the centre of the hydrogel 
was compared with that obtained from the edge to investigate homogeneity of cellular 
viability throughout the gel.  
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2.14 Statistical analyses 
Experimental data were analysed by one-way analysis of variance (ANOVA) with post-
hoc analysis carried out using Bonferroni’s multiple comparison test (MCT).  Equality of 
variance across cell samples was verified using Bartlett’s Test. All data are expressed as 
mean ± standard error of the mean (s.e.m) with ‘n’ referring to the number of different 
experiments within each particular study, each derived from a different rat litter. Analysis 
was conducted using Prism statistical analysis software, version 7 (GraphPad Software 
Inc.). 
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Chapter 3 
Endocytotic potential governs 
magnetic particle loading in dividing 
neural cells 
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3.1 Introduction  
The use of MPs with cell therapies is becoming an established field for magnetic cell 
localisation and imaging applications. In turn, this is paving the way for safe and efficient 
delivery of cell transplant populations to sites of injury and allowing for non-invasive 
monitoring of grafts (Chen et al ., 2013; Jenkins et al., 2014; Riegler et al., 2010; Yanai et 
al., 2012). As discussed previously within the main introduction, to address the limitations 
inherent to the regenerative capacity of the CNS, an emerging area for such applications is 
that of cell transplantation to facilitate repair of neurological injury. In this regard, a 
number of studies have utilised astrocytes as a transplant population (Nicaise et al., 2015 
for review). Despite the safety of MNPs for labelling of this particular neural cell (Pickard 
et al., 2011), in transplant populations it has been neglected in favour of heavy reliance on 
histological findings (Davies et al., 2006, 2011; Fan et al., 2013; Filous et al., 2010; 
Pencalet et al., 2006; Selkirk et al., 2002; Wang et al., 1995; Zhang et al., 2016). This, 
then, remains a clear oversight when furthering the use of this neural cell type for cell 
therapies. 
Labelling cells prior to transplantation requires a cell-particle combination that results in 
rapid and safe particle uptake by the majority, if not all cells.  However, the regenerative 
capacity of most transplant populations relies partially on their proliferative capacity which 
results in rapid dilution of intracellular particle accumulations in labelled cells (Kim et al., 
2012). Particle loss can also occur via exocytosis, potentially compromising magnetic cell 
localisation and imaging capacity (Jin et al., 2009). Although, it has been disputed that 
particles, once internalised by the cell are not released from healthy cells, but instead their 
accumulation is diluted through cell division (Harrison et al., 2016).  In this respect the 
high proliferative capacity of cultured astrocytes (Errington et al., 2010; Kim et al., 2011) 
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may rapidly dilute particle accumulation. Therefore, a further requirement for transplant 
cell labelling is long-term retention of sufficient particles per cell to facilitate its continued 
utility in imaging and tracking approaches. To counter the proliferative nature of this cell, 
one way that long-term particle retention could be achieved is by initial high loading of 
MP-label into graft cells. 
The factors that govern MP loading are varied and dependent on the particular cell:particle 
combination (Kettler et al., 2014 for review).  Astrocytes display high levels of membrane 
activity. It has been shown in a recent ultrastructural study using high resolution SEM that 
astrocytes are the dominant neuroepithelial population in terms of particle uptake. Relative 
to other major neural cell types such as neurons and oligodendrocytes, astrocytes display 
extensive membrane ruffling with numerous filopodia and membrane pits in line with 
greater particle uptake/transfection (Fernandes & Chari, 2014). Moreover, it is well 
established that uptake of nanoparticles is mediated via a range of endocytotic mechanisms 
(Canton & Battaglia, 2012; Kou et al., 2013; Verma & Stellacci, 2010; Yameen et al., 
2014; Zhao et al., 2011).  In this context, astrocytes employ a number of endocytotic 
pathways for nanoparticle uptake which, in turn, are mostly determined by the size of the 
particle employed (Rejman et al., 2004; Chaudhuri et al., 2011). The predominant MP-
uptake pathways reported in astrocytes are receptor-mediated (caveolae and clathrin) with 
macropinocytosis playing a greater endocytotic role in uptake of larger particles (Megias et 
al., 2000; Pickard et al., 2011; Walz, 2000).   In respect of particle properties, while size is 
a factor determining the uptake pathway (Zhao et al., 2011), it has also been reported that 
stiffer particles result in more rapid uptake due to their interaction with the plasma 
membrane (Oh & Park, 2014). Enhanced particle loading appears to be dependent on 
surface coating (Alexis et al., 2008), biomolecular corona (Lesniak et al., 2013) and surface 
charge (Alexis et al., 2008; He et al., 2010; Harush-Frenkel et al., 2007). However, the 
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benefits conveyed by particle properties appear to be highly dependent on the particle:cell 
combination (Alexis et al., 2008). A clear understanding, then, is required of both the 
physico-chemical and the biological parameters that govern particle loading in this 
particular neural cell.  Indeed, in the use of MPs with astrocytes there is still a knowledge 
gap regarding the factors that contribute to successful magnetolabelling and label retention.  
A recent study investigated the uptake of particles with tailored magnetite concentration. 
These particular particles are formulated using biocompatible and biodegradable 
components; properties that highlight their translational potential and justify their use in 
this study (Adams et al., 2015). It was recently proved that systematic tailored increases in 
the magnetite content of these particles could significantly enhance cell labelling (>95% 
cells labelled) in the typically ‘hard-to-label’ transplant population of NSCs (Adams et al., 
2015).  However, this study did not evaluate the longer-term retention of these particles by 
the labelled cells, or establish the pattern of ‘inheritance’ of particles by daughter NSCs 
post-proliferation.  It is unclear how astrocytes, with their high level of endocytotic 
activity, will handle such high magnetite content MPs.  The aim therefore of this study 
is to investigate the effect of different combinations of magnetite particle and magnetic 
field condition, on particle uptake and extent of accumulation in cortical astrocytes – a 
primary-derived neural cell. The hypothesis is that optimal particle/magnetic field 
combination can result in greater enhancement of cell labelling for neural transplant 
populations. 
In realising this aim, a consistent and accurate approach is needed to quantify cellular 
particle accumulation. Previously, particle accumulation – in a range of neural cells – has 
been assessed semi-quantitatively and categorised as ‘low’, ‘moderate’ or ‘high’ based on 
visual assessment of the area ratio of particles to cell nucleus [NSCs (Adams et al., 2013); 
OPCs (Jenkins et al., 2013) and astrocytes (Pickard et al., 2011)]. The major disadvantages 
 101 
in other approaches considered (i.e. plate readers; flow cytometry) are their reliance on 
culture-wide assays rather than single-cell quantification. In turn, they assume 
homogeneity in particle uptake, contrary to the heterogeneity reported in primary neural 
cells (Adams et al., 2013; Jenkins et al., 2013; Pickard et al., 2011). Moreover these 
approaches are unable to discriminate between intracellular and extracellular particles, and 
in respect of astrocytes, this could be up to 50% of the signal, resulting in an unacceptable 
level of ‘false-positives’.  
Of key importance in respect of the assessment of uptake and safety, use of enzymatically 
detached cells do not maintain the morphological features that are pertinent to these 
assessments as conducted within the present study. Furthermore, none of the 
aforementioned approaches are able to distinguish intracellular particle localisation, a 
determinant of particle trafficking. Thus, an approach is required that will i) quantify 
particle uptake and extent of accumulation on a cell-by-cell basis, ii) will exclude 
extracellular and membrane-adherent particles with consistent accuracy, iii) will be able to 
identify cells with unhealthy morphologies and iv) will yield measures that are 
representative of the heterogeneity in particle uptake seen within a primary-derived neural 
cell population. 
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3.2 Objectives 
1)   Develop a robust and simple methodology for quantification of particle 
accumulation in astrocytes  
2)  Investigate the effect of combinations of tailoring particle magnetite content 
and magnetic field, on particle uptake by astrocytes 
3)  Study particle retention by astrocytes over an extended time period (21 days) 
4)  Investigate the profile of particle inheritance in daughter cells of MP-labelled 
astrocytes 
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3.3 Experimental procedures 
3.3.1 Reagents and equipment: All reagents and equipment used are as described 
previously in sections 2.1; 2.2.3; 2.3; 2.4 & 2.5. Three types of MPs of differing magnetite 
content [MP-0x (non-magnetite); MP-1x; MP-5x] were used for uptake experiments and 
were evaluated for their labelling efficiency and extent of accumulation in cortical 
astrocytes. The nomenclature used to refer to the different MPs is indicative of their weight 
percent ratio (as characterised in 2.4.1).  
3.3.2 Development of a robust methodology for quantification of particle accumulation 
within astrocytes: To devise a quantitative analytical method that offered a robust measure 
of particle accumulation, a methodology was developed based on the pixel intensity (PI) 
exhibited by the dense accumulation of particles. This density prevented exact particle 
counts per cell; however integrated density (ID) values provided a measure of PI (ImageJ 
software, NIH USA). A measure such as this would prevent operator bias; a concern when 
utilising semi-quantitative visual assessment categories of low, medium and high particle 
accumulation. The PI method could then be extrapolated to particle uptake in other cell 
types, and, as such, used laboratory wide. 
Prior to taking any measures, triple-merged fluorescence micrographs and their un-merged 
counterparts were scaled to show measurements per micron (µm) and, for each MP-
labelled astrocyte, the total area per cell occupied by intracellular MPs was outlined. This 
outline was then transferred to the unmerged particle channel image from which a cellular 
ID measure was obtained. Five background ID readings were taken from the same 
unmerged particle channel image, the mean of which was subtracted from the cellular ID 
measure, resulting in a PI measure relative to the accumulation of particles in an individual 
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cell; using the formula: - PI = ID – (A * Br) where ID=integrated density, A=cell area, 
Br=mean background reading and PI=pixel intensity. 
A major consideration during development of this methodology was taking accurate 
measures from overlapping cells (Figure 3.1). 
 
Figure 3.1 Development of parameters for PI analysis Representative fluorescence 
images of MP-loaded cells (a) and (b) with corresponding particle image (c).  Cell 
boundaries are outlined (b) for the purposes of measuring particle density from the 
particle image (c). For overlapping cells (b and c; white outline) where the corresponding 
particle image showed a clear association with the underlying cell (b and c; red arrow) 
particles could be confidently ascribed to that cell. Where particles were coincident (b and 
c; red outline, white arrow), both cells were measured with coincident particles assigned 
to the cell to the right (c; star).  
 
a b 
c 
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Where clear boundaries could be ascertained, and there were no particles in the overlying 
cell, the measure from the particle image captured only the particles from the underlying 
target cell [red arrow; Figure 3.1 (a and b) and corresponding particle image (c)]. Where 
particles from two cells were coincident on the particle image [white arrow; Figure 3.1 (b) 
and (c)], and could not be definitively ascribed to either cell, then both cells were 
measured, with the coincident particles assigned to the right-hand cell [Figure 3.1 (c)].  
This deliberation was chosen to prevent any bias in assigning coincident particles. 
The robustness of this method was tested with a number of data sets and the results 
compared with those of semi-quantification categorisation. 
3.3.3 Influence of tailoring particle magnetite content on astrocyte loading: The MPs 
used in this study were evaluated for cellular labelling efficiency and extent of cellular 
accumulation over time. Use of these superparamagnetic particles was in combination with 
a magnetic field/gradient. 
For the particle uptake experiments cortical astrocytes were routinely plated on PDL-
coated coverslips in a 24-well plate and incubated for 24-48 h to allow for cell adherence 
and growth of processes prior to addition of the MPs (MP-0x (non-magnetite); MP-1x or 
MP-5x) (as detailed in 2.4.2). For each condition, particles were added at a dilution of 1 
µl/mL D10 medium in a total volume of 0.3 mL, and exposed to either a static [0 Hz (F0)] 
or an oscillating [1 Hz; 200 µm amplitude (F1)] magnetic field for 30 min before being 
incubated for 4 or 24 h at 37° C (5% CO2/95% humidified air).  For the no field condition 
(NF), cells were incubated in the absence of a magnetic field. At the determined time-
point, cells were subject to two PBS washes to remove any free particles (two PBS washes 
have been found to be sufficient in removing free particles, as verified by fluorescence/z-
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stack microscopy). Following the washes, cells were fixed in 4% PFA and prepared for 
imaging and analysis.  
3.3.4 Studying the retention of particles over an extended time period:  In trialling the 
long-term studies it was clear that the proliferative nature of the cell population resulted 
very rapidly in over-confluent cultures within the well-plate, highlighting the possibility of 
density-dependent inhibition (Davies & Ross, 1980). Therefore, to facilitate continued 
viability, coverslips containing MP-loaded cells were transferred to PDL-coated 6-well 
plates at 96 h post-particle addition. At day 7 in culture, the coverslip containing cells was 
transferred to a fresh PDL-coated 6-well plate, cultured up to day 14 before being 
transferred again, and cultivated up to 21 days (Figure 3.2).  
 
 
Figure 3.2 Schematic illustrating the transfer of coverslips Schematic illustrating the 
transfer of coverslips, containing MP-loaded cells, from 24-well plate to 6-well plate to 
facilitate continued viability over long term culture of astrocytes. Coverslips were 
transferred to fresh wells at 96 h; day 7 and day 14 and cultivated up to day 21. 
24-well plate 6-well plate 
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Long-term experiments were conducted over a 21-day period. Informed by the results of 
the shorter-term experiments, astrocytes in the long term experiments were labelled with 
MP-1x or MP-5x particles and exposed to an applied oscillating magnetic field at a 
frequency of 1 Hz and an amplitude of 200 µm for 30 min. At 24 h post-particle addition, 
cells were washed twice in PBS to remove any free particles, and maintained in D10 
medium with a 50% refresh every 2-3 days, incubated at 37° C (5% CO2/95% humidified 
air).  A proportion of the cultures were fixed (washed twice in PBS and fixed with 4% PFA 
for 25 min at RT) at 6 different time points - day 1 and every 4 days thereafter up to day 
21.  
Assessment of long-term particle retention was quantified by percentage of MP-labelled 
cells (MP-labelling efficiency); extent of particle accumulation (as quantified by PI), and 
particle safety. 
3.3.5 Safety evaluation of procedures: Safety was of primary concern with the use of these 
procedures and to this end cellular viability was assessed by average cell counts, culture 
purity, phenotype distribution and levels of pyknosis. All safety analyses were assessed 
from triple-merged fluorescence micrographs. 
3.3.6 Investigating profiles of particle inheritance in daughter cells of MP-labelled 
astrocytes: Dynamic time-lapse imaging over 48 h allowed determination of the pattern of 
particle inheritance in daughter cells of dividing astrocytes (as detailed in 2.5.1 & 2.10.1). 
Visual observation of time-lapse imaging videos provided counts of symmetrical/non-
symmetrical particle inheritance events. A total of 30 mitotic events were recorded (60 
daughter cells), with each classified as ‘symmetric’ or ‘asymmetric’ depending on the 
proportions of total MP inherited by each daughter cell as determined for both daughter 
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cells. Events were classified as symmetrical inheritance when each daughter cell contained 
40-60% of the total MP, with asymmetric defined as > 60% in one daughter cell.  
3.3.7 Immunocytochemistry: Immunolabelling of cells in uptake experiments was as 
detailed in section 2.9.1, with FITC secondary antibody used in these experiments due to 
the BODIPY® 546-570-PLA fluorophore coating of the particles. 
3.3.8 Imaging: Imaging of these experiments was conducted as detailed in section 2.10.1 
3.3.9 Analyses: Triple-merged fluorescence micrographs allowed quantification of culture 
and particle uptake characteristics and safety assessments across each experimental 
condition. MP-labelling efficiency (% labelled cells) and the extent of particle 
accumulation within cells (PI) were quantified using triple-merges of DAPI, GFAP and 
particle images/channels.  
3.3.10 Statistical analysis: Data were analysed using one-way analysis of variance 
(ANOVA) with post-hoc analysis conducted using Bonferroni’s multiple comparison test 
(MCT); the results expressed as mean ± s.e.m.  For the trial analysis data only (Section 
3.4.1), equality of variance as tested by Bartlett’s Test showed the data to be non-
parametric, therefore this data set was analysed using Kruskal-Wallis.  
The number of cultures used in this series of experiments was 3 (n = 3) unless otherwise 
noted, each derived from a different rat litter. 
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3.4 Results 
3.4.1 Evaluating the robustness of quantitative PI analysis 
 Particle density within a cell was represented by PI. To test the validity and the robustness 
of this method a trial analysis was first conducted followed by analysis of a number of data 
sets from this study, the results of which were compared with those of semi-quantitative 
categorisation.   
Trial analysis entailed each individual cell being categorised as ‘low’, ‘moderate’ or ‘high’ 
for extent of particle accumulation and simultaneously assigned a PI value (representative 
of intracellular particle density). The resulting PI value was then binned according to its 
corresponding visual categorisation (i.e. PI value to ‘low’, ‘moderate’ or ‘high’) to 
determine whether the two measures were in any respect comparable. Results from the trial 
data reported significant differences between the categories suggesting PI values are 
comparable to the visual observations typically used within the semi-quantitative method 
i.e. low PI values correspond to ‘low’ visual observation of particle accumulation [Figure 
3.3 (a)].  Based on the interquartile range [Figure 3.3 (b)] this preliminary data reported a 
distinct range of PI values for each category, although some overlap was noted.  The 
findings also reported no difference in PI values between particle types across the 
categories [Figure 3.3 (a and b)]. 
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Figure 3.3 Intracellular particle density in individual cells was assigned a PI value 
and categorised according to the semi-quantitative method of ‘low’, ‘moderate’ or 
‘high’. The PI value was then binned according to its corresponding category. Bar 
graph (a) showing a significant difference between categories for intracellular particle 
density as measured by PI (*p < 0.05; **p < 0.01; ***p <0.001; Kruskal-Wallis). Box and 
whisker plot (b) showing the distribution of the PI values when used as a measure of 
intracellular particle density. Based on the interquartile range [denoted in graph (b)] 
distinct PI ranges for each category were reported, although some overlap is noted. 
Results expressed as mean ± s.e.m. PI = Pixel Intensity 
 
In evaluating the trial analysis, consideration was given to whether binning the PI values 
into categories may be biasing the results. Therefore to further test the validity of this 
method, the PI values were not binned during the following set of analyses.  
Hence, to validate the method and test the robustness of this approach, a number of data 
sets from the current study were analysed for internalised particle accumulation. Two 
analytical methods were simultaneously employed here –semi-quantitative visual analysis 
and quantitative PI analysis (Figure 3.4). 
a b Intracellular particle density 
using MP-1x and MP-5x 
Distribution data of PI values 
 111 
 
 
 
 
Figure 3.4 Intracellular particle density measured using semi-quantitative visual 
analysis and quantitative PI analysis Following addition of MP-0x, -1x or -5x particles 
to astrocytes, and subsequent 30 minute application of one of three differing magnetic field 
conditions [no field (NF); static field (F0) or oscillating field (F1 Hz: 200µm amplitude)], 
the extent of intracellular particle density was measured at 4 h and 24 h post-particle 
exposure. Bar graphs displaying extent of intracellular particle density at 4 h (a & b) and 
at 24 h (c & d) post-particle exposure. The data sets were analysed using both semi-
a 
Semi-quantitative visual 
analysis 
Quantitative pixel intensity 
analysis 
Intracellular particle density 
at 4 h post-particle exposure 
Intracellular particle density 
at 4 h post-particle exposure 
b 
Intracellular particle density 
at 24 h post-particle exposure 
Intracellular particle density 
at 24 h post-particle exposure 
c d 
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quantitative visual analysis (a & c), which is based on area of particle density relative to 
the cross-section of the nucleus and categorised as ‘low’, ‘moderate’ or ‘high’ and 
quantitative PI analysis (b & d), which is a measure of the pixel intensity of the area 
coverage of particles within the cell  Similar significant findings were reported by the two 
analytical methods employed, although PI analysis reported the data in greater detail 
[compare (a) versus (b); (c) versus (d)]. Significant differences are indicated in terms of 
magnetic field (†p <0.05; †††p <0.001) and particle (***p <0.001) and ‘low’ (#p <0.05; 
###p <.001); ‘moderate’ (^p <0.05; ^^^p <0.001) and ‘high’ (++p <0.01). Results expressed 
as mean ± s.e.m. MP: magnetic particle; PI: pixel intensity 
 
Both analytical approaches reported similar findings. Significant differences in extent of 
particle accumulation were reported between MP-5x and MP-1x across the applied 
magnetic field conditions, and between MP-5x and MP-0x across all field conditions, for 
both 4 h and 24 h post-particle exposure [compare Figure 3.4 (a and b); (c and d)]. 
However, PI analysis reported the results in greater detail. In this regard, at 4 h post-
particle exposure significant increases in intracellular particle density were shown for MP-
1x versus MP-0x (at F=1 Hz); MP-5x (F=1 Hz & F=0 Hz) versus MP-5x (NF) and MP-1x 
(F=1 Hz) versus (MP-1x F=0 Hz & NF) [Figure 3.4 (b)].  At 24 h, use of PI analysis also 
showed significant increases in particle density for MP-1x versus MP-0x across all field 
conditions [Figure 3.4 (d)], again a finding not reported under semi-quantitative visual 
analysis [compare Figure 3.4 (c and d)].   
Taken together the findings indicate that use of PI is a valid tool as a representative 
measure of intracellular particle density, and as such, provides a quantifiable and unbiased 
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measure of particle accumulation within the cell. Therefore, all subsequent data of 
intracellular particle accumulation were analysed using this quantitative approach. 
3.4.2 Influence of tailoring particle magnetite content on astrocyte loading 
Particles of varying magnetite content, in combination with differing magnetic fields, were 
evaluated for cellular labelling efficiency and extent of accumulation over time. Visual 
analysis of MP-labelling at 4 and 24 h showed widespread cellular uptake throughout 
cultures for all three particle types, and revealed cellular heterogeneity in terms of relative 
particle accumulation showing low, moderate or high uptake [Figure 3.5 (a - c)]. Both 
peri-nuclear and cytoplasmic distributions of MPs were observed post-labelling 
(cytoplasmic as opposed to peri-nuclear localisation; nomenclature not intended to 
preclude possibility that particles may be localised to endosomes within the cytoplasm). 
The astrocyte cultures used in this study were of high purity as judged by expression of the 
astrocyte marker GFAP (99.4 ± 0.2 % of cells were GFAP+ve; n =6) [Figure 3.5 (d)], with 
cells displaying healthy morphologies typical of type 1 and type 2 astrocytes [Figure 3.5 (a 
and inset)], with type 1 cells dominating (97.1 ± 1.6 % of GFAP+ve cells) [Figure 3.5 (e)].  
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Figure 3.5 Culture characteristics of MP-labelling of astrocytes Representative 
fluorescence images (a – c) of MP-5x uptake in type 1 and type 2 astrocytes at 24 h post-
particle addition [(a) and inset]. Arrows indicate (a) ‘low’, (b) ‘moderate’ and (c) ‘high’ 
levels of intracellular particle accumulation. Z-stack fluorescence micrograph [(b) inset] 
demonstrating intracellular localisation of particles. Bar graphs displaying (d) the high 
purity of this cell population (99.4 ± 0.2% of the cells were GFAP+ve), and (e) the 
proportions of astrocyte phenotype represented within the cell population (97.1 ± 1.6%; 
2.9 ± 1.6% - type 1 & type 2 respectively). Results expressed as mean ± s.e.m (Number of 
replicates = 6). Scale of main and inset images = 50 µm MP: magnetic particle.  
 
Particle uptake was rapid, and for magnetite-loaded cells a substantial proportion (ca. 50%) 
of cells was MP-labelled at 4 h post-particle addition. MP-5x particles showed 
a b c 
d e GFAP+ve labelled cells (%) Proportion of MP-labelled 
GFAP+ve phenotype (%) 
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significantly increased labelling efficiency compared with the other particle types, and in 
turn, MP-1x showed significantly increased MP-labelling compared with MP-0x [Figure 
3.6 (a)]. By contrast, application of a magnetic field had no effect on labelling efficiency 
with either MP-0x or MP-1x at 4 h. Furthermore, magnetic fields had no effect on the 
proportion of cells labelled with the MP-5x particles, which was very high (> 90%) even 
under the no magnetic field condition [Figure 3.6 (a)].  
In respect of the extent of particle accumulation at 4 h, cells labelled with MP-5x particles 
showed significantly higher particle accumulation compared with MP-0x and MP-1x 
particles for both magnetic field conditions [Figure 3.6 (b)]. Application of a magnetic 
field also resulted in significantly greater accumulation of MP-5x particles compared with 
the no field condition [Figure 3.6 (b)]. 
At 24 h post-particle exposure, a greater proportion of cells were MP-labelled compared 
with 4 h for all particle types [compare Figure 3.6 (a and c)]. Of note, for MP-1x and MP-
5x particles virtually all of the astrocytes (>98%) were MP-labelled [Figure 3.6 (c)] and 
notably, magnetic field application at both frequencies was without effect at this time point 
as would be expected given the near complete labelling of the cells. 
The extent of particle accumulation was also much greater at 24 h compared with 4 h for 
all magnetite containing particles [compare Figure 3.6 (b and d)]; please  note scale 
difference of y-axes, with particle accumulation significantly higher versus MP-0x [Figure 
3.6 (d)]. Interestingly, for MP-5x particles application of a magnetic field promoted 
particle accumulation [Figure 3.6 (d)], an effect not observed for MP-1x particles. 
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Figure 3.6 MP-labelling of astrocytes at 4 h and 24 h post-particle exposure, with and 
without magnetic field application Bar graph (a) displaying MP-labelling efficiency 
(proportion of cells showing particle uptake) in astrocytes at 4 h. Bar graph (b) showing 
intracellular particle density (extent of particle accumulation per cell) in astrocytes across 
magnetic fields at 4 h. Bar graph (c) showing MP-labelling efficiency at 24 h. Bar graph 
(d) showing extent of intracellular particle density across magnetic fields at 24 h. 
Differences are indicated in terms of magnetic field (†††p < 0.001) and particle (*p < 
0.005; **p < 0.01; ***p < 0.001) Results expressed as mean ± s.e.m. Number of replicates 
= 6. Bar graphs b & d previously referred to in Fig. 3.4 MP: magnetic particle.   
a b 
MP-labelling efficiency at 4 h 
post-particle exposure 
Intracellular particle density 
at 4 h post-particle exposure 
Intracellular particle density at 
24 h post-particle exposure 
d c 
MP-labelling efficiency at 24 h 
post-particle exposure 
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3.4.3 Studying the retention of particles over an extended time period  
Over the extended time period, transfer of coverslips containing MP-loaded cells into 
larger wells facilitated the proliferative spread of astrocytes (Figure 3.7), thus helping 
prevent over-confluency of cultures and subsequent growth contact inhibition. As can be 
seen from the long term analyses below, the increase in cell numbers over the 21 days 
suggested little inhibition of cell growth. And likewise, the decrease in intracellular particle 
retention over this extended time period also implied that growth contact inhibition was not 
mediating particle retention. 
 
 
 
 
 
 
 
Figure 3.7 Larger wells facilitated the spread of astrocytes from the coverslip onto the 
base of the well plate Phase contrast images (a & b) showing that, for long term 
culturing, placement of coverslips into larger well plates facilitated the spread of 
astrocytes from the coverslip onto the base of the well plate (red arrow denotes coverslip 
edge). Over long term culturing, no difference in spread was observed between (a) un-
labelled (no particles) and (b) MP-labelled (MP-5x) astrocytes. MP: magnetic particle. 
 
b a 
Un-labelled (no particles) MP-5x labelled 
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Utilising the parameters which yielded optimal MP-loading at 24 h (F=1 Hz; 200 µm 
amplitude; see Figure 3.6), long-term particle retention was studied for magnetite-
containing particles in combination with applied oscillating fields.  For both MP-1x and 
MP-5x particles, substantial label retention (> 50%) was evident over 21 days. For MP-1x 
particles, approximately 92% of cells were labelled at day 1, with this value declining 
significantly by day 17 to ca. 51% of cells [Figure 3.8 (a)]. For MP-5x particles, in 
contrast, a greater labelling efficiency (ca. 99% of cells) was obtained at day 1 which 
declined significantly by day 21, albeit with > 78% of cells remaining labelled at this time 
point [Figure 3.8 (b)].  
A steady reduction in particle retention was noted over the 21-day time period, with 
considerable heterogeneity observed among cells in terms of extent of particle retention. 
Visual observations over time for MP-1x showed a clear transition from peri-nuclear 
clustering of particles [Figure 3.8 (c; inset)] to a more cytoplasmic distribution (again, 
termed as such only as opposed to peri-nuclear localisation; nomenclature not intended to 
preclude possibility that particles may be localised to endosomes within the cytoplasm)  
[Figure 3.8 (c; main image)] suggesting reverse trafficking of particles.  While a similar 
pattern was seen overall with MP-5x particles [Figure 3.8 (d; inset)], it was noticeable that 
a subpopulation of astrocytes retained large particle accumulations clustered around the 
nucleus even at 21 days [Figure 3.8 (d; main image)].  
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Figure 3.8 Long-term particle retention following 30 min application of an oscillating 
magnetic field Following addition of particles and 30 min application of a magnetic field, 
long-term particle retention [MP-labelling efficiency (proportions of MP-labelled cells) 
and intracellular particle density (extent of particle accumulation per cell)] was assessed 
at six time-points over 21 days. Bar graphs showing MP-labelling efficiency post-exposure 
to (a) MP-1x and (b) MP-5x particles (***p < 0.001). Representative triple-merged 
MP 
GFAP 
DAPI 
a b 
e f 
Long-term labelling 
efficiency using MP-1x 
Long-term labelling 
efficiency using MP-5x 
Long-term extent of 
accumulation using MP-1x 
Long-term extent of 
accumulation using MP-5x 
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fluorescence images (c & d) showing differences in extent of intracellular particle density 
seen at day 1 (insets) and day 21 (main images) post-labelling with (c) MP-1x and (d) MP-
5x particles. Arrows indicate ‘high’ levels of peri-nuclear labelling at day 21 with MP-5x 
particles. Bar graphs displaying extent of (e) MP-1x and (f) MP-5x intracellular particle 
density accumulation over 21 days, following application of an oscillating magnetic field. 
Within each particle condition versus day 1 (*p < 0.05; **p < 0.01; ***p < 0.001) Results 
expressed as mean ± s.e.m (Number of replicates = 3). Scale = 50 µm MP: Magnetic 
particle 
 
3.4.4 Safety evaluation of long-term particle retention 
Safety of these protocols was of paramount importance, specifically with regard to particle 
retention over an extended period of time. Safety assessments indicate long-term retention 
of the particles did not impair the proliferative capacity of astrocytes. Average cell 
numbers showed a significant increase by day 9 for both MP-1x and MP-5x particles and 
for both magnetic field conditions, with no significant differences compared with untreated 
(no particles) controls at 21 days [Figure 3.9 (a and b)]. Culture purity remained at >99% 
over the 21 days [Figure 3.9 (c and d)].  
There was no effect of either particles or magnetic field condition on astrocyte phenotype 
distribution (84.6 ± 0.7% type 1 compared with 15.4 ± 0.7% type 2, average across all 
conditions) [Figure 3.9 (e and f)].   
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Figure 3.9 Cellular viability evaluation of long-term particle retention in astrocytes in 
vitro The safety of long-term particle retention in astrocytes in vitro was evaluated over 21 
days, with assessment of average cell counts, culture purity (%) and phenotype distribution 
a b 
c d 
e f 
Average number GFAP+ve 
cells over long term (F0 Hz) 
Average number GFAP+ve 
cells over long term (F1 Hz) 
GFAP+ve cells over long 
term (F1 Hz; %) 
GFAP+ve cells over long 
term (F0 Hz; %) 
GFAP+ve cell type over 
long term (F0 Hz; %) 
GFAP+ve cell type over 
long term (F1 Hz; %) 
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(%) assessed at six time-points over the term of the experiment. Bar graphs displaying 
astrocyte number per microscopic field post-labelling under (a) static (F=0 Hz) and (b) 
oscillating (F=1 Hz; 200 µm) magnetic field conditions (*p < 0.05; ***p < 0.001 versus 
day 1). Bar graphs displaying proportions of GFAP+ve cells post-labelling under (c) static 
field and (d) oscillating field conditions. Bar graphs showing the distribution of astrocyte 
phenotypes (Type 1; Type 2) post-labelling under (e) static field and (f) oscillating 
magnetic field conditions. Results expressed as mean ± s.e.m (Number of replicates = 3) 
MP: Magnetic particle 
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Across all time points a small proportion (<2%) of nuclei were observed as pyknotic, with 
pyknosis associated with aberrant intense GFAP staining, indicative of membrane 
detaching from the substrate [Figure 3.10 (a and b)]. By contrast, using histological 
analyses, the majority of labelled cells showed no obvious aberrations in GFAP staining or 
in astrocyte morphologies compared with controls. 
 
 
Figure 3.10 Identification of pyknotic cells in astrocyte cultures The viability of 
astrocyte cultures was assessed by identifying cells with fragmenting and condensing 
nuclei, frequently associated with aberrant GFAP staining and evidence of membrane 
detachment from the substrate, all features indicative of pyknosis (red arrows indicate 
same pyknotic cell in main image and inset). Healthy nuclei were associated with adherent 
cells and normal GFAP staining (white arrows indicate same cells in main image and 
inset). Bar graph (b) displaying the percentage of pyknotic nuclei. Results expressed as 
mean ± s.e.m (Number of replicates = 3) MP: Magnetic particle 
  
a b 
Proportion of pyknotic 
cells (%) 
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3.4.5 Investigating profiles of particle inheritance in daughter cells of MP-labelled 
astrocytes 
To gain further insight into the pattern of particle distribution into daughter cells, 
astrocytes labelled with MP-5x particles were studied using dynamic time-lapse imaging of 
proliferating cells (Figure 3.11; Please see Supplementary Video 1 – disc 1). This revealed 
that daughter cells exhibited a predominantly asymmetric profile of particle inheritance. 
From observation of 30 mitotic events, 21 were asymmetric compared with 9 showing 
symmetrical inheritance [Figure 3.11 (a)]. Of note, it was also observed that distribution of 
particles within the parent cell prior to division [Figure 3.11 (b and f)] was a predictor of 
the inheritance profile in the daughter cells. Namely, parent cells exhibiting a symmetric 
peri-nuclear distribution of particles [Figure 3.11 (b - d)] gave rise to daughter cells with 
symmetric inheritance of particles [Figure 3.11 (e)], and mitosis of parent cells with 
asymmetrically distributed particles [Figure 3.11 (f - h)] resulted in asymmetric inheritance 
[Figure 3.11 (i)]. 
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Figure 3.11 Particle inheritance in MP-labelled astrocytes Particle inheritance in 
astrocytes was assessed from observation of 30 mitotic events, captured over 48 h, using 
dynamic time-lapse imaging. Symmetric or asymmetric classification was dependent on the 
proportion of particles inherited by each daughter cell as determined for both daughter 
cells. Symmetrical inheritance was determined when each daughter cell contained 40-60% 
of the total particles, with asymmetric defined as > 60% in one daughter cell. Pie chart (a) 
displaying quantification of particle inheritance profiles in MP-labelled astrocytes. 
Representative sequential still images (b – i) from dynamic time-lapse imaging (please see 
Supplementary Video 1 – disc 1) of dividing astrocytes post-labelling with MP-5x particles 
without application of a magnetic field, showing examples of (b – e) symmetric and (f – i) 
asymmetric particle inheritance between daughter cells (arrows). MP: Magnetic particle  
a Particle inheritance between daughter 
cells of dividing astrocytes 
b 
f i h g 
c d e 
Particle inheritance  
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3.5 Discussion 
This study has investigated the interaction between the physico-chemical properties 
(namely, magnetite content) of polymeric iron oxide particles and a highly endocytotic 
neural cell (primary-derived cortical astrocytes). In consideration of astrocytes as a 
transplant population and looking to achieve intracellular particle uptake prior to 
transplant, two delivery routes have been typically considered; exploitation of the cell’s 
intrinsic ‘engulfing’ behaviour or the temporary disruption of the cell membrane, for 
example by electroporation or ultrasound bubble stimulation (Chaudhuri et al., 2011). The 
former approach relies on natural biological mechanisms and thus offers a safer labelling 
approach as it causes less cell death and therefore limits immunogenicity, particularly 
when long-term safety is a critical consideration (i.e. post-transplantation into host tissue) 
(Guo et al., 1996; Krueger et al., 1998).  
The novel development of the PI analytical methodology applied within this study 
provided an unbiased objective approach for the quantification of nanoparticle uptake. 
Used at the single-cell level it allowed for simultaneous evaluation of cellular 
morphological features and subcellular particle localisation – the latter a determinant of 
particle trafficking within the cell. Of key benefit to the wider research field, this 
methodology is low cost as it is used in combination with easily accessible open access 
software. Due to its provision for non-bias, it can used across operators, laboratory-wide 
offering determination of particle accumulation in all cell types. However, this 
methodology requires further development, as PI values are only relative to the measures 
within each specific experiment. They are not representative of the number of particles or 
the level of iron within a cell. To address this disadvantage, flow cytometry could be used 
to isolate a specific number of particles and provide an iron content analysis; the PI of 
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which could then be assessed through fluorescent microscopy. A robust measure of iron 
content/particle number per cell could thus be elucidated from PI values. 
The findings of this current study demonstrate that enhanced magnetite concentration in 
particles leads to greater particle loading in highly endocytotically active cells. In turn, this 
initial high loading is associated with longer particle retention (≥ 21 days) versus cells 
loaded with particles of lower or no magnetite content. It can be argued from these findings 
that greater labelling efficiency with high magnetite particles within a short time frame (i.e. 
4 h), is most likely attributable to accelerated gravitational particle sedimentation onto the 
cells, namely due to the increased magnetite density of the MP-5x particles. However the 
compatibility of magnetolabelling with a wider range of MPs for use as clinical contrast 
agents [i.e. imaging and tracking with magnetic resonance imaging (MRI)] or with 
polymeric particles for drug delivery/magnetic cell targeting, is still relatively unexplored.   
With the MPs studied here, application of static or oscillating magnetic fields did not 
influence the proportions of labelled cells, but notably, significantly enhanced the extent of 
intracellular particle accumulation. Taken together, the data suggest that a tailored 
combination of high magnetite content particles, magnetic field application and longer 
particle exposure times (24 h) provided the ideal combination (for this particular 
cell/particle) for greater labelling efficiencies and intracellular particle loading to be 
achieved.  
Key to the labelling of a cell transplant population for imaging and tracking purposes is 
that of label dilution. In this respect the prolonged retention of the higher magnetite 
particles (21 days) is of high relevance as proliferative dilution/exocytosis and label loss 
present major challenges to translational applications (Errington et al., 2010; Kim et al., 
2012). It is possible that the longer retention is simply relative to the higher initial loading 
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of particles into the cells. It has also been considered that cell-contact inhibition may be 
‘trapping’ the particles within the cells. From this it could be reasoned that this high level 
of particle retention is an artefact of an overly confluent culture. However, the increase in 
cell growth and the decrease in particle density over this extended time period, would 
dispute this. Effects such as slower exocytosis of higher magnetite content particles cannot 
be ruled out, although some studies suggest label dilution is due to proliferating cells and 
division of particles into daughter cells rather than exocytotic activity (Kim et al., 2012; 
Harrison et al., 2016). What can be noted however is that the combination of high survival 
of such cells post-labelling, in conjunction with such slower excretion, may serve to limit 
the availability of free particles for secondary uptake by resident cells in the host tissue.   
The overall trend in labelling seen here was similar to that seen in NSCs, although, in the 
latter, magnetic field application significantly enhanced labelling efficiency with low 
magnetite particles (Adams et al., 2015). It can, however, be speculated that it is the higher 
levels of endocytotic activity in astrocytes that results in rapid particle uptake and that it is 
this characteristic that outweighs the benefits of field application, particularly for higher 
magnetite content particles with more rapid sedimentary profiles. Moreover, in comparison 
of intracellular label in astrocytes versus NSCs, a greater level of accumulation is noted in 
the former (Adams et al., 2015; Tickle et al., 2016). This may be related to the 
morphological features and intrinsic endocytotic profiles of the cells. For example, 
scanning electron micrographs show broad flattened morphologies for astrocytes (in 
culture) with elaboration of large amounts of cell membrane, and surface features 
suggestive of high cellular membrane activity. In contrast, NSCs are bipolar cells with 
smaller cell bodies, relatively quiescent membranes and considerably less surface area 
available for particle uptake (Fernandes & Chari., 2014). Together, these findings 
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highlight the importance of studying the interactions of neural cell type and its intrinsic 
endocytotic behaviour in conjunction with particle tailoring strategies. 
A less obvious point to note here is the importance of controlling cell densities for such 
work; indeed in some populations containing actively dividing cells, there is a density-
dependent inhibition of endocytosis which could negatively impact particle uptake 
processes (Davies & Ross, 1980). As can be seen with the neural cell utilised for this study, 
the majority of neural transplant populations are highly proliferative and are typically 
(although not in this case) propagated under growth factor drive. It remains important 
therefore that optimal cell densities for each cell type are established, with cellular 
confluence carefully monitored prior to particle addition in labelling protocols for 
biomedical application. 
The safety of the procedures utilised here was of paramount concern, given the combined 
variation of multiple parameters (particle properties, magnetic field application and 
duration of particle exposure). The procedures did not result in acute or long-term 
alterations in MP-labelled cells, as determined by an array of safety assays which assessed 
cell survival, proliferative capacity and cell phenotype. The findings here parallel 
observations seen with NSCs, highlighting the neurocompatibility of the particles used 
(Adams et al., 2015). The safety profile of these particles could be attributable to the slow 
degradation profile of the PLA matrix component which limits the rate at which iron 
leaches from degrading particles; rapid leaching is widely recognised as a major factor in 
MP toxicity (Petters et al., 2015; Soenen et al., 2010). Moreover, the safety profile 
featured here is also consistent with the observed stability of intracellular particles in 
astrocytes when part of a mixed glial population (Jenkins et al., 2013).  
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Use of dynamic, live cell imaging is a novel approach in studying the distribution 
(inheritance) of particles into the progeny of neural cells derived from primary cultures. 
The observations here show that particle inheritance is largely asymmetric (namely, 
particle distribution is uneven between daughter cells). These findings are consistent with 
previous studies utilising cell lines, where particle uptake and redistribution to daughter 
cells after mitosis has been typically reported as being a ‘random’ and asymmetric process 
(Errington et al., 2010; Kim et al., 2012; Rees et al., 2014; Summers et al., 2013). The 
reasons for this uneven distribution are unclear, but may relate to the non-uniform 
distribution of particles around the nuclear poles in the parent cell, a feature that was 
consistently observed in the majority (ca. 75%) of labelled astrocytes. In turn, the reasons 
for this polarised initial distribution are unknown, although it has been suggested that 
intracellular particle distribution may be dependent on particle size/shape and/or particle 
interaction with signalling pathways (Chaudhuri et al., 2011; Gratton et al., 2008; Hussain 
et al., 2014).  
Nonetheless, these findings suggest significant implications for the use of a tailored MP 
strategy for biomedical applications involving astrocytes, and indeed other proliferative 
neural transplant populations. Label dilution with cell division contributes to reduced 
efficacy of particle labelling for imaging, tracking and targeting applications, although the 
results indicate that not all cells would be affected to the same extent. Unequal inheritance 
would imply that with each division the usefulness of the intracellular particle load would 
exponentially diminish for a subpopulation of daughter cells. Conversely, useful levels of 
label would be retained and persist in a larger subpopulation of daughter cells for a longer 
period of time. This would not be the case with symmetrical inheritance. Hence, 
asymmetrical loading of particles in daughter cells would result in the ability to track 
overall biodistribution of the cellular graft for an extended period of time (in relation to 
 131 
symmetrical loading), even where a small sub population would be lost to the 
imaging/tracking process.  
Overall, an understanding and characterisation of the mode of particle inheritance in the 
daughter cells of a labelled transplant population are important parameters contributing to 
particle detection for tracking/targeting purposes. Moreover, in this regard, what is also 
needed is a clear understanding of the biological and chemical factors influencing cellular 
particle uptake (Figure 3.12). 
 
 
Figure 3.12 Factors influencing cellular particle uptake Schematic diagram showing 
factors that influence cell loading with particles, illustrating the combined dynamics of the 
physicochemical characteristics of MPs and the biological function of the cell. 
Fluorescence micrograph shows MP-5x labelled astrocytes (Chaudhuri et al., 2011; El-
Sayed et al., 2005; Errington et al., 2010; Gratton et al., 2008; Hussain et al., 2014; 
Kettler et al., 2013; Kim et al., 2011; Lesniak et al., 2013; Ruoslahti et al., 2010). MP: 
Magnetic particle 
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Astrocytes participate in complex signalling pathways and secrete several biomolecules 
needed for homeostatic functions (Abbott et al., 2006; Chu et al., 2014; Walz, 2000). What 
is not clearly understood is the influence exerted on these pathways by the 
physicochemical factors of the particles themselves, although studies have gone some way 
to elucidating this (Hussain et al., 2014). Systematic investigation of each of these 
parameters (for example utilising proteomic and bioinformatics pathway analyses) and 
their relative importance to neural transplant therapies would allow for the tailored 
development of optimal labelling protocols for translational applications.   
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Chapter 4 
Non-invasive tracking of neural cells in 
implantable materials 
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4.1 Introduction 
There are two main considerations, each with its own challenges that are key to the utility 
of a neural cell transplant for regeneration of the damaged spinal cord. The first is 
enhancing the efficacy of neural cell transplant delivery into the host parenchyma, 
achievable through use of a protective 3-dimensional construct. The second consideration, 
particularly in respect of its clinical relevance, is the ability to non-invasively track the 
transplant cell population over time (as discussed previously within the main introduction).  
Regenerative medicine following spinal cord injury is moving apace. Research has moved 
into clinical trials, with the implantation of OECs into the lesion site seeing functional 
regeneration within the spinal cord, coincident with some restoration of sensory and 
locomotor function (Granger et al., 2012; Tabakow et al., 2014). However, as already 
discussed, success rates are modest, being hampered by the lack of efficacy in surgical 
delivery of the cell population (Guest et al., 2011; Pearse et al., 2007); a challenge that 
demands a protective delivery system for cell transplant populations, to build on the 
success seen so far.   
Hydrogels are emerging as a viable solution to address this challenge (Perale et al., 2011 
for review), with a growing number of studies implanting 3-dimensional constructs as an 
acellular bridge/scaffold within the lesion cavity, resulting in significant axonal 
regeneration (Han et al., 2010; Kaneko et al., 2015; Li et al., 2015; Nam et al., 2010). 
These constructs are also widely utilised in combination with stem cells (Cen et al., 2009; 
Heymer et al., 2008; Syková et al., 2006) and SchCs (Woerly et al., 1996; Xu et al., 1997; 
Xu et al., 1999); each cell:construct promoting a conducive environment for regeneration , 
putatively due to the neuroprotective and neuro-immunomodulatory mechanisms of the 
cell transplant. 
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Studies delivering primary neural cells as a cell construct into injured spinal cord are, to 
date, few (Joosten et al., 2004; Tian et al., 2005). In this respect, use of astrocytes as a 
transplant population for spinal cord repair, despite reporting significant regenerative 
success in locomotor function when delivered as a cell suspension (i.e. Davies et al., 2006, 
2011; Fan et al., 2013; Filous et al., 2010; Pencalet et al., 2006; Selkirk et al., 2002; 
Wang et al., 1995), appears to have been neglected as a transplant population within the 
protective environment of a hydrogel. One such study reports the transplant of neonatal 
astrocytes encapsulated in collagen into the lesion site of a hemi-sected spinal cord 
(Joosten et al., 2004). Although successful axonal regeneration led to a level of restoration 
in locomotor function, the utility of this cell:collagen construct does not appear to have 
been developed further. Indeed, astrocyte characterisation within a 3-dimensional construct 
has only recently begun to be explored (Balasubramanian et al., 2016; Frampton et al., 
2011; Placone et al., 2015; Seyedhassantehrani et al., 2016; Winter et al., 2016). MP-
labelling of astrocytes report high uptake with no adverse effects on viability in both in 
vitro and ex-vivo studies (Pickard et al., 2011).  Despite this, as yet no study has furthered 
the possibility of MP-labelling astrocytes to facilitate non-invasive tracking of this 
potential cell transplant population. There still remains a heavy reliance on the use of 
histological analyses to determine transplant cell localisation/migration.  
In this regard the second consideration, non-invasive tracking of the transplant cells, is 
achievable through the use of MRI. In clinic this imaging technique is widely used, 
facilitated by a number of clinically relevant gadolinium-based contrast agents (e.g. 
Omniscan). In this regard, MPs are ideally suited as a contrast agent in MRI as they present 
a strong negative signal that addresses the low sensitivity associated with this imaging 
technique (Bulte & Kraitchman., 2004).  
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MR imaging of neural cell suspensions labelled with superparamagnetic nanoparticles has 
been extensively undertaken (i.e. OPCs – Bulte et al., 1999; NSCs – Bulte et al., 2001; 
ESCs – Hoehn et al., 2002; Jendelová et al., 2004), as has MR imaging of mesenchymal; 
bone-marrow and adipose-derived stem cells within hydrogels (Cen et al., 2009; Heymer et 
al., 2008; Syková et al., 2006). Although interestingly, the majority of these studies, 
including the few studies combining primary neural cells and hydrogels as a spinal cord 
implant (i.e. Joosten et al., 2004; Tian et al., 2005), have still shown a heavy reliance on 
histological findings to report cell localisation and integration.  
In progressing the use of cell transplant to clinical trials (i.e. Granger et al., 2012; Saberi 
et al., 2008; Tabakow et al., 2014) it is of note that no consideration was given to the 
labelling of the transplant cells for subsequent tracking. Animal and clinical trials utilising 
SCs as a transplant population for SCI, have acknowledged this ‘oversight’ as a significant 
limitation (Pearse et al., 2007; Saberi et al., 2008). Consequently, the concept of utilising 
MRI to non-invasively track a neural cell transplant population within a hydrogel is, thus 
far, an under acknowledged area in this emerging field of regenerative therapy.  
This chapter aims to find a viable solution to this challenge facing regenerative 
applications. It aims to develop a robust protocol for the synthesis of i) a protective 
delivery system for ii) a MP-labelled iii) neural cell transplant population (astrocytes). The 
combination of these three elements offers a 3-dimensional collagen hydrogel, containing a 
MP-labelled cortical astrocyte transplant population – a cell type that has shown 
considerable success in regeneration of the spinal cord – and moreover, due to the high 
concentrate magnetite particle employed in the labelling of these cells, has the potential to 
be tracked non-invasively using MRI.  
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In order to further develop this area in regenerative therapy there are a number of technical 
issues that first need to be considered.  The argument for a 3-dimensional environment 
over 2D monolayer cultures has already been addressed as has the argument for the use of 
a collagen construct over a number of other biologically derived hydrogels (General 
introduction; section 1.5.2). However, the challenges inherent to the development of a cell-
viable 3-dimensional collagen construct are varied.  
The first challenge involves optimising particle uptake and accumulation within the cells to 
ensure an intense signal under MRI (Bernsen et al., 2015; Wang & Shan, 2012). Of equal 
importance is utilising an optimal approach to ensure a viable 3-dimensional cellular 
construct for potential use as an implant for regenerative application.  
In this respect, the second challenge to be addressed is the porosity of the construct to 
ensure cellular viability (Melchels et al., 2010).   Too tight a matrix results in cell death 
from i) inhomogeneous cell distribution and ii) pockets of necrosis within the construct due 
to oxygen and nutrients being unable to penetrate through to the centre of the hydrogel 
(Malda et al., 2004), and metabolic waste products unable to be removed from the 
hydrogel (Mertens et al., 2014b).  
The third challenge, and one of the major challenges faced in clinic, is the inhomogeneity 
of the cell transplant following delivery (Guest et al., 2011; Pearse et al., 2007). This 
represents a major challenge within a 3-dimensional construct (Unsworth et al., 2003). 
Inhomogeneous cell distribution results in cell death leading to subsequent inhibition of a 
cellular network conducive to a regenerative environment (Wakatsuki & Elson, 2003). It is 
these challenges that have informed the objectives for this study. 
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4.2 Objectives 
1)   To establish MP-labelled astrocyte monolayers on a collagen substrate, the 
findings of which will inform development of intraconstruct gels 
2)   To assess cellular viability and homogeneity within the gels, and assess the safety 
of the protocols used 
3)   To characterise the cellular and endocytotic features of cortical astrocytes within 
the 3-dimensional environment of an intraconstruct hydrogel and to evaluate 
comparable features of astrocyte monolayers  
4)  To develop a 3-dimensional MP-labelled astrocytic hydrogel with the utility for 
non-invasive tracking of the neural cell population using MRI 
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4.3 Experimental procedures 
4.3.1 Reagents and equipment: All reagents and equipment used are as described 
previously in sections 2.1; 2.2.3; 2.3 & 2.4. MP-5x particles were used throughout the 
hydrogel experiments. Use of this particle, due to its enhanced magnetite concentration, 
has proved the most effective in cellular uptake and long-term particle retention in cortical 
astrocytes as a monolayer culture. Moreover, for the purposes of non-invasively tracking a 
MP-labelled transplant population, a particle with such high magnetite concentration 
promises a strong hypointense signal under MRI. 
4.3.2 Establishing MP-labelled astrocyte monolayers on a collagen substrate: Following 
formation and MP-labelling of a supra-construct hydrogel (as detailed in 2.7.1-2), sample 
gels were fixed at different time-points post-particle addition (24 h – 14 DIV), with culture 
characteristics, outcomes and cellular assessments used as proof-of-concept findings to 
inform subsequent intraconstruct hydrogel experiments.  
To investigate the ultrastructural membrane features associated with endocytotic activity, 
at 24 h post-particle addition in-situ labelled supraconstruct hydrogels were fixed for 2 h at 
RT with 2.5% glutaraldehyde solution, diluted with 0.1 M sodium cacodylate buffer with 2 
mM CaCl2 at pH 7.4. This was followed by a further overnight fixing step at 4 °C in 0.25% 
glutaraldehyde solution diluted in 0.1 M sodium cacodylate buffer.  
Preparation for FESEM: Following this, the gels were prepared for FESEM imaging 
using the osmium-thiocarbohydrazide step-wise procedure (Vriend & Geissinger, 1980) 
followed by critical point drying of the samples. Modifications were made to the protocols 
to prevent shrinkage and distortion of the gels during the dehydration steps. 
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Following glutaraldehyde fixation, the gels were rinsed in 0.1 M sodium cacodylate buffer 
(3x) and then rinsed in deionised water (dH2O) (6x) before being steeped in osmium and 
incubated for 2 h at RT. Following 6 further rinses in dH2O the gels were covered with 
thiocarbohydrazide and incubated for 20 min at RT, followed by 6 rinses with dH2O and 
stored overnight in dH2O at 4 °C. The osmium and thiocarbohydrazide steps were repeated 
with 6 dH2O rinses between each step before the final addition of an osmium layer over the 
gels. Following 2 h incubation at RT and six rinses in dH2O, the gels were placed in 70% 
ethanol (ETOH) for 4 h at RT, before being transferred and stored in 80% ETOH overnight 
at 4 °C. 
Modification of step-wise dehydration: The gels were then stored at 4 °C for a period of 7 
days during which time they were subject to an extended series of dehydration steps. After 
24 h in 80% ETOH, they were transferred to 90 % ETOH for 48 h, with a 100% refresh at 
24 h.  The gels were then transferred to 100% ETOH for a further 48 h with a 100% refresh 
at 24 h, before being transferred to 100% DRY ETOH. At 4 h, a 100% refresh was 
followed by a further 48 h 100% DRY ETOH dehydration step. The gels were then subject 
to full dehydration in a Critical Point Dryer (CPD) following the standard procedure. 
Briefly, keeping gels immersed in 100% DRY ETOH, they were wrapped in vellum tissue 
and placed in the CPD tray, also filled with 100% DRY ETOH, and the tray inserted into 
the machine.  With the machine cooled to 12 °C, three changes of liquid CO2 (to facilitate 
removal of ETOH from the sample) were immediately performed with three further 
changes performed every 15 minutes over the following 2 h. At 2 h, 4 additional changes 
of liquid CO2 were performed with a further 2 full changes made following the complete 
absence of moisture. Following the final change, the samples were heated to 34 °C and the 
pressure elevated to 1200 psi to remove all final traces of ETOH and fully dehydrate the 
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gels. The samples were cooled to 12 °C before removal and mounting onto carbon pads for 
visualisation under FESEM. 
4.3.3 Developing an MP-labelled cellular intraconstruct hydrogel with the utility for 
non-invasive tracking of the neural cell population using MRI: Achieving an 
intraconstruct hydrogel followed the same protocol used for hydrogel assembly (as 
detailed in sections 2.7.1 & 2.7.3) with the addition of 10% cell suspension replacing 10% 
D10 medium (Figure 4.1).  
 
 
Figure 4.1 A schematic outlining the formation of an intraconstruct hydrogel 
Primary-derived cortical astrocytes (a) were cultured in flasks for 24 h, with the cell 
suspension (b) added to collagen solution. An intraconstruct hydrogel (c & d) was formed 
in a well plate and allowed to set for 1 h before addition of D10 medium. At 3 h post-
construct the hydrogel (e) was transferred to (f) a larger well plate to allow it to free-float 
in medium. 
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Exogenous particle-labelling approach: Addition of MP-5x particles to form 
intraconstruct hydrogels utilised two approaches; ‘exogenous’ MP-labelling and ‘in-situ’ 
MP-labelling. The former approach consisted of particle addition to astrocyte monolayers 
cultured in T175 flasks, the cells then exposed to a static magnetic field for 30 mins as MP-
labelling of astrocyte monolayers showed that exposure to a magnetic field enhanced levels 
of particle accumulation. Control cells (no particles) were also exposed to a static field. At 
24 h post-particle addition the cells were rinsed with PBS to remove any free particles and 
dissociated with TrypLE™; the resulting MP-labelled cell suspension then added to the 
collagen solution (protocol detailed in 2.7.1 & 2.7.3-4) (Figure 4.2).  
 
 
Figure 4.2 A schematic outlining formation of an exogenous MP-labelled 
intraconstruct hydrogel Cortical astrocyte monolayers (a) were labelled with MP-5x 
particles and exposed to a static magnetic field for 30 mins. At 24 h post-particle addition 
(b) the MP-5x labelled cell suspension was added to the hydrogel solution, followed by (c 
& d) formation of the intraconstruct hydrogel. At 1 h post-construct (e) medium was added 
to the gel, and at 3 h post-construct (f) the gel was transferred to a larger well plate and 
free-floated in D10 medium to prevent inhomogeneous cell distribution. MP: Magnetic 
particle 
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Quantification of particle uptake, particle accumulation and long-term particle retention 
was conducted from these gels.  
In-situ particle-labelling approach: The latter approach, that of in-situ MP-labelling of 
astrocytes, consisted of MP-5x particles being added directly to the cell suspension prior to 
association with the hydrogel solution (as detailed in 2.7.1; 3-4).  This approach allowed 
observation under FESEM, TEM and dynamic live imaging of ultrastructural membrane 
features and particle inheritance, together with observations of endocytotic activity in 
intraconstruct hydrogels i.e. intracellular particle uptake and trafficking. 
Promoting homogeneity of cellular distribution: In developing the intraconstruct 
hydrogel, using either approach, it became apparent that the gels were subject to contact-
tension from the culture plastic (Buxboim et al., 2010; Discher et al., 2005), inducing 
inhomogeneous cell distribution i.e. cells were drawn towards the edge and the bottom of 
the gel. This phenomenon also influenced cell morphology in that cells at the base of the 
gel took on a flattened membranous morphology more typical of monolayer cultures, with 
clumping of cells a prominent feature at the gel edge where it contacted with the plastic. 
To address this, at 3 h post-construct, the hydrogels were transferred from the 24-well plate 
into a larger well-plate using a modified paddle spatula (Figure 4.3). Modification of the 
angle of the paddle head enabled careful transfer of the gels without damage to the 
collagen substrate or the internalised cells. Once transferred into a well containing 4 mL of 
D10 to facilitate free-floating of the gel, they were incubated at 37 °C (5% CO2/95% 
humidified air) and maintained over the course of the experiment with a 50% D10 refresh 
every 2 days. 
 144 
 
Figure 4.3 Schematic of modified paddle spatula and transfer technique Image 
showing (a) the modified angle head (arrow) of the paddle spatula. This modification 
enabled (b) gentle insertion of the paddle spatula between the cellular hydrogel and the 
wall of the well. This allowed media flow beneath the hydrogel (c) lifting the gel 
sufficiently from the base of the well to insert the paddle spatula under the hydrogel 
without exerting any force.  The hydrogel (d) could then be transferred to the (e) larger 
well plate to free-float in medium. Free-floating the gels helped promote a homogenous 3-
dimensional cellular network, unaffected by the tension forces from the culture plastic.  
 
Preparing the intraconstruct hydrogels for MRI: Exogenous MP-labelled intraconstruct 
hydrogels facilitated investigation of the utility of the MP-5x particle as a contrast agent 
for non-invasive tracking of the cell population under MRI. Due to the small size of the 
gel, it was necessary to place them within a carrier tube for insertion into the machine, for 
which a 30 mL universal tube was ideally suited.  The gel was sandwiched between layers 
of agarose gel within the tube to prevent air pockets distorting the MR image resolution.  A 
low-gelling temperature agarose gel (A4018 – Sigma) was used due to its gelling 
temperature of <30 °C – the majority of agarose gels form at temperatures in excess of 37 
b c d e 
a 
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°C, which would cause degradation of the collagen hydrogel and potentially disrupt the 
internalised cells.  
Briefly, a 1% w/v agarose solution with PBS buffer was heated to its melting point of >65 
°C to dissolve the agarose before being placed on a heat plate to cool to ca. 32-35 °C. The 
consumables used i.e. 10 mL pipettes and universal tubes, were also maintained at this 
temperature to prevent premature setting of the agarose gel during dispensing. Once cooled 
ca. 7 mL gel solution was added to the tube and allowed to set at 4 °C, whereupon the 
intraconstruct hydrogel was placed on this bottom layer before being sandwiched by a 
further layer of cooled (ca. 32-35 °C) agarose gel, and stored at 4 °C until imaged under 
MRI.  
4.3.4 Assessing cellular viability and safety of the protocols used: Safety of the protocols 
was of paramount importance in ensuring high cellular viability within the intraconstruct 
hydrogels. In this respect, cell health was quantified by cell counts and live/dead assays. 
EdU cell proliferation assays were conducted to assess the proliferative capacity of the 
cells (as detailed previously in 2.8.2). Each of these culture characteristics was measured 
from acquired z-stack images from the centre and edges of the gels. The homogeneity of 
cell distribution throughout the gels was investigated by comparative cell counts from the 
base, middle and top of the gel at the centre and the edges of the gel. Proliferation counts 
and live/dead assays were also quantified in this manner to determine homogeneity 
throughout the gel construct.  
In this respect, account was taken of the effect of cell growth within the collagen substrate 
itself as formation of the cellular network causes gel contraction. To determine any adverse 
effect of gel contraction on cellular viability, culture characteristics were assessed across 
the time-frame of the experiments.  
 146 
4.3.5 Investigating cellular characteristics of cortical astrocytes in a 3-dimensional 
environment: Differences in in vitro cellular morphology have been linked to the substrate 
on/in which they are cultured. 2-dimensional substrates force cell attachment and 
subsequently perfusion to opposing cell faces (East et al., 2010), unlike cells grown within 
a 3-dimensional gel construct which display morphological characteristics closer to their in 
vivo counterparts (Hu et al., 2014). As discussed previously in the introduction (see 1.5.2), 
functional behaviour of astrocytes has also seen alteration dependent on the substrate on 
which the cells were grown [2-dimensional hard substrate compared with 3-dimensional 
hydrogel (Hu et al., 2014; Moshayedi et al., 2010)]. From this, a putative link has been 
suggested between altered morphology and consequent altered cellular function (Hu et al., 
2014; Lee et al., 2008; Miron-Mendoza et al., 2013; Mohayedi et al., 2010).  
 
Figure 4.4 Characteristic morphologies of cortical astrocytes Fluorescence images 
displaying the characteristic morphologies of cortical astrocytes observed within (a) an 
intraconstruct hydrogel and (b) a monolayer culture. Note the small cell soma (a; 
arrowhead) and highly branched complexity of cells grown within a 3-dimensional 
collagen substrate. Compare this with the flattened, membranous morphology (b; 
arrowhead) typical of astrocyte monolayers cultured on coverslips, and the truncated 
processes of these cells (b; arrow). Scale of images = 50 µm 
a b 
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In these series of studies, observation of cell morphologies within the exogenously MP-
labelled intraconstruct gels, were uncharacteristic of those observed in monolayer cultures 
of cortical astrocytes. The former display a complexity of primary, branched processes and 
a smaller cell soma and nucleus than the latter, which displayed flattened, membranous 
morphology with, where present, truncated processes (Figure 4.4).  
These observations informed the array of morphological/morphometric analyses described 
below to quantify astrocyte morphology within a 3-dimensional collagen structure in 
comparison with monolayer astrocyte cultures grown on a hard substrate. Fluorescence 
images were scaled to show measurements per micron (µm) with the following 
morphological features quantified on a single cell basis; area of the cell soma; the size of 
the nucleus, and a measure of the ramified nature (branch-like processes) of astrocytes 
using the formula: - 4 x π x A/P2 where A=cell area and P=cell perimeter. This formula 
denotes the spherical nature of a cell, with a calculated value of 1 denoting a rounded cell 
morphology, and a value of <1 indicative of the level of complexity of the cell i.e. more 
branched (East et al., 2009). 
The number of primary processes was quantified, with process length calculated as a 
length ratio of the cell size, based on the formula: - L/D where L=length of the process 
(µm) and D=distance from the nucleus to the tip of the process (Hu et al., 2014) 
This measure provided a further indicator of the ramified nature of the cell, and the length 
of process compared to the size of the cell soma.  
4.3.6 Investigation of endocytotic features associated with particle uptake: To investigate 
these features, a novel approach was developed to facilitate visualisation of in-situ MP-
labelled intraconstruct hydrogels under TEM. The approach entailed embedding of the gels 
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within Spurr resin. Following glutaraldehyde fix and initial steeping in osmium (as 
previously detailed in 4.3.2), the gels were rinsed in dH2O (6x) and immediately taken 
through a modified series of ETOH dehydration steps as detailed above (Section 4.3.2) 
before embedding in Spurr resin. 
 The conventional Spurr embedding protocol which is generally used for infiltration into 
non-decalcified tissue or single cells (Spurr, 1969) was modified for use with the collagen 
gels. Briefly, at RT in the appropriate fume cupboard, gels were infiltrated in 3:1 100% 
DRY ETOH:Spurr resin mix overnight. The following day the gels were infiltrated in 1:1 
Spurr resin:100% DRY ETOH for 4 h. After 4 h, gels were infiltrated in 3:1 resin:100% 
DRY ETOH for a further 4 h before being infiltrated in pure Spurr resin overnight. The 
next day the gels were infiltrated in fresh pure Spurr resin for 8 h with a 100% change 
every 2 h, and then placed in an appropriate embedding mould and covered with fresh pure 
Spurr resin. The samples were then placed in a heated oven at 60 °C and the resin 
polymerised for 24 h.  
4.3.7 Immunocytochemistry: Immunolabelling of the cells using a modified protocol was 
as detailed in sections 2.9.2 and 2.9.3, with FITC secondary antibody used in these 
experiments due to the BODIPY® 546-570-PLA fluorophore coating of the particles. 
4.3.8 Imaging: Imaging of this series of experiments was conducted using Z-stack 
microscopy; Dynamic time-lapse imaging; FESEM; TEM and MRI (please refer to section 
2.10.2 for detailed information) 
4.3.9 Analyses: Quantification of culture characteristics and safety assessments were 
conducted from Z-stack triple-merged fluorescent micrographs. Dynamic time-lapse 
imaging allowed observation of particle inheritance. Ultrastructural membrane features and 
gel characteristics were visualised from FESEM micrographs, with cell cytoskeletal and 
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subcellular features visualised from TEM micrographs. Endocytotic activity such as 
intracellular particle uptake and trafficking and associated membrane features were also 
visualised from TEM micrographs. The utility of MP-5x particles as a suitable contrast 
agent for tracking of a cell transplant population, were visualised from MRI images. 
4.3.10: Statistical analysis: Data were analysed by one-way analysis of variance 
(ANOVA) with post-hoc analysis carried out using Bonferroni’s multiple comparison test 
(MCT). All data are expressed as mean ± s.e.m. The number of cultures used in this series 
of experiments was 3 (n = 3) unless otherwise stated, each derived from a different rat 
litter. 
  
 150 
4.4 Results 
4.4.1 Establishing MP-labelled astrocyte monolayers on a collagen substrate 
Pre- MP-labelled supraconstruct hydrogels show high levels of cell clumping 
Extensive cell clumping was observed throughout the supraconstruct gels using this 
approach [Figure 4.5 (a)], a feature which did not alter over the time-frame studied [Figure 
4.5 (c & d)]. Individual cells, albeit a small minority (ca. 5%), displayed small cell soma 
with numerous fine processes [Figure 4.5 (b & c)]. Particle uptake and cellular 
accumulation were evident although difficult to assess due to the high level of cell 
clumping observed with these gels. 
In-situ MP-labelled supraconstruct hydrogels show high particle uptake and 
accumulation 
 In contrast, in-situ supraconstruct gels showed lower levels of cell clumping with 
individual cells (ca. 70%) making up the larger proportion of the cell population. At 24 h 
post-particle addition, cells displayed small cell soma and long processes [Figure 4.6 (a)], 
and over the following 14 d, cells developed a highly ramified morphology [Figure 4.6 (b 
– d)] and the beginnings of a complex network [Figure 4.6 (d)]. Tight spheres of cells were 
still evident at 7 d [Figure 4.6 (b; inset)] with areas of clumped cells prevalent at 14 d, with 
levels of pyknosis - characterised by high levels of fluorescence indicative of detaching 
cell membrane - localised to the clumped cells [Figure 4.6 (e)]. High levels of particle 
uptake and accumulation were observed within the individual cells of these gels, with peri-
nuclear localisation featuring strongly, both at 24 h and at 14 d [Figure 4.6 (c & d)]. A 
high level of free particles were observed adherent to the collagen substrate [Figure 4.6 
(e)] 
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Figure 4.5 Pre- MP-labelled supraconstruct hydrogels over 14 days Fluorescence 
images showing pre-labelled supraconstruct gel at (a) 24 h and (b) 48 h post-seeding. Note 
the inhomogeneous distribution of the astrocyte monolayer (a; arrowhead).  Note also the 
differing morphologies apparent at 48 h whereby the majority of cells have remained 
rounded (b; red arrow), by contrast, note the ramified nature of a minority of cells at this 
same time point (b; white arrow). Fluorescence image (c) and FESEM micrograph (d) at 
14 d. Note the highly clumped nature of the cell population (c & d; arrowhead). Note the 
differing morphology displayed by the individual cells not in contact with others (c; arrow) 
Scale of images (a & c = 100 µm); (b = 50 µm); (d = 300 µm). FESEM: Field Emission 
Scanning Electron Microscopy; MP: Magnetic particle 
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Figure 4.6 In-situ MP-labelled supraconstruct hydrogels over 14 days Phase image (a) 
showing in-situ labelled cortical astrocytes at 24 h post-MP-5x particle addition. 
Fluorescence images showing typical cell morphology at (b) 7 and (c – e) 14 days post-
MP-5x-particle addition. At (b) 7 days a large proportion of the culture was made up of 
individual cells although (b; inset) tight spheres of cells were evident. At 14 days the 
culture was made up of similar proportions of (c) individual cells, (d) cell networks and (e) 
areas of cell clumping with localised pyknosis (e; arrowhead). Note the highly ramified 
nature of the cortical astrocytes (a – d; arrow) and the peri-nuclear localisation of 
particles at 24 h (a; arrowhead) and at 14 days (d; arrowhead). Note the high level of free 
particles adherent to the collagen substrate (e; arrow) Scale of images (a – e = 50 µm); 
(b; inset = 10 µm). MP: Magnetic particle 
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MP-5x particle uptake and accumulation in pre- MP-labelled versus in-situ MP-labelled 
supraconstruct hydrogels 
 Comparative observations of MP-5x particle uptake and cellular accumulation between 
pre-labelled (Figure 4.5) and in-situ labelled (Figure 4.6) supraconstruct gels, revealed 
higher levels of particle uptake and accumulation in the latter condition. The high level of 
cell clumping observed on the pre-labelled gels though, prevented accurate analysis of 
particle uptake and accumulation [Figure 4.5 (c)]. This overall pattern of cell clumping 
was observed from 24 h onwards [Figure 4.5 (a - d)]. In contrast, a very low level of cell 
clumping was observed with the in-situ labelled approach [(i.e. figures 4.5 (c & d) and 4.6 
(e)].  
Under the in-situ labelled condition, a high level of ‘free’ particles were observed adherent 
to the collagen substrate, a characteristic not observed with pre-labelled gels [Compare 
figures 4.5 (c) and 4.6 (e)]. Notably with the in-situ gels, fewer particles were observed 
where individual cells or cellular networks were prevalent; this in contrast to areas of 
highly clumped cells [Figure 4.6 (c; d; e respectively)].  
Results from supraconstruct gels inform the development of intraconstruct hydrogels 
The findings from supraconstruct hydrogels informed the development of intraconstruct 
hydrogels as a ‘protective’ environment for a neural cell transplant population. Cell 
clumping was an issue for both seeding approaches in supraconstruct gels, being more 
prevalent in the pre- MP-labelling approach. The cells may be responding to the 
topography and the surface tension of the collagen substrate, in that the MP-labelled cells 
may have settled within the fibril ‘troughs’ of the construct. However, this characteristic 
was less prevalent when cells were labelled in- situ, suggesting that the pre-labelled cells 
were heavier due to their particle load, and therefore, may have settled deeper into the 
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construct topography than cells that were seeded particle-free. This possibility is in line 
with the increased weight of the MP-5x particles. Indeed, in 2D monolayer cultures, rapid 
cell:particle contact was observed with MP-5x particles (see Chapter 3). Cell clumping 
appears pertinent to supraconstruct gels and therefore, utilising an intraconstruct approach 
delivers the potential to address this.  
A further key consideration noted from the resultant findings of the two MP-labelling 
approaches was the high level of free particles observed adherent to the collagen substrate 
with the in-situ MP-labelling approach, a feature not observed with pre- MP-labelling. This 
high level of particles potentially presents a two-fold disadvantage for tracking purposes. 
Firstly, free particles themselves would lead to a high frequency of false-positive signal. 
Secondly, free particles could be taken up by the host cells i.e. macrophages and microglia, 
resulting in erroneous recordings in tracking of the transplant population. Taken together, it 
was considered that the formation of intraconstruct hydrogels utilising pre- MP-labelled 
cortical astrocytes (termed ‘exogenous MP-labelled’ in regard to intraconstruct gels) would 
be the more effective approach (detailed in section 4.4.5). 
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4.4.2 Assessment of cellular viability and the safety of the protocols with intraconstruct 
hydrogels 
The average number of cells for both control and MP-labelled gels showed a significant 
drop in cell numbers at 7 d post-construct, although no difference was noted between the 
time-points at 14 d [Figure 4.7 (a)]. Cell viability remained constant at ca. 82% over the 
14 d in both control and MP-labelled gels [Figure 4.7 (b)]. Comparable proliferation rates 
were seen at 24 h between cells cultured as monolayers on glass [Figure 4.7 (c)] and cells 
within intraconstruct gels. The proliferative capacity of the cells was significantly reduced 
at 7 and 14 d post-construct suggesting a more quiescent culture over time [Figure 4.7 (c - 
e)].  
Gel thickness was ~ 1000 µm at time of construct. Distribution of cells was observed to be 
homogenous throughout the gel at 24 h and 14 days post-construct [Figure 4.8 (a and b); 
please see Supplementary Video 2 & 3 – disc 1]. Investigation of homogeneity of cell 
distribution found no difference in cell counts across the width of the gel [Figure 4.8 (c)] 
and throughout the depth of the gel in both control and MP-labelled gels over the 14 d time 
frame [Figure 4.8 (d)]. No difference was found in cellular viability across the width 
[Figure 4.8 (e)] and throughout the depth [Figure 4.8 (f)] of the gel. 
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Figure 4.7 Viability assessments show a high level of cellular viability and safety of 
protocols over time Bar graph (a) displaying the average number of cells in control and 
MP-5x labelled gels over 14 d post-construct. A significant difference in cell number was 
noted between 24 h and 7 d (*p < 0.05) in both control and MP-labelled gels. Bar graph 
(b) shows cellular viability to be ca. 82% over 14 d. Representative fluorescence 
micrographs of (c) a pair of EdU-identified dividing astrocytes at 24 h, cultured on glass 
(c; inset shows un-merged images), and (d) a pair of dividing astrocytes within an 
intraconstruct gel at 14 d. Bar graph (e) showing EdU-identified proliferative capacity of 
the cells over 14 d. At 24 h no difference in proliferative capacity was reported between 
cells in the two different environments. Proliferation was significantly higher at 24 h post –
construct versus 7 d and 14 d in both control and MP-labelled gels (*p < 0.05).  Scale of 
image = 50 µm (n = 3) Results expressed as mean ± s.e.m. MP: Magnetic particle 
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Figure 4.8 Safety assays show homogenous nature of cellular distribution in gels over 
time Illustrative fluorescence images showing the homogenous cell distribution throughout 
the hydrogels at 24 h (a) and 14 days (b) post-construct (Supplementary Videos 2 & 3 – 
disc 1).  Bar graphs show homogeneity in cellular distribution across (c) the width of the 
c d 
e f 
Cellular distribution across 
the width of the construct 
Cellular distribution through 
the depth of the construct 
Cellular viability across the 
width of the construct (%) 
Cellular viability through the 
depth of the construct (%) 
a b 
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gel, and (d) throughout the depth of the gel in both control and MP-labelled gels. Bar 
graphs show homogeneity in cellular viability across (e) the width and (f) throughout the 
depth of the gel over 14 d. (n = 3) C=centre; E=edge; L1 – L4=the layers through the 
depth of the gel where L1 = the base and L4 = the top of the gel. Results expressed as 
mean ± s.e.m. MP: Magnetic particle  
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The collagen intraconstruct hydrogels showed significant contraction over time compared 
with their initial size at the time of construct (16 mm).  A significant difference was seen in 
gel diameter within 3 h post-construct, reducing to ca. 9 mm at 14 d. Although the level of 
gel contraction appeared greatest within the first 24 h, the gel continued to show significant 
contraction over the 14 d. No difference in gel contraction was observed between control 
gels (cells, no particles) and MP-labelled gels (Figure 4.9).  
 
 
 
Figure 4.9 Gels show contraction of size over time Representative photographs (a) of 
gels at 24 h and 14 d. The initial gel diameter was 16 mm (gel thickness ~ 1000 µm), gels 
having been cast within the well (a; white arrow). Note the difference in gel diameter 
between these two time frames. Graph (b) showing the significant reduction in gel 
diameter over the 14 d time frame compared with the initial gel diameter at the time of 
construct (***p < 0.001; **p < 0.01). Gels showed a significant level of contraction 
between each time point - 3 h vs. 24 h; 24 h vs. 7 d; 7 d vs. 14 d (^^^p < 0.001; ^^p < 0.01; 
^ < 0.05).  Images not to scale (n = 3). Results expressed as mean ± s.e.m. MP: Magnetic 
particle 
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4.4.3 Characterisation of cellular and endocytotic features of cortical astrocytes within 
an intraconstruct hydrogel: comparison to astrocyte monolayers  
A highly connective, complex cellular network was evident throughout the intraconstruct 
gels at 14 d post-construct, with similar levels of complexity observed in control gels and 
MP-5x labelled gels [Figure 4.10 (a & b)]. Networks of aligned astrocytic processes were 
evident throughout the gel [Figure 4.10 (a)]. Cell clumping was negligible (ca. < 1%). A 
high level of intracellular particle retention was observed in the MP-labelled cells [Figure 
4.10 (b & c)] with peri-nuclear localisation of the particles still evident at this time-point 
[Figure 4.10 (c)]. 
 
Figure 4.10 Intraconstruct hydrogels at 14 d post-construct Fluorescence micrographs 
of (a) an intraconstruct hydrogel containing un- labelled cells (no MP-5x particles) and 
(b) MP-5x labelled cells. Note the complex cellular network, with dense “bundles” of 
aligned astrocytic processes evident throughout the gel (a & b; arrowhead). A high level of 
intracellular particle retention was evident (b; arrow). TEM micrograph of (c) an 
exogenous MP-labelled intraconstruct gel, at day 15. Note the high particle accumulation 
within the cell at this time point (arrow).  Scale of images (a & b = 50 µm); (c = 5 µm) 
[Fig. 4.10 (a) replicate of Fig. 4.4 (a)] Nu: Nucleus. MP: Magnetic particle 
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a b c 
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Cortical astrocytes grown within the 3-dimensional environment of intraconstruct 
hydrogels displayed a set of characteristics distinctly different to that of cortical astrocytes 
cultured as 2-dimensional monolayers on glass coverslips. The former are of a highly 
ramified nature, having a small soma and nucleus in comparison to the highly 
membranous, flattened morphology typical of astrocyte monolayers. They possess a high 
number of long, threadlike filopodia compared with the short, truncated processes of 
astrocytes cultured on glass [Compare figure 4.11 (a and b)]. 
A measure [Figure 4.11 (c)] to compare the cell shape (round vs. ramified) of cells grown 
in the 2- or 3-dimensional environment found no difference between the cells in either 
environment at 24 h, indicating the rounded nature of the cells in the 3-dimensional gels at 
this time point. At 14 d, the cells within the hydrogel showed a significant difference in 
cell shape - being more highly branched at this time point –in comparison to their 
morphology at 24 h and to the morphology of cells cultured as monolayers [Figure 4.11 
(d)].  
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Figure 4.11 Cortical astrocytes grown within a 3-dimensional hydrogel show 
morphological characteristics different to that of astrocyte monolayers cultured on 
glass Fluorescence micrographs at 14 d depict (a) the highly ramified morphology of 
cortical astrocytes grown within an intraconstruct hydrogel. Note the size of the cell soma 
and nucleus (a; arrows). Note the length and the overall complexity of the fine meshwork 
Cell shape of GFAP+ve cells in 2- and 3-
dimensional environments over 14 days 
GFAP 
DAPI 
a 
d 
c 
b 
14 days post-construct 
GFAP 
DAPI 
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of processes on these cells Compare this with (b) cortical astrocytes cultured as 
monolayers on glass. Note the larger size of the cell soma and nucleus and the highly 
membranous, flattened morphology of these cells. Note also the shorter, truncated 
filopodia extending from the astrocytes (b; arrows). By comparison (c) note the length of 
the primary processes of cells within intraconstruct gels (c; arrow) and their branched 
morphology (c; arrowhead). Representative fluorescence micrographs (b & c), illustrate 
how cells were measured to determine their shape (rounded or ramified). Graph (d) shows 
the rounded/ramified nature of cells grown within hydrogels or as monolayers on glass. 
(***p < 0.001).  Scale of images (a; b & c = 50 µm) (n = 3) Results expressed as mean ± 
s.e.m. MP: Magnetic particle 
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Comparative measures of cell morphology showed cells grown in intraconstruct hydrogels 
had a significantly smaller cell surface area at 24 h and at 14 d post-construct. It was 
notable that at 14 d, the reported difference in cell surface area between cells from the two 
environments, although significant for MP-labelled cells, was less than at 24 h. This is 
possibly indicative of the similarity in overall surface area at 14 d, taking into account the 
highly ramified nature, at this time point, of cells grown in hydrogels [Figure 4.12 (a)].  
The average nuclear size of cells grown in gel constructs was significantly smaller at 14 d 
in comparison to cells cultured as monolayers. At 24 h, possibly due to the early time 
point, the reported difference was less with a significant difference reported between 
control cells [Figure 4.12 (b)]. 
The average number of primary processes was the same at 24 h, a finding supported by 
data showing similar measures of roundedness in cell shape at this time point. Cells in 
intraconstruct hydrogels showed a significantly higher number of processes at 14 d 
compared with cells grown as monolayers [Figure 4.12 (c)], indicating the level of 
complexity observed in these cells. Compared with cells cultured as monolayers, the 
average length ratio of primary processes was significantly higher in cells grown within 
hydrogels, indicating a significantly longer process length in relation to the size of the cell 
soma, and also being a further indicator of the smaller size cell soma of these cells [Figure 
4.12 (d)]. 
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Figure 4.12 Comparative measures of cells grown in either a 2- or 3-dimensional 
environment show significant differences in morphology Bar graphs showing the 
significant difference in (a) average cell area (µm2) and (b) nucleus size (µm2) between 
cells grown within a hydrogel vs. cells grown on glass. Bar graph (c) showing the average 
number of primary processes is significantly higher at 14 d for cells grown within a 
hydrogel. Bar graph (d) showing the average length ratio of primary processes is higher in 
cells grown within a gel compared with cells cultured on glass [process length was 
calculated as a length ratio of the cell size i.e. L/D where L=process length (µm) and 
D=distance from nucleus to process tip] (***p <0.001; **p <0.01; *p <0.05) (n = 3). 
Results expressed as mean ± s.e.m. MP: Magnetic particle 
a Average cell area  b 
Average number of 
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4.4.4 Endocytotic features associated with particle uptake in an intraconstruct hydrogel 
Ultrastructural membrane features visualised under FESEM 
Cortical astrocytes are regarded as a highly endocytotic neural cell and are known to show 
avid particle uptake. In this regard, use of FESEM enabled visualisation of a number of 
ultrastructural membrane features associated with cellular endocytotic activity. Cell 
morphologies showed high levels of filopodia, membrane ruffling and pits; characteristics 
indicative of a highly endocytotic cell (Figure 4.13).  
  
 
Figure 4.13 Ultrastructural membrane features of cortical astrocytes FESEM 
micrographs displaying ultrastructural features associated with endocytotic activity. 
Supraconstruct gels showed differing morphologies between (a) areas of clumped cells and 
(b) individual cells. Cells were observed (b) on top of areas of highly connected astrocytes 
[also (a; red arrow)]. Cells displayed extensive levels of filopodia (b; white arrowhead) 
with membrane ruffling observable (a & b; red arrowhead). Pits were visible [(a; inset) 
and (b); white arrow). Note the membrane ruffling (a; inset; white arrowhead) and 
circular membrane nodule (b; black arrowhead) associated with the pits.  Scale of images 
(a = 30 µm; inset = 3 µm); (b = 7.5 µm) FESEM: Field Emission Scanning Electron 
Microscopy  
a b 
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Ultrastructural membrane and subcellular features visualised under TEM 
 Ultrastructural and subcellular observations of cortical astrocytes within intraconstruct 
hydrogels were facilitated by TEM microscopy. The cells were seen to be actively 
engaging with the collagen substrate, indicative of the remodelling of their environment. 
Together with a high level of membrane activity associated with the surrounding collagen 
fibrils [Figure 4.14 (a & b)], astrocytes displayed a number of typical endocytotic features 
pertinent to particle uptake and trafficking.  
Invaginations and coated ‘pits’ were prominent features of the cell membrane. Both coated 
and non-coated invaginations were observed localised to areas of high membrane activity 
and may be membrane folding or ruffling associated with macropinocytosis [Figure 4.14 
(a and inset)]. The coating observed on the invaginations/pits suggests a receptor-mediated 
endocytotic pathway which may be clathrin, although this was not verified [Figure 4.14 (b 
& c)].  
High levels of MP-5x particle accumulation were observed within the cells at this time 
point, with the majority showing peri-nuclear localisation [Figure 4.14 (a; b & inset)]. 
Endosomal uptake of particles was also evident [Figure 4.14 (d)]. The high magnetite 
concentration particles were visualised as dark ‘spheres’ under TEM, with many displaying 
a small hollowed out core surrounded by a dense ‘ring’; features that are consistent with 
the magnetite matrix composition of these particles [Figure 4.14 (a – b & inset; d). 
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Figure 4.14  A number of endocytotic features were observed, associated with particle 
uptake and trafficking TEM micrographs (a, b & c) at 15 d post-construct showing the 
highly active membrane of cortical astrocytes within a collagen construct. A high level of 
active engagement with collagen fibres was observed (a; red arrow and delineated in red) 
with the notable association of coated (a; inset – black arrow) and non-coated (a; black 
arrow) invaginations and membrane ruffling localised to this active area.  A high number 
of coated pits were also evident (b & c; red arrow). Representative TEM micrograph (b) 
showing a high accumulation of MP-5x particles (a & b; white arrow) with the majority 
showing peri-nuclear localisation (b; inset). TEM micrograph (d) shows endosomal uptake 
(d; red arrow) of particles (d; white arrow). Note the appearance of the magnetite particle 
under TEM– a dark ‘sphere’ with a small hollowed out core surrounded by a dense ‘ring’, 
15 d post-construct 
a b 
c 
d 
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consistent with the high magnetite matrix composition of these particles (a – b, d; white 
arrow).  Scale of images (a; a-inset & b = 1 µm); (b; inset = 0.25 µm); (c = 0.5 µm); (d = 
0.25 µm) [Fig.4.14 (b) replicate of Fig. 4.10 (c)] MP: Magnetic particle; Nu: Nucleus; 
TEM: Transmission Electron Microscopy 
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4.4.5 Development of exogenous MP-labelled cellular intraconstruct hydrogel with the 
utility for non-invasive tracking of the neural cell population using MRI 
At 24 h post-construct a high level of particle accumulation and co-localisation of particles 
with cells was noted, as was the homogenous distribution of the cells throughout the 
intraconstruct gel. A low level of free particles was observed at this time point suggesting 
loss of particles from cells during gel construct. Clumping of cells was not evident in these 
gels at this time [Figure 4.15 (a)].  
MR imaging of these gels at 24 h showed a strong loss of signal (hypointense) from the 
MP-5x-labelled astrocytes within the gel [Figure 4.15 (b)]; loss of signal indicative of the 
presence of an effective contrast agent (i.e. MP-5x particles).  By contrast, note the high 
level of MR signal (hyperintense) from the control gel (cells; no particles) [Figure 
4.15(c)].  
At 14 d there was a notable absence of particles from the extracellular space suggesting 
continued particle uptake by the cells within the gel construct [Figure 4.15 (d)].  MR 
imaging of these gels at 14 d recorded a hypointense signal from MP-5x labelled cells, 
with, by contrast, a hyperintense signal recorded from the control gel [Figure 4.15 (e & f)]. 
Networks of dense “bundles” of aligned astrocytic processes were evident within the 
cellular network at this time point. Cell clumping was negligible (ca. <1%). 
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Figure 4.15 MP-5x labelled astrocytes within intraconstruct hydrogels provide a 
hypointense signal under MRI Fluorescence micrograph of (a) an exogenous MP-5x 
labelled intraconstruct hydrogel at 24 h post-construct. Note the high level of particle 
accumulation (a; arrow). Comparable MR images showing (b) MP-5x labelled and (c) 
control (cells; no particles) intraconstruct gels at the same time-point (b & c; arrows – 
hydrogels indicated in orthogonal view). Fluorescence micrograph of (d) an exogenous 
MP-labelled intraconstruct gel at 14 d post-construct. Note the absence of particles in the 
extracellular space at this time-point (arrow). Networks of aligned astrocytic processes 
were evident throughout the cellular network (d; arrowhead). Comparable T2-weighted 
MRI scans of (e) MP-5x labelled and (f) control gels at 14 d post-construct (arrow; 
hydrogel indicated in orthogonal view). Note the hypointense signal recorded from the 
MP-5x labelled cells within the gels (b & e) at both time-points with by contrast, the 
hyperintense signal recorded from the cells in the control gels (c & f).  Scale of images (a 
a b c 
d e f 
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= 100 µm); (b & c, e & f = 5 mm); (d = 50 µm) MP: Magnetic particle; MR: Magnetic 
resonance; MRI: Magnetic resonance imaging 
 
Particle inheritance in daughter cells of dividing astrocytes 
 With use of dynamic time lapse imaging, cells were visualised to be dividing in real time 
[Figure 4.16 (a – f)]. The particles were inherited by the daughter cells [Figure 4.16 (f)], 
thereby retaining tracking capacity.  
 
 
Figure 4.16 Particle inheritance between daughter cells of dividing astrocytes 
Dynamic time-lapse still images showing (a – f) an MP-5x labelled cortical astrocyte 
undergoing division at 7 d post-construct (Please see Supplementary Video 4 – disc 1). The 
particles are inherited by the daughter cells (f; arrow head), thereby retaining their utility 
as a trackable cell population.  Scale = 50 µm MP: Magnetic particle 
 
  
a b c 
f e d 
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MP-labelled intraconstruct gel at 37 d post-construct 
Intracellular particle retention was still visible in intraconstruct gels at 37 d post-construct. 
MR imaging of these gels showed a hypointense signal from the MP-labelled gel. The 
signal from these gels was observed as higher than that observed at 24 h and at day 14 
indicating a lower level of particle accumulation within the cells at this time point. 
Hypointense localised signal was recorded from this gel. By contrast, a hyperintense signal 
was recorded from the comparable control gel (Figure 4.17). 
 
 
Figure 4.17 Hypointense signal recorded from MP-5x labelled cells within 
intraconstruct hydrogels at 37 d post-construct Confocal fluorescence micrograph of (a 
& b) an MP-labelled intraconstruct hydrogel at 37 d post-construct (Please see 
Supplementary Video 5 – disc 1). Note the intracellular localisation of particles at this 
extended time-point (a; arrow). Comparable T2-weighted MRI scans show (c) a 
hypointense signal from the MP-labelled cells within the gel (arrow – hydrogel indicated 
in orthogonal view) and (d) a hyperintense signal from the un-labelled cells within the 
control gel (arrow – hydrogel indicated in orthogonal view).  Scale of images (a = 100 
µm); (c & d = 5 mm) MP: Magnetic particle; MRI: Magnetic resonance imaging 
a Day 37 
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4.5 Discussion 
Protective neural cell delivery systems offer a viable solution to the technical issues faced 
in cell transplant for spinal cord regenerative therapy. In order to develop such a system, 
there were a number of technical considerations in facilitating the development of a viable 
3-dimensional neural cell construct with imaging potential for regenerative applications. 
Here the major challenges inherent to the development of such a construct have been 
addressed. 
Exogenous MP-labelled intraconstruct hydrogels offered the most promising approach as a 
3-dimensional construct, with collagen providing the ideal substrate (as discussed 
previously; see section 1.5.2). Its macroporous nature allowed the cells the opportunity to 
orient and remodel the fibres to support their growth; possessing the potential to mimic 
endogenous tissue (Trappman & Chen, 2013; Wakatsuki & Elson, 2003) and facilitating a 
highly viable complex cellular network throughout the gel. At 14 d post-construct, large 
networks of aligned “bundles” of astrocytic processes were evident throughout the cellular 
network. This suggests promise for the construct’s utility as an implant, as cellular 
alignment offers a greater potential for guidance of ingrowing neuronal axons into the 
construct in vivo (Winter et al., 2016). In this regard, free-floating of the gel played a key 
role in promoting a homogenously distributed cell population, and one which possessed 
morphological characteristics closer to their in vivo counterparts – small cell soma, stellate 
morphology with a diffuse network of fine extensive processes (Balasubramanian et al., 
2016). This in comparison to cortical astrocytes cultured as monolayers on glass 
(Moshayedi et al., 2010), or indeed cortical astrocytes grown within anchored gels, which 
are predominantly bipolar in shape and aligned to the tension exerted upon the gel (East et 
al., 2010; Grinnel, 2000).  
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The major challenge in clinic is lowered cellular viability, the cause and the effect of 
inhomogeneity of the transplanted cells (Guest et al., 2011; Pearse et al., 2007), and a 
major obstacle also realised within 3-dimensional constructs (Unsworth et al., 2003). 
Within the intraconstruct gels developed here, cellular distribution was homogenous 
throughout the breadth and depth of the constructs with cellular viability remaining 
consistently high across the time course.  
In this respect, safety of the protocols was of paramount concern. The consistent cellular 
viability and the homogenous nature of cellular distribution and proliferation within the 
constructs suggested effective availability of oxygen and nutrients (Malda et al., 2004) and 
efficient removal of metabolic waste products from the hydrogel (Mertens et al., 2014). In 
each of these parameters, no significant difference was reported between MP-labelled and 
control hydrogels (cells, no particles) with similar levels of cellular viability and 
homogeneity of distribution and proliferation reported in both constructs over time.  A 
drop in average cell numbers following 24 h post-construct was noticed within the gels, 
although cellular viability remained consistent at approximately 82% across the time 
period. A significant decrease in proliferative capacity was also recorded following 24 h 
and this, combined with the low level of cell death occurring over the time-span may 
account for this initial drop in cell number. 
In respect of cellular proliferation, of critical importance to their utility within an implant is 
the growth curve of the cell transplant population (as previously discussed within the main 
introduction). Within intraconstruct hydrogels, following the significant reduction after the 
initial 24 h, proliferation remained consistently low across the time period studied, 
indicating a relatively quiescent population. In this respect, there is a wide body of 
evidence that reports the ECM proteins within collagen I regulate the proliferative capacity 
of cells (Trappman & Chen, 2013). This inhibition is mediated further following gel 
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contraction, whereby down regulation of extracellular signal regulated kinase (ERK) 
arrests cells in G0 phase of the cell cycle (Grinnel. 2000). This interruption to the cell cycle 
may have further relevance to the level of relative quiescence observed within these gels in 
this particular neural cell, with studies reporting that of cell-cycle-arrested astrocytes, only 
35% subsequently return to the cell cycle, either at any one time or if at all (Murphy, 
1990).   
As discussed previously cells, in establishing a connective, complex network, remodel the 
collagen fibrillar matrix and in so doing, contract and compress the gel. As reported 
extensively in other studies, gel contraction of free-floating gels is in direct relationship to 
the density of both the cell population and the collagen construct. Rapid contraction occurs 
within the first 12 h, the rate of which significantly decreases thereafter (Brown, 2013). 
The hydrogels in this study showed a similar rate of contraction, with no difference noted 
between MP-labelled and control gels. Safety assessments conducted over the time course 
showed gel contraction had no adverse effects on the viability of the intraconstruct 
hydrogels. The safety of the findings reported here were in line with many other 
cell:construct systems, whereby matrix-beneficial constructs have shown no significant 
adverse effects on cell viability (Frampton et al., 2011).  
MP-5x particles were utilised in these gels due to the high level of uptake, accumulation 
and long-term retention previously observed with these particles in cortical astrocyte 
monolayers cultured on glass (Tickle et al., 2016).  In respect of their utility as a contrast 
agent under MRI within the intraconstruct gel, the level of particle accumulation in these 
cells proved highly efficient in providing a hypointense signal at 24 h through 14 d to 37 d 
post-construct. The level of particle accumulation observed in the cells within the 
intraconstruct gel was lower than that typically observed in astrocyte monolayers; an 
interesting observation considering the cells were pre-labelled as a monolayer culture prior 
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to association with the hydrogel. Some particle loss was observed at 24 h post-construct. 
Although, the level of free particles noticeably decreased from approximately 48 h 
onwards, suggesting continued cellular uptake of the particles from within the gel.  A 
probable explanation for lower intracellular particle accumulation may be due to their 
significantly smaller cell soma. The extent of particle loading within a cell is typically 
considered as being relational to their surface area and endocytotic activity i.e. comparison 
between astrocytes and NSCs (Tickle et al., 2016). However, it could be postulated that 
particle loading may also be directly associated with the size of the cell soma.  This 
presents itself as a key factor in consideration of the optimal cell:label combination for 
transplant.   Be that as it may, in respect of the particle load in cortical astrocytes within the 
construct developed here, a hypointense signal was observed in these cells over an 
extended time period.  
In respect to its application to regenerative therapies, a concern with MRI was the potential 
for false-positive signal over an extended time frame. Despite no observation of free 
particles at 14 d, they were observable within the ECM of the gel at day 37. There are 
opposing views on the role exocytosis plays in particle release, with either vesicle or 
lysosome secretion factoring in particle trafficking from the cell (Oh & Park, 2014). It is 
also argued that exocytosis does not play a role in particle release, but that particle dilution 
in cells is a result of cell division and the subsequent inheritance of the particles by the 
daughter cells (Harrison et al., 2016; Kim et al., 2012). With regards to these constructs, 
the mechanism remains unclear. Particle loss may occur during cell division, although this 
was not observed in this study, with particles remaining cell-bound throughout.  In this 
context, proliferative capacity was significantly reduced from day 7 onwards, suggesting a 
higher level of particle retention over time. A reasonable proposition, therefore, for the 
extracellular particles observed at this time point may be the release of particles from 
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apoptotic cells – a feature observed with collagen encapsulated cells (Wakatsuki & Elson, 
2003).   
What does remain unclear was why a less hypointense signal was recorded from the 
intraconstruct gel at day 37 versus the earlier time points. This would suggest removal of 
the free particles from the gel into the media, which, given the macroporous nature of the 
collagen may be a possibility.  This would not though, explain the high observance of free 
particles within the gel.  Even so, while lower hypointensity overall was recorded at this 
extended time point, hypointense ‘spots’ were observed throughout the gel, suggesting 
localised particle retention in cells. This possibility was corroborated by fluorescence 
microscopy, thus verifying the construct’s continued utility over an extended time frame.  
In regards to the potential use of this construct as a protective delivery system, is the effect 
of construct contraction following implant into a spinal cord lesion. Within the limitations 
of this study, the possible outcomes remain unclear. Nevertheless, collagen constructs as 
an implant have reported sufficient axonal infiltration into the construct within three weeks 
post-implant, coincident with almost complete degradation of the collagen construct at this 
time point. Moreover, subsequent neuronal regeneration and restoration of locomotor 
function was reported (Kaneko et al., 2015). Thus, while the findings cannot be considered 
analogous to the constructs engineered within the present study, they offer promise. 
In respect of characterisation of cortical astrocytes, much has already been discussed 
regarding the morphological differences observed in these cells dependent on their 
environment. The similarity in endocytotic function with regards to particle uptake was 
evident, with uptake, accumulation and long-term retention a prominent feature in these 
cells, irrespective of their environment. The physico-chemical properties of MPs in relation 
to uptake, have previously been elucidated (please refer to Chapter 3; Tickle et al., 2016) 
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so will not be addressed further here. However, the use of FESEM and TEM in this study 
offered some insight into the potential endocytotic mechanisms utilised by these cells.  
The technical development of embedding the hydrogels within a resin carrier allowed 
effective use of TEM to study the morphologies, membrane features and intracellular 
particle localisation in soft matrices. This is a novel development of key importance to the 
understanding of cell characteristics within a 3-dimensional soft matrix environment. 
Within these intraconstruct gels, the high level of membrane interaction with the collagen 
matrix was a key feature. From this, it could be speculated that this mechanism is related to 
the cells’ remodelling and (re)adapting of their environment.  
A number of endocytotic features such as membrane ruffling, filopodia and pits were 
evident. Speculative association of these features with endocytotic mechanisms such as 
macropinocytosis and clathrin-mediated endocytosis corroborated previous findings 
(Pickard et al., 2011). Cell trafficking of the particles was indisputable, with peri-nuclear 
localisation a prominent feature. What was clearly evident within the cells was endosomal 
uptake of the particles. The particles used in this study are 254-280 nm in diameter. Given 
the reported diameters of clathrin-coated pits (ca. 100-150 nm) and caveolae invaginations 
(ca. 60 nm) this would suggest that macropinocytosis (> 0.5 µm) is the endocytotic 
mechanism employed here (Zhu et al., 2013).  Although, clathrin-mediated uptake of 200 
nm diameter particles has been reported (Oh et al., 2009), with particles of 500 nm 
diameter reported associated with caveolae-mediated endocytosis (Rejman et al., 2004), 
hence there may be a number of endocytotic pathways employed in uptake of these 
particular particles. What is incontrovertible is that particles (or at least, some) are 
trafficked via endosomes, which suggests, considering the peri-nuclear localisation, that a 
number of strategies for endosomal escape are being employed by (the majority of) the 
particles. It has been suggested that oscillating magnetic fields may alter the intracellular 
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processing of particles to facilitate endosomal escape (Adams et al., 2013; Dobson, J., 
2008; Fouriki et al., 2010; McBain et al., 2008; Pickard & Chari, 2010), although, this 
would not be a viable explanation here as these cells/particles have not been exposed to 
such a field. An alternative intracellular route has been associated with caveolar-mediated 
uptake, whereby stimulated caveolae uptake resulted in formation of “caveosomes” 
(multiple caveolae structures) that bypassed the endosome-lysosome route (Kiss & Botos, 
2009). This ‘recruiting’ of multiple structures may explain how caveolar-mediated 
endocytosis has been associated with uptake of much larger particles, and thus, may offer a 
plausible explanation here. However, the strategies employed remain to be elucidated.  
Further characterisation of these constructs is required. Taken together, the findings from 
this study suggest the protocols employed here are robust for the development of an 
exogenously MP-labelled intraconstruct hydrogel. Such a construct offers potential as a 
protective neural cell delivery system with the capability for non-invasive tracking under 
MRI.  
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Chapter 5  
Influence of amplitude of oscillating 
magnetic fields on MNP-mediated 
gene transfer to astrocytes 
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5.1 Introduction  
Magnetofection - as discussed previously within the main introduction (Section 1.5) - 
offers significant benefits for regenerative neurology applications. In this context, 
functionalized magnetic particles (MNPs) have high promise for regenerative therapies, 
both as a label for non-invasive tracking of transplant populations (White & Jakeman., 
2008) and, for the purposes of this series of studies, as a transfection vector for genetic 
modification of neural cells (Plank et al., 2011).  
Of key importance, a high level of safety is associated with this technology (for example 
Plank et al., 2003), although there remains significant technical knowledge gaps in respect 
of the parameters that govern the efficacy of magnetofection with neural cells. This is 
potentially a very useful technology to regenerative therapy and therefore it is pertinent to 
explore its possibilities with these neural cells. The use of a static magnetic device 
overcomes the spatial barrier between cells and particles (Laurentt et al., 2011), efficiently 
and rapidly delivering the nucleic acid to the target cells; the combination of magnetic field 
and superparamagnetic particles becoming a driving force in drawing the particles and the 
associated plasmid down to and across the cell membrane (Huth et al., 2004; Ma et al., 
2011; Plank et al., 2011). In this regard, Furlani and colleagues reported that the space 
between the magnet and the cell chamber affected the rate of particle accumulation: an 
important consideration in gene transfection studies (Furlani & Ng., 2008).   
A major disadvantage associated with static magnetic fields has been the focused particle 
accumulation at the centre of a cell culture chamber (Furlani & Ng, 2008).  This 
homogeneity of particle sedimentation has the potential to cause a ‘bottleneck’ predicting 
uptake in only a small percentage of cells located at the ‘hotspot’. The probable result of 
this is low particle uptake but with a high potential for toxicity. A recent innovation to 
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magnetofection to modulate this high particle load at the cell membrane, has been the use 
of dynamic magnetic fields (Baryshev et al., 2011; Dahmani et al., 2013; McBain et al., 
2008), including devices that oscillate along an axis with programmable frequency and 
amplitude. Oscillating fields have yielded higher levels of transfection compared with 
static fields, in a range of major neural transplant cell types such as cortical astrocytes 
(Pickard & Chari, 2010); OPCs (Jenkins et al., 2011) and NSCs - generally held to be 
‘hard-to-transfect’ (Adams et al., 2013; Pickard et al., 2011). The mechanisms by which 
oscillating fields elicit greater transfection efficiency are not fully understood. It is likely 
that the lateral motion imparted to the particles, increases the probability of particle-cell 
contact across the whole of the cell culture. It has also been suggested that the lateral 
motion of unattached particles across the cell membrane, or vibration of membrane-
bound/internalised particles may mechanically stimulate endocytosis due to the shearing 
forces at the cell level (Huth et al., 2004; Kamau et al., 2006; McBain et al., 2008; Pickard 
& Chari, 2010). Considering the major obstacle in gene delivery is thought to be related to 
the endocytotic capability of the target cell (Fernandes & Chari., 2014), this stimulatory 
mechanism is a predictor of high levels of particle uptake. Likewise it has been suggested 
that oscillating fields may alter the intracellular processing of particles, for example by 
facilitating endosomal escape (Adams et al., 2013; Dobson, J., 2008; Fouriki et al., 2010; 
McBain et al., 2008; Pickard & Chari, 2010).  
In the context of utilising oscillating magnetic fields, McBain et al. studied the correlation 
between oscillation amplitude and efficacy of gene delivery to a human airway epithelial 
cell line (McBain et al., 2008). Using cell size as a comparator, amplitude parameters were 
based on oscillations smaller than cell size (100 nm), larger than cell size (200 µm) and 
much larger (1 mm). Compared with static systems they found improved transfection 
efficiency in the presence of applied oscillating fields (frequency (F) = 2 Hz, amplitude = 
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200 µm).  Based on their examination of a range of frequencies/amplitudes, the authors 
suggest that ‘amplitude is of greater importance than frequency’ in enhancing gene 
transfer, at least in the frequency range tested (1-4 Hz).  Conversely, studies investigating 
optimal frequency for gene transfer to astrocytes, used a fixed amplitude of 200 µm to test 
a range of frequencies (F = 1; 3; 5 Hz). Of these, 1 Hz was reported to be optimal for gene 
delivery and hence, suggested as being frequency-dependent (Pickard & Chari, 2010).  
This latter study indicates that frequency may play a greater role in enhancing gene transfer 
than was previously assumed, at least in neural cells.  However, it is still unclear whether 
the most effective identified frequency in a specific neural cell type can potentially 
yield better transfection outcomes, when paired with optimal oscillation amplitude.  
Additionally, in terms of further enhancing non-viral gene delivery using MNPs, repeat 
administration of MNP:plasmid complexes (“multifection”) have been shown to enhance 
transfection efficiency in NSCs, both as neurospheres (Pickard at al., 2011) and as a 
monolayer culture (Shah et al., 2013). Both studies found that the combinatorial effects of 
multifection and application of a magnetic field (termed ‘magneto-multifection’) increased 
transfection efficiency in NSC cultures. Therefore employing the optimal frequency and 
amplitude for astrocytes, magneto-multifection may enhance transfection efficiency and/or 
the extent of transgene expression. This is based on a number of considerations. One, 
repeat administration of MNP:plasmid complex at 8 h intervals could increase the 
likelihood of plasmid DNA (pDNA) exposure to a greater proportion of target cells. Two, 
previous studies (Pickard & Chari, 2010) have observed gfp expression in astrocytes in as 
little as 4 h, indicating rapid intranuclear delivery and transgene expression in a small 
number of cells. Potentially, levels of gfp expression could be significantly enhanced in 
this same subpopulation, being subject to repeat exposure of MNP:plasmid complex over 
the short time interval employed.   
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An important, but often overlooked consideration in transfection studies utilising MNPs, is 
the correlation of particle uptake with transgene expression. The perceived expectation is 
that increased particle load will, in turn, increase delivery of the pDNA to the target cell. 
While use of magnetofection strategies have reported significantly increased transfection 
efficiencies (i.e. number of transfected cells) in a number of neural cell types (i.e. Adams et 
al., 2013; Jenkins et al., 2011; Pickard & Chari, 2010; Pickard et al., 2011), no study has, 
as far as can be ascertained, explored the correlation between particle load and transgene 
expression. This has specific consequences in the context of drug/gene delivery for clinical 
application. A high number of cells expressing a low level of transgene expression offer a 
different clinical outcome than that of a low number of cells showing high transgene 
expression. 
To address the key aims of this study – investigating the effects of amplitude and magneto-
multifection on transgene expression in astrocytes - two hypotheses are proposed  
i) that the amplitude of the oscillating magnetic field can influence transfection 
outcomes in astrocytes and  
ii) that the sequential application of transfection complexes/magnetic fields can 
enhance transfection outcomes in astrocytes.  
In order to test these hypotheses, a number of parameters were assessed.  Previous studies 
(Pickard & Chari, 2010) reported a frequency of 1 Hz to be optimal for gene transfer to 
astrocytes, and hence this informed the fixed frequency utilised for this present study. 
Following a similar rationale to McBain et al. the range of amplitudes tested here was 
based on measures of the cell type used i.e. astrocytes, rather than a generic cell 
measurement as utilised in the McBain study. In respect of the findings by Furlani & Ng, 
 186 
the effect of increasing the distance through use of a coverslip in the well plate was also 
assessed.  
5.2 Objectives 
1)   Investigate the influence of amplitude of oscillating magnetic fields on MNP-
mediated gene transfer to astrocytes  
2)   Investigate if magneto-multifection modifies MNP-mediated gene transfer to 
astrocytes  
3)  Investigate the correlation between MNP uptake and transgene expression in 
astrocytes 
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5.3 Experimental procedures 
5.3.1 Reagents and equipment:  All reagents and equipment used are as described 
previously in sections 2.1; 2.2.3; 2.3 & 2.6.  For the NeuroMag and NeuroMag Fluo, the 
recommended concentration by Oz Biosciences for magnetofection of neurons is 7 µl/mL. 
However, lower concentrations of these particles have been required for safe transfection 
of neural stem cells (Pickard et al., 2011); indeed, previously conducted cytotoxicity 
studies investigating particle concentrations for gene transfer to astrocytes, reported the 
optimal NeuroMag concentration for routine magnetofection in astrocytes is one tenth the 
concentration that of neurons (0.7 µl/mL) (Pickard & Chari, 2010).   With regards to the 
DNA binding efficiency of NeuroMag, this has previously been identified as maximal at a 
ratio of 3.5 µl NeuroMag to 1 µg DNA (Pickard & Chari, 2010).  These then informed the 
NeuroMag concentration and MNP:plasmid ratio used in the present study. 
5.3.2 Area and Feret’s Diameter (FD) as representative measures of cell size:  A similar 
rationale to McBain et al. (2008) was used in determining the range of amplitudes to be 
tested; namely cell size as a parameter for amplitude selection. Primary-derived astrocytes 
in culture exhibit two phenotypes which differ in shape and size and are widely referred to 
as type 1 and type 2. Type 1 exhibit a variable ‘polygonal’ morphology made up of a 
highly membranous cell body with truncated processes. Type 2 have a small soma and are 
highly branched. Therefore two measures were selected, FD and cell area, as being 
representative of both phenotypes and the variable morphology observed within this neural 
cell population.  
Area was used as astrocytes in culture are highly membranous (type 1) or highly branched 
(type 2) and therefore much larger than a generic cell size in vivo. FD was used as a 
measure of cell size as it accounts for the varied polygonal morphology typical of type 1 
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and the highly branched morphology of type 2 measuring, as it does, the widest and the 
shortest diameters of the cell taking into account the ‘projected’ cross section from these 
measures.  The term ‘Feret’ refers to a caliper diameter (width) of an object with the 
resulting value based on the maximum (XFmax) and minimum feret (XFmin) with the 
feret angle (XFmax90) used in calculation of the XFmin in increments of 0.5° steps. FD 
uses the following formula: - √ (XFmin * XFmax). It provides a measure of the distance 
between two parallel lines, tangent to the projected cross section of the maximum and 
minimum width of a cell, and as such reflects the varying morphologies seen in this cell 
population. 
5.3.3 MNP-mediated gene (gfp) transfer:  To investigate the influence of amplitude on 
gene transfer, astrocytes were routinely plated on PDL-coated coverslips in a 24-well and a 
96-well plate with MNP-mediated gene (gfp) transfer protocols conducted at 24-48 h post-
plating to allow for cell adherence and growth of processes (please refer to 2.6.3 for 
detailed protocols on complex formation and subsequent addition of complex to cells). 
Briefly, 60 ng of pmaxGFP plasmid was mixed with 0.21 µL NeuroMag or NeuroMag 
Fluo in a final volume of 75 µL DMEM, and for each well of the 96-well plate, 12 ng of 
pmaxGFP was mixed with 0.042 µL NeuroMag or NeuroMag Fluo in a final volume of 15 
µL DMEM. These were allowed to complex for 20 mins before addition to the cells. In 
each separate magnetofection condition, cells were exposed for 30 min to a magnetic field 
set at a frequency of 1 Hz, with each condition having a different amplitude within the 
range of 100 µm – 1000 µm (parameters described in detail below; section 5.4.1). 
Addition of DMEM or DMEM plus plasmid was added to control wells. At 48 h post-
particle addition, cells in the 24-well plates were fixed and prepared for imaging and 
analysis. Cells in the 96-well plates were immediately subjected to an MTS assay (Section 
2.6.3; 2.13.2 for further details).   
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5.3.4 Investigating MNP uptake versus transgene expression:  Alongside investigation of 
amplitude parameters on transfection efficiency, NeuroMag Fluo was used in a subset of 
experiments to reveal any potential relationship between extent of particle uptake and gfp 
expression. Transfection protocols were performed under the same experimental conditions 
as above.   
5.3.5 Pilot study: Investigating effect of coverslip depth on gene (gfp) transfer: For the 
pilot study, astrocytes were plated in a PDL-coated 24-well plate, with or without a PDL-
coated coverslip with cells exposed to the differing magnetofection conditions as described 
above (section 5.3.3) (Figure 5.1). 
 
Figure 5.1 Schematic of experimental setup investigating effect of coverslip depth on 
gene transfer Astrocytes were plated into a 24-well plate, with or without a coverslip. 
MNP-mediated gene transfer to the cells was conducted using transfection protocols with 
the cells exposed for 30 minutes to an oscillating magnetic field set at a frequency of F1 
Hz, and a varied range of oscillation amplitude (100 µm – 1000 µm).  
 
Cells were fixed at 48 h post-transfection with quantification of transfection efficiency 
carried out from the coverslip and the well plate.   
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5.3.6 Magneto-multifection MNP-mediated gene (gfp) transfer:  As for previous gene 
transfer experiments, astrocytes were routinely plated in a 24-well and a 96-well plate with 
MNP-mediated gene (gfp) transfer protocols conducted at 24-48 h post-plating (as 
described above and detailed in 2.6.3).  Briefly, following addition of the MNP:plasmid 
complex, cells were exposed to the optimal magnetic field reported for astrocytes for 30 
min, and then incubated in the absence of a magnetic field for 30 min, before being subject 
to 100% D10 medium refresh to remove any particles not already internalised. Cells were 
then incubated for a further 7 h before being subjected to a repeat gene transfer protocol as 
before (i.e. an interval of 8 h between repeat MNP:plasmid administration). Single 
transfection from each MNP:plasmid administration acted as controls [Time 1 (T1); Time 
2 (T2)] for the magneto-multifection condition, allowing comparisons between this 
condition and T1 and T2 (Figure 5.2).  
 
Figure 5.2 Schematic of time course of magneto-multifection protocol Cells in the 
magneto-multifection condition were exposed to repeat transfection at T1 and T2 with an 
interval of 8 h. Controls  for magneto-multifection were subjected to single transfection at 
T1 or T2. Cells in the T1 and T2 condition were terminated at 48 h following single 
transfection; cells in the magneto-multifection condition were terminated 48 h following 
repeat administration i.e. at 56 h. T1:Time 1; T2: Time 2 
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5.3.7 Investigating proportions of cells showing repeat uptake: To investigate the 
proportion of cells transfected at each time point within the magneto-multifection 
condition, plasmids encoding for red fluorescent protein (rfp) and green fluorescent protein 
(gfp) were used at the different time points. It has been reported that use of rfp results in 
lower transfection efficiency than that seen with gfp due to the larger plasmid size of the 
former (4.6 kb versus 3.5 kb) (Pickard et al., 2015). Therefore experiments were 
duplicated with the use of rfp at T1 and gfp at T2, then the use of gfp at T1 and rfp at T2 
(n=2; duplicates of each culture). Use of these two plasmids also enabled investigation of 
repeat transfection in individual cells (i.e. rfp and gfp co-expression). 
Each condition was terminated 48 h following final MNP:plasmid administration. Control 
wells for the gene transfer protocol consisted of cells not exposed to MNP:plasmid 
complex. Cells plated in the 96-well plates were immediately subjected to an MTS assay 
(detailed in section 2.6.3; 2.13.2).   
5.3.8 Immunocytochemistry:  Immunolabelling of cells in gene (gfp) transfer experiments 
was as detailed in section 2.9.1. 
5.3.9 Imaging:  Imaging of these experiments was conducted as detailed in section 2.10.1 
5.3.10 Analyses:  Culture characteristics, cellular assays, transfection efficiency and extent 
of gfp expression were quantified from fluorescence micrographs (detailed in section 2.11 
& 2.12.2). Transfection efficiency was determined as the percentage of GFAP+ve 
astrocytes co-expressing gfp expression, with the data normalised to the control amplitude 
condition (F = 1 Hz; 200 µm).  Extent of gfp expression was assessed using fluorescence 
intensity as a representative measure (Section 2.12.2). Analysis of MTS assays were as 
described previously (Section 2.13.2).  For the MNP:plasmid M-Mfect experiments, 
transfection efficiency at T1 was determined as the percentage of GFAP+ve cells 
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exhibiting reporter protein expression. Co-expressing (rfp + gfp) cells were confirmed by 
coincident expression of red or green fluorescent protein on unmerged images, with the 
merged image exhibiting a combination of red and green fluorescent protein. Observations 
on the extent of NeuroMag Fluo uptake by astrocytes were estimated based on a previously 
described semi-quantitative method of low, medium or high particle accumulation within 
the cell (Jenkins et al., 2013). 
 5.3.11 Statistical analysis:  Data were analysed as detailed previously (Section 2.14). The 
number of cultures used in this series of experiments was 3 (n = 3) unless otherwise noted, 
with each culture derived from a different rat litter. 
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5.4 Results 
5.4.1 Measure of cell size to inform amplitude parameters 
Using ImageJ software, fluorescence microscopy images were scaled to show 
measurements per micron (µm) with measures taken from 160 type 1 and type 2 astrocytes 
from three different control cultures. The formula for FD was applied to the values, the 
results averaged to show a mean FD of 98.3 µm (type 1) and 54.4 µm (type 2). The mean 
area of type 1 astrocytes measured was 1277.8 µm2 with 309.7 µm2 recorded for type 2 
(Figure 5.3).  
 
Figure 5.3 Measure of cell size Representative fluorescence image (a) depicting 
schematic of the parameters utilised to calculate Feret’s diameter [FD = √ (XFmin * 
XFmax)]. Note the polygonal morphology characteristic of astrocytes in culture. Note also 
the heterogeneity in morphology within this primary-derived cell population (arrows). 
Type 1 phenotype is highly membranous with a flattened morphology and truncated 
processes and shows a high level of variability in size (red arrows). In comparison, type 2 
phenotype has a small soma and is highly branched (white arrow).  Bar graph (b) shows 
the mean cell size according to area (µm2) and FD (µm). Scale of image = 50 µm Results 
expressed as mean ± s.e.m. 
Mean cell size  b 
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These values proposed an overall range of cell measures from which amplitude could be 
tested; 100 µm (average measure of FD) - 1000 µm (average measure of area) with 
intermediate steps tested within that range i.e. 100, 200, 400, 700, 1000 µm in total.  The 
most effective parameters reported for magnetofection of astrocytes, namely 200 µm; 1Hz, 
were used as a control condition (Adams et el., 2013; McBain et al., 2008; Pickard & 
Chari, 2010; Pickard et al., 2015; Jenkins et al., 2011). 
5.4.2 Pilot study: Investigating effect of coverslip depth on gene (gfp) transfer 
It has been reported that the space between magnet and chamber has an effect on particle 
accumulation, raising the question that use of a coverslip in the well may affect MNP-
mediated gene transfer. Microscopy observations from initial transfection studies showed 
high numbers of transfected cells at the edges of the coverslip (the well trough). From this, 
it could be postulated that the depth of a coverslip (ca. 0.15 - 0.2 mm) in the well plate may 
influence MNP-mediated gene transfer due to the increased space between magnet and 
cells. It could be argued that removal of the coverslip would address this. However, 
coverslips facilitate easier processing of the sample for microscopy purposes. The depth 
and, of key importance, the refraction from glass coverslips are far less than that of culture 
plastic, resulting in higher resolution images; a key feature for accurate visual analysis. 
Accordingly, prior to performing the experiments, a pilot study was conducted to 
investigate the effect of coverslip depth on gene transfer. 
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Figure 5.4 Effect of coverslip depth on gene (gfp) transfer Bar graph showing (a) 
transfection efficiencies of cells plated on a coverslip and those plated directly into a well. 
Across all amplitude conditions, no differences were observed in transfection efficiency 
between coverslip and well. A trend towards increased transfection efficiency was noted at 
the higher amplitudes, peaking at 400 µm amplitude. Representative fluorescence images 
of transfected cells on (b) glass coverslips and (c) in a well illustrate the difference in 
resolution between glass and culture plastic.  (n =2). Scale = 50 µm Results expressed as 
mean ± s.e.m. (Number of replicates = 3) 
Comparable transfection efficiencies 
between coverslip and well trough 
Transfected astrocytes - coverslip Transfected astrocytes – well  
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The preliminary findings from this pilot study found that the depth of the coverslip did not 
adversely affect the efficiency of the magnetic field, with no obvious differences observed 
in transfection efficiencies between astrocytes plated on coverslips and those plated 
directly in a well [Figure 5.4 (a)]. Hence, as no adverse effect on transfection efficiency 
was found, the experiments were conducted using coverslips within the well. In this 
respect, use of coverslips resulted in higher resolution micrographs [Figure 5.4 (b)] 
compared with micrographs taken from cells within culture plastic [Figure 5.4 (c)]. 
Of further note from these results is the observed peak in transfection efficiency at 400 µm 
amplitude [Figure 5.4 (a)]. This preliminary finding suggests this amplitude may be 
optimal (at this frequency) for transfection efficiency in astrocytes. 
5.4.3 Safety assessment of MNP-mediated gene (gfp) transfer to astrocytes 
Safety was of prime concern with the use of these protocols. Astrocyte cultures were of 
high purity as judged by GFAP expression (99.3 ± 0.2%) [Figure 5.5 (a)].  The cells 
predominantly exhibited the membranous, flattened morphologies characteristic of type 1 
astrocytes (92.6 ± 2.7% of GFAP+ve cells), with the morphological characteristics 
associated with type 2 (small soma, highly branched) accounting for 7.2 ± 2.7% of 
GFAP+ve cells. Proportions of astrocyte phenotype were similar across all conditions 
[Figure 5.5 (b)]. 
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Figure 5.5 Influence of amplitude on proportions of astrocytes and on astrocyte 
phenotype Bar graphs showing (a) the high purity of the cell population (99.3 ± 0.2%) 
expressing GFAP and (b) the mean proportions of the two astrocyte phenotypes 
represented within this cell population (92.6 ± 2.7%; 7.2 ± 2.7% - type 1 and type 2 
respectively). No differences were seen between proportions of astrocytes or astrocyte 
phenotype. Results expressed as mean ± s.e.m. (Number of replicates = 3) 
 
Safety analyses revealed no acute toxicity, with cellular viability assays reporting no 
difference between the conditions with respect to cell counts or the percentage of pyknotic 
nuclei (ca. 1% across all conditions) [Figure 5.6 (a) & (b) respectively]. Cellular viability 
within this experiment was corroborated by MTS assays, where no alterations to metabolic 
function were detected for any of the experimental conditions [Figure 5.6 (c)] 
 
 
 
 
Proportion of astrocyte 
phenotype (%) 
a b GFAP+ve labelled cells (%) 
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Figure 5.6 Cell viability analyses report no acute toxicity No acute toxicity was reported 
with these protocols. Bar graphs of cellular viability assays reported (a) no differences in 
the average number of nuclei per microscopic field with (b) a low level of pyknosis (< 1%) 
across conditions. No differences in (c) metabolic activity were reported between 
conditions (MTS assay). Results expressed as mean ± s.e.m.  (Number of replicates = 3) 
 
 
 
Average number GFAP+ 
cells 
Levels of pyknosis (%) 
Comparative metabolic 
activity 
a b 
c 
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5.4.4 Influence of amplitude of oscillating magnetic fields on MNP-mediated gene (gfp) 
transfer to astrocytes 
To investigate the influence of amplitude on gene transfer to astrocytes, utilising a fixed 
frequency of 1 Hz, a number of amplitudes were tested within a 100 – 1000 µm range, 
namely 100 µm; 200 µm; 400 µm; 700 µm;  1000 µm. Initial observation found no 
astrocytes exhibiting gfp expression in the plasmid-only control cultures. Of the transfected 
astrocytes, across all experimental conditions, analysis showed the overwhelming majority 
were identified phenotypically as type 1, with less than 2% exhibiting type 2 morphologies 
[Figure 5.7 (a)]. Therefore, analyses relating to transfection were restricted to type 1 
astrocytes. 
There was a tendency towards greater transfection efficiency at the higher amplitudes, 
peaking at an amplitude of 400 µm, with transfection efficiency at this amplitude being 2-
fold greater than the control amplitude (200 µm), although no significant difference in 
transfection efficiency was found between the control amplitude and any of the ‘test’ 
amplitudes (100; 400-1000 µm) [Figure 5.7 (b)].   
The extent of gfp expression in astrocytes (as evaluated by the measure of fluorescence 
intensity) was significantly elevated at an amplitude of 200 µm compared with amplitudes 
of 100 and 400 µm, with a notable trend towards higher values of gfp expression at 
amplitudes of 700 and 1000 µm [Figure 5.7 (c) and (d)].  Taken together, these findings 
show that transfection efficiency (i.e. numbers of transfected cells) is unaffected by 
amplitude but rather, amplitude plays a greater role than previously perceived in 
influencing the extent of transgene expression in individual cells.   
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Figure 5.7 Influence of amplitude of oscillation on transfection efficiency and extent 
of transgene expression in astrocytes Fluorescence micrograph (a) depicting the 
different phenotypes; type 1 (arrow) and type 2 (arrowhead) astrocytes. Small numbers of 
gfp+ve type 2 astrocytes were noted (inset shows counterpart micrographs). Bar graph (b) 
showing no significant difference in transfection efficiency between amplitudes, although a 
tendency towards increased efficiency at the greater amplitudes is noted, peaking at an 
amplitude of 400 µm; this amplitude reporting transfection efficiency as 2-fold greater 
than the control condition (200 µm). Representative fluorescence micrograph (c) showing 
differences in gfp expression between the 200 µm amplitude condition (main image) and 
Proportion of transfected 
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Extent of transgene 
expression 
b 
d 
a 
c 
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the 400 µm condition (inset); arrows indicating cells with high levels of gfp expression. 
Bar graph (d) showing extent of gfp expression (as measured by florescence intensity) was 
significantly elevated at 200 µm amplitude compared to 100 µm and 400 µm (Bonferroni’s 
post-hoc tests; *p < 0.05), with a trend towards higher values with increased amplitude 
(700 – 1000 µm).   Scale of images (a & b = 50 µm) Results expressed as mean ± s.e.m.  
(Number of replicates = 3). gfp: green fluorescent protein  
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5.4.5 Safety assessment of magneto-multifection MNP-mediated gene (gfp) transfer to 
astrocytes 
Of prime concern was the safety of the magneto-multifection protocol when used with 
astrocytes and to this end, a number of safety analyses was conducted.  The percentage of 
cells expressing GFAP was consistent across all conditions (98.1 ± 0.5%) [Figure 5.8 (a)], 
and no difference was found in average cell number per microscopic field between control 
and experimental conditions [Figure 5.8 (b)]. Of astrocyte phenotype, type 1 astrocytes 
accounted for ca. 92% of GFAP+ve cells with type 2 accounting for ca. 8% [Figure 5.8 
(c)]. Type 1 phenotype made up the majority of transfected cells (ca. 89% versus type 2; 
ca. 11%) [Figure 5.8 (d)]. Low levels of pyknosis were observed across all conditions (ca. 
3% overall), with no difference reported in metabolic activity between cells exposed to 
plasmid only or MNP:plasmid complex across each of the experimental conditions [Figure 
5.8 (e) & (f), respectively]. Thus, the high cellular viability reported within these 
experiments demonstrated the safety of the magneto-multifection protocols used. 
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Figure 5.8 Safety assessment of magneto-multifection protocols Bar graphs showing 
(a) the percentage of GFAP+ve labelled cells was consistent across all conditions with (b) 
no difference in average cell count. Bar graphs showing (c) proportion of astrocyte 
Proportion of astrocyte 
phenotype (%) 
Transfection efficiency in 
astrocyte phenotype (%) 
Levels of pyknosis (%) Comparative metabolic 
activity 
c d 
f e 
T1 
T2 
M-Mfect 
NMag  
 
NMag  
 
NMag  
 
Plasmid 
 
Plasmid 
 
Plasmid 
 
a 
Average number of 
GFAP+ve cells 
b 
GFAP+ve labelled cells (%) 
 204 
phenotype was predominantly type 1 (ca. 92% versus ca. 8% type 2) with (d) type 1 
phenotype accounting for 89% of transfected cells versus 11% type 2 phenotype. Bar 
graphs showing (e) low levels of pyknosis across all conditions (ca. 3%) with (f) cellular 
viability assay showing no difference in comparative metabolic activity in the cells. Results 
expressed as mean ± s.e.m. 
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5.4.6 Magneto-multifection MNP-mediated gene (gfp) transfer  
Repeat transfection has reported enhanced transfection efficiency in other neural cell 
populations. Having identified the optimal parameters (from those tested) for transfection 
of astrocytes, magneto-multifection was utilised to further enhance gene delivery to this 
neural cell.  
For magneto-multifection, plasmids encoding for red fluorescent protein (rfp) and green 
fluorescent protein (gfp) were used to indicate transfection efficiency at the two time points 
[Figure 5.9 (a)] and investigate the level of co-expression [Figure 5.9 (b)]. Repeat 
administration significantly increased transfection efficiency compared with single 
MNP:plasmid dose at T1 or T2 alone [81.5 ± 1.9% (M-Mfect) versus 37.9 ± 8.8% (T1) and 
versus 43.7 ± 8.1% (T2)] [Figure 5.9 (c)].  Investigation of repeat exposure to individual 
cells revealed ca. 22% of cells showed co-expression of rfp and gfp [Figure 5.9 (b; image 
and inset) & (d)].  The majority of transfected cells exhibited gfp expression as opposed to 
rfp expression; this to some extent was anticipated due to the increased plasmid size 
encoding for rfp (Pickard et al., 2015) [Figure 5.9(d)].  
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Figure 5.9 Magneto-multifection and transfection efficiency Representative 
fluorescence micrographs illustrating (a) two different sub-populations of cells are 
transfected at T1 and T2; characterised respectively by rfp and gfp expression 
[arrowheads; main image (corresponding un-merged images showing rfp and gfp 
expressing cells)]. (b) The prevalence of a subpopulation of cells co-expressing rfp and gfp 
expression, indicating repeat uptake of MNP:plasmid complex [white arrows; main image 
(corresponding un-merged images showing coincident rfp and gfp expression)]. Bar 
graphs showing (c) repeat administration of MNP:plasmid complex significantly increased 
transfection efficiency compared with a single dose at T1 or T2 (**p < 0.01; *p < 0.05 
respectively) and (d) a greater number of transfected cells exhibit gfp expression than 
exhibit rfp expression, with a subpopulation of cells exhibiting rfp and gfp co-expression. 
d Proportion of GFAP+ve cells 
showing transgene expression (%) 
a 
c Proportion of transfected 
cells (%) 
b 
T1 T2 T1 T2 
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Results expressed as mean ± s.e.m.  (Number of replicates = 3).  gfp: green fluorescent 
protein; rfp: red fluorescent protein 
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5.4.7 Correlation between MNP-uptake and transgene expression   
If the nanoparticles are DNA transporters, then is it reasonable to expect a dose 
relationship between nanoparticle uptake and gene expression? To explore this possibility, 
a subset of experiments was conducted using NeuroMag Fluo, a transfection-grade particle 
conjugated with a rhodamine fluorophore. This allowed observations of particle 
accumulation co-localised with gfp expression. Approximately 80% of cells exhibited 
NeuroMag Fluo labelling and of these only ca. 50% were transfected [Figure 5.10 (a)]. 
Type 1 astrocytes typically show 100% uptake; this lower level of uptake may be due to 
type 2 showing little or no uptake. Labelled cells showed low, moderate or high levels of 
particle accumulation as measured by a visual semi-quantitative analysis [Figure 5.10 (b)].   
Investigation of the correlation between particle accumulation and transgene expression (as 
measured by fluorescence intensity) revealed an inverse relationship [Figure 5.10 (c)]. 
High transgene expression was associated with low levels of particle accumulation, 
whereas cells that were highly labelled exhibited (on the whole) a low extent of transgene 
expression. In this regard although low particle accumulation was always associated with 
reporter protein expression, the observed correlation between higher levels of particle 
accumulation and gfp expression was inconsistent. Higher levels of accumulation were 
observed in association with either high, moderate, low or no gfp expression [Figure 5.10 
(d)], suggesting a highly complex relationship between particle uptake and protein 
expression, and the factors mediating this interaction. 
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Figure 5.10 Relationship between particle uptake and transgene expression Bar 
graphs showing (a) a discrepancy between the proportions of labelled cells and cells 
exhibiting gfp expression, with (b) labelled cells predominantly showing low levels of 
particle accumulation. Bar graph (c) shows an inverse relationship exists between particle 
accumulation and levels of gfp expression. Fluorescence micrograph (d) shows (i) high 
levels of gfp expression (white arrow head) in cells exhibiting low levels of particle uptake, 
(ii) extensive particle uptake coupled with negligible gfp expression (inset; red arrow) and 
conversely, high levels of gfp expression (inset; white arrow) (n = 2). Scale of main image 
= 50 µm Results expressed as mean ± s.e.m.  (Number of replicates = 3).  gfp: green 
fluorescent protein 
c 
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5.5 Discussion  
Two key features of MNP-mediated gene transfer to astrocytes have been investigated. 
Firstly, the influence of varying amplitude of oscillation on MNP-mediated gene delivery 
and secondly, the use of a magneto-multifection strategy to investigate whether gene 
transfer could be enhanced further in this neural cell population. The findings from each 
study and their implications to regenerative neurology applications are addressed here. 
One of the parameters to be assessed was the effect of coverslip depth on gene transfer to 
astrocytes. The findings here were in contrast to those reported by Furlani & Ng. This may 
be related to the strength of the magnets involved. The magnet utilised in this study exerted 
approximately half the magnetic field strength of the one utilised by Furlani & Ng (NdFeB 
magnet = 421 ± 20 mT vs. NdFeB magnet = 1 T, respectively). From this it could be 
postulated that distance would exert a greater adverse effect on particle accumulation in 
this study. However, this was not the case. The difference in distance between the two 
studies [1.0 mm (Furlani & Ng) compared with approximately. 0.15-0.2 mm - being the 
depth of the coverslip in this study] is a more likely explanation for the decrease in particle 
accumulation seen in the Furlani & Ng study, and why the shallow depth of the coverslip 
showed no such limitation. 
In respect of the influence of amplitude on transfection efficiency, findings from the first 
study demonstrated that while amplitude of oscillation does not influence proportions of 
transfected cells, it does nevertheless modulate levels of transgene/protein expression 
within a cell.  McBain et al. (2008) measured levels of transgene expression at three 
frequencies combined with four amplitudes, and concluded that “perhaps the amplitude is 
more important than frequency” (McBain et al., 2008), an observation broadly in 
accordance with the enhanced levels of transgene expression reported here. Although, it 
should be noted that McBain used a bioluminescence assay; its major limitation being its 
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inability to discriminate between higher proportions of transfected cells versus individual 
cells expressing higher transgene levels.  By comparison, the methods employed in this 
study enabled separate quantification of proportions of transfected cells (transfection 
efficiency) and extent of transgene expression within a cell (please refer to sections 
2.12.2respectively for detailed methodology).  
The findings of this study reported no significant difference in proportions of transfected 
cells between 200 µm (the ‘control’ condition) and the ‘test’ amplitudes. Although, a trend 
towards increased transfection efficiency at the higher amplitudes was noted, peaking at an 
amplitude of 400 µm. However, quantification of extent of transgene expression reported a 
significant increase in gfp expression at an oscillating amplitude of 200 µm compared with 
100 and 400 µm amplitude. Based on these findings, it could be proposed that oscillation 
frequency determines transfection efficiency (i.e. the proportions of transfected cells) 
(Pickard & Chari, 2010), but that it is amplitude that determines the extent of transgene 
expression in individual cells, at least in astrocytes; a novel finding in magnetofection 
studies and of potential importance to regenerative neurology applications. In this regard, 
before elucidating further, investigation of the relationship between MNP uptake and gene 
delivery is necessary to understand the potential mechanisms involved. 
Primarily, particle uptake is dependent on the endocytotic activity of the target cell (Adams 
et al., 2015; Fernandes & Chari, 2014; Treuel et al., 2013), and in this respect primary-
derived astrocytes possess a highly endocytotic membrane showing avid uptake of 
particles in both labelling and MNP-mediated gene transfer studies (Jenkins et al., 2013; 
Pickard et al., 2011; Tickle et al., 2015; 2016). In this present study use of MNPs that 
possessed both transfection and imaging capabilities enabled exploration of the 
relationship between MNP uptake and gene delivery. Of the 80% labelled cells, only 
approximately 50% exhibited transgene expression. Quantification of particle 
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accumulation co-localised with gfp expression revealed an inverse relationship between 
transgene expression and particle uptake. Interestingly, high transgene expression was 
associated with low particle uptake whereas cells that were highly labelled, for the most 
part exhibited a low extent of transgene expression. Taken together, these findings propose 
that high levels of transgene expression exhibited by a cell is inversely dependent on 
intracellular particle uptake, and in this respect, enhanced protein expression at the 200 µm 
amplitude may be due to lower uptake in individual cells. From this it could be postulated 
that a cell population with an overall low level of particle loading in individual cells, may 
offer potential for therapeutic transgene applications.   
Understanding the mechanisms informing this complex relationship between uptake and 
transgene expression, is difficult to establish and requires further investigation. What is 
clear from these findings is that particle uptake per se is not the sole determinant of 
successful transfection, as was highlighted by the inconsistent particle:reporter protein 
association observed in highly labelled cells.  Indeed for non-viral gene delivery, 
heterogeneity between uptake versus expression appears to be commonplace (Akita et al., 
2007; Tinsley et al., 2004; Wilke et al., 1996). Although, the culture wide assays used to 
measure transgene expression in these studies did not allow for any particle:transgene 
relationship to be elucidated on a cell-by-cell basis, as has been undertaken here. 
Nevertheless, in respect of this observed heterogeneity, it is not clear what accounts for 
these observations, but it may involve differences in intracellular processing of 
MNP:plasmid complexes. Intracellular particle clumping may have prevented DNA 
breaking away from the particles. Cultures derived from primary sources often exhibit 
heterogeneous behaviour (Singhal et al., 2016) and these differences may be related to 
individual cells (i) being at different stages of the cell cycle (Kim et al., 2012; Tseng et al., 
1999) or (ii) belonging to subpopulations with differing intracellular processing 
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characteristics. For example, it is feasible that cells lacking transfection despite extensive 
particle uptake sequester the particles within intracellular vacuoles (Tinsley et al., 2004) or 
subject the plasmid to degradative processes.  
In respect of cell cycle dynamics, this could offer a plausible explanation for the 
heterogeneity between particle uptake versus expression. The study of cell cycle dynamics 
in relation to gene transfer has reported a trafficking of the various elements – particle and 
pDNA - throughout the entire duration of the cell cycle. However, it has also clearly 
identified optimal timings (‘hot spots’) at different stages of the cell-cycle for uptake, 
delivery and subsequent transgene expression (Akita et al., 2007; Brunner et al., 2002; 
Castro et al., 1997; James & Giorgio, 2000; Tseng et al., 1999) (Figure 5.11).  In this 
context it is of note that particle uptake and subsequent intracellular processing are not a 
continuous event but have been identified as a multi-stage process (Pollard et al., 1998; 
Tinsley et al., 2004; Zabner et al., 1995). This implies a longer time-course than has been 
previously supposed, and that the occurrence of one event does not necessarily confer the 
occurrence of a subsequent event.  In respect of the findings from this current study, it 
could therefore be speculated that a high loading of particles into a cell may result in a 
longer trafficking time or ‘held’ at one stage of the process, offering a possible explanation 
for the inconsistency observed in highly labelled cells.  
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Figure 5.11 Schematic illustrating the putative interaction between cell cycle 
dynamics and MNP-mediated gene transfer The cell cycle of astrocytes in culture is 
generally held to be ca. 14-20 h, with an M-phase of 2 -3 h and an S-phase of ca. 7 – 10 h.  
Particle uptake as a delivery vector for pDNA is reported as being greatest during the 
G2/M-phase, with intranuclear pDNA delivery reported as showing a comparable rate of 
delivery throughout the cell cycle, with potentially higher levels of uptake during mitosis. 
Subsequent transgene expression is understood to be dependent on mitotic events although 
significant increases have been reported throughout a larger proportion of the cell cycle 
prior to mitosis (G0 - quiescent phase; G1-S-G2 – interphase; M – cell division).  
 
Single MNP-mediated gene transfer to astrocytes shows approximately 60% transfection 
efficiency (Pickard et al., 2010; Tickle et al, 2015). With regard to the use of a magneto-
multifection strategy to further enhance gene transfer, the findings here show significantly 
increased transfection efficiency compared with single transfection protocols (> 80% 
 
Transgene 
expression 
 
 
Intranuclear delivery 
of plasmid  
 
Particle:plasmid 
association with cell 
membrane  Quiescent phase 
 215 
versus 60%). The results show that not only is a wider population of the target cells being 
transfected, but a subpopulation of those cells also show repeat transgene expression, 
indicative of repeat MNP:plasmid uptake. 
 Taken together, these overall findings have significant implications for tissue engineering 
and transplant mediated delivery of therapeutic biomolecules, offering a two-fold benefit 
for drug/gene delivery in regenerative therapy applications. For example, for clinical 
applications enhanced transgene expression would produce greater quantities of 
therapeutic biomolecules intended to promote neuroregenerative processes i.e. growth 
factors such as BDNF and FGF2 which promote nerve fibre regeneration (for example, 
Deinhardt & Chao, 2014; Liang et al., 2010; Zagrebelsky & Korte, 2014) and blood vessel 
growth respectively (Gorin et al., 2016). Hence a subpopulation of cells exhibiting high 
levels of gene expression could be more beneficial for slow release applications, due to the 
timeframe over which the transgene is diluted through proliferative processes. Conversely, 
a population containing a large proportion of transfected cells (albeit with low transgene 
expression per cell) can be advantageous for immediate ‘one-step’ release of a drug or 
growth protein.  
Consequently, these findings emphasise the importance of identifying the most effective 
combinations of frequency and amplitude for use in magnetofection protocols, to optimise 
gene transfer to a particular neural cell population. However it is clear that more research is 
needed to fully elucidate the relevance of intracellular processing and cell cycle dynamics 
to gene transfer, and to firmly establish the mechanisms underlying magnetofection 
strategies. It is evident that the use of a magnetic field, at the optimal frequency and 
amplitude for each specific cell type, enhances transfection efficiency overall and, 
probably of key importance for regenerative applications, considerably enhances the extent 
of gene expression in individual cells. Of major importance, contrary to the widely held 
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belief that increased labelling is a precursor to enhanced transgene expression, the findings 
from this study would suggest that optimal transgene expression, at least in respect of 
astrocytes, may be due to lower particle uptake per cell – a novel finding in 
magnetolabelling studies. 
Further detailed analyses of these processes using electron microscopy, lysotracker 
analyses and plasmid-tagging, in conjunction with cell cycle synchronisation, are 
warranted to elucidate the cellular mechanisms that contribute to successful MNP-
mediated transfection in neural cells. Moreover, of key importance here is the bespoke 
optimisation of magnetofection strategies on a cell-specific basis. 
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Chapter 6 
Future direction and concluding 
comments 
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6.1 Summary of key research findings 
The research that comprises this thesis has studied three aspects of a combinatorial 
approach applicable to the delivery of primary-derived astrocytes as a cell transplant 
population; MNP-mediated gene transfer, MP-labelling for non-invasive cell tracking 
under MRI, and the development of a viable 3-dimensional hydrogel construct to act as a 
carrier for protective delivery of a neural cell transplant. The key research findings from 
each series of studies are summarised below. 
Chapter 3 Endocytotic potential governs magnetic particle loading in dividing neural 
cells 
Astrocytes are a highly endocytotic neural cell, and as such, showed rapid (4 h) uptake of 
high magnetite content particles (MP-5x). At 24 h post-particle exposure, MP-labelling 
efficiency was >98% for both MP-1x and MP-5x particles. Application of a magnetic field 
at both time points significantly promoted MP-5x particle accumulation within the cells. 
Despite the proliferative nature of these cells, the initial high loading of these particles 
facilitated long term retention over an extended time frame of 21 days. Dynamic time-lapse 
imaging showed particle dilution to be a result of particle inheritance to the daughter cells 
of dividing astrocytes. This inheritance was asymmetrical, resulting in a sub-population of 
cells with continued utility for tracking. Viability assays reported the high safety profile of 
these particles and the methodologies employed. A novel methodology was developed 
which provided an unbiased, robust quantifiable measure of particle accumulation on a 
cell-by-cell basis.  
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Chapter 4 Non-invasive tracking of neural cells in implantable materials 
The substrate on which astrocytes were cultured differentially affected their morphological 
characteristics. Cells grown within a 3-dimensional hydrogel showed morphologies closer 
to that of their in vivo counterpart, having a small cell soma and being highly branched, 
and also possessing a stellate morphology. Use of a combinatorial approach, that of 
growing exogenously MP-labelled astrocytes within a 3-dimensional hydrogel construct, 
addresses the challenge presented with transplant of cell suspension into a lesion site. In 
this context, cellular distribution of MP-5x labelled astrocytes was homogenous throughout 
the width and the depth of the construct, with networked bundles of aligned astrocytic 
processes throughout the gel. The cells showed a more quiescent profile within the gel, 
consistent with other studies showing that collagen inhibited proliferation of encapsulated 
astrocytes. Safety assessments showed a high level of cell viability and safety of protocols 
over time. A novel approach was developed to investigate endocytotic features in 
astrocytes. This comprised the embedding of the gel within Spurr resin, facilitating 
visualisation of the subcellular features under TEM. 
Chapter 5 Influence of amplitude of oscillating magnetic fields on MNP-mediated gene 
transfer to astrocytes 
Transfection efficiency in astrocytes is not enhanced further by amplitude of oscillation, 
but rather, amplitude plays a greater role in influencing the extent of transgene expression 
in individual cells. A magneto-multifection strategy significantly increased transfection 
efficiency compared with single MNP:plasmid dose. Correlation between MNP uptake and 
transgene expression revealed an inverse relationship, in that high transgene expression 
was associated with low levels of particle accumulation. This would propose two different 
strategies for potential drug/gene delivery to the injury site. High numbers of transfected 
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cells would deliver a single efficient short term delivery of the therapeutic molecule, 
whereas a cell population with high levels of transgene expression could potentially deliver 
a steady longer term release of the therapeutic molecule to the target site. 
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6.2 Future direction 
To have clear direction, it is necessary to have an understanding of the barriers to recovery, 
and matching these to a range of potential repair strategies (Ahuja & Fehlings, 2016; 
Dunnett & Rosser, 2014; Xu & Onifer, 2009) (Table 6.1). 
 
Table 6.1 Barriers to recovery and proposed mechanism 
Barriers to recovery Proposed mechanism 
Spinal cord loses its structural framework Bridging the lesion gap with implants 
functionalised with neurotrophic factors and 
guidance channels 
Glial scarring as a result of astrogliosis 
resulting in barrier to axonal ingrowth 
A better understanding of the glial scar and how 
to incorporate this knowledge in promoting 
regeneration of SCI 
Fibroblast infiltration results in dense 
fibrous scar binding growth inhibitory 
molecules 
Reducing growth inhibitory molecules; Addition 
of neurotrophic and growth factors   
Upregulation of CSPGs and cytokines 
further inhibit neurite outgrowth and axon 
regeneration 
Use of chondroitinase ABC to reduce CSPG 
upregulation; elevating potential for axon 
capacity for regeneration 
Loss of oligodendrocytes results in neuron 
demyelination leading to lack of myelin 
support and release of growth inhibitors 
from degrading myelin 
Overcoming myelin-associated inhibitors; cell 
transplant of OPCs in implant to promote 
myelination; implant promotes axonal ingrowth 
CSPGs activate the RHO-Rock cascade 
resulting in growth cone collapse and 
retraction 
Downstream inhibition of EGFR inhibits RHO-
Rock cascade; facilitate reinnervation of 
denervated targets 
Syrinx formation prevents axonal ingrowth Bridging the gap and enhancing directed axonal 
growth with guidance channels 
No trophic or structural support to support 
ingrowing axons 
Bridging the gap with functionalised implants  
Infiltration of Schwann cells causes pain 
and spasticity 
Protecting from secondary injury 
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Significant advances have been made in recent years in regeneration of the injured spinal 
cord which has translated to functional outcomes, in research and in the clinic. The 
challenges still to be met however cannot be addressed through the continued use of 
separate procedures. There is an array of factors that contribute to the damage inherent to a 
SCI, and therefore it is impractical to suppose that one therapeutic strategy alone will 
overturn the failure to regenerate and see successful functional recovery (Xu & Onifer., 
2009). It is becoming increasingly clear that the way forward to recovery and regeneration 
of the injured spinal cord is that of a combinatorial approach. So what is the future 
direction for the research strategies developed within this project? 
The findings of this research have been discussed extensively within each relevant chapter, 
and therefore will not be elucidated further here. However, based on these findings, there 
are a number of areas in which these approaches could be developed. 
1).     Cell cycle dynamics are a plausible explanation for the heterogeneity between 
particle uptake versus transgene expression in MNP-mediated gene transfer to astrocytes 
(Chapter 5). In this context, a number of ‘hot spots’ have been identified for each stage of 
particle uptake  - from particle:plasmid association with the cell membrane, to intranuclear 
delivery of the pDNA, to subsequent transgene expression by the cell (Akita et al., 2007; 
Brunner et al., 2002; Castro et al., 1997; James & Giorgio, 2000; Tseng et al., 1999). 
What is unclear are the factors that govern these mechanisms. Bearing in mind that 
intracellular processing has been identified as a multi-stage process (Pollard et al., 1998; 
Tinsley et al., 2004; Zabner et al., 1995), do the dynamics of the cell cycle ‘hold’ particles 
at certain stages? A further question that arises from this is (how) are these dynamics 
influenced with application of a magnetic field?  An important consideration with a study 
of this kind is that in stopping or synchronising the cell cycle, only approximately 35% of 
astrocytes subsequently rejoin the cell cycle, either overall or at any one time (Murphy, 
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1990). This has implications at an experimental level, as a large proportion of the cell 
population has effectively been removed. This would need addressing first, to be able to 
fully elucidate the findings in relation to the dynamics of the cell cycle. 
2).     The most effective combinations of frequency and amplitude (F1 Hz; 200 µm) for 
use in magnetofection protocols for astrocytes (Chapter 5) significantly increased 
transfection efficiency (>80%), and of key importance to regenerative applications, 
considerably enhanced the extent of gene expression in individual cells. An inverse 
relationship was found between particle uptake and transgene expression, in that high 
transgene expression was correlated with low particle uptake. As discussed within the 
relevant chapter, this offers a two-fold benefit for drug/gene delivery in regenerative 
therapy applications in respect of slow release or immediate ‘one-step’ release of a drug or 
growth protein. Thus, it is critical to further investigate the mechanisms underlying this to 
propose the opportunity of specifically engineering the desired transgene-expressing 
subpopulation. This understanding would prove highly applicable to gene/ drug delivery to 
promote recovery. 
The use of a hydrogel construct in a combinatorial approach is an exciting, emerging field, 
and the findings from this project offer many opportunities for developing this further in 
respect of both basic and translational science. 
3).     Having developed and optimised the methodologies for a 3-dimensional hydrogel 
construct capable of supporting a viable MP-labelled astrocyte population, it would now be 
pertinent to use this combinatorial approach to form an intraconstruct gel with transgene 
(gfp) expressing astrocytes. Considering that application of optimal magnetofection 
parameters are required to enhance transfection efficiency and extent of transgene 
expression in these cells, an exogenous magnetofection approach would be required prior 
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to associating the cells with the collagen construct. Of particular interest here is that gfp 
expression in 2-dimensional culture (Chapter 5) peaks at approximately 48 h, being the 
timeframe over which this transgene is diluted through proliferative processes. Considering 
that substrate differentially affects astrocyte morphology and function (Chapter 4), how 
would the substrate (2-dimensional culture plastic vs. 3-dimensional gel) affect the 
timeframe of gfp expression? 
4).    The translational purpose of combining transgene-expressing astrocytes within a gel 
construct is to act as a carrier for delivery of a genetically engineered cell transplant to a 
target site. Thus, it is pertinent to investigate and elucidate both the time-frame and the 
mechanism of delivery from the construct to the lesion site. In reducing animal use, an in 
vitro 3-D organotypic slice model has been developed that replicates spinal cord cellular 
responses to in vivo SCI (Weightman et al., 2014; 2016). Use of this model could be 
proposed with these functionalised gels. Transplant of these gels into the lesion slice model 
would allow investigation and evaluation of time frame and mechanism of delivery, with 
the potential for findings analogous to in vivo SCI.  
5).     To fully realise a combinatorial approach applicable to clinical application, a 
magnetic particle is needed that offers high efficiency in gene delivery and high sensitivity 
as a contrast agent for non-invasive tracking with MRI. In this regard, a multifunctional 
magnetic particle has been trialled in NSCs that may offer promise to astrocytes (Adams et 
al., 2016). It showed high sensitivity with MRI, although transfection efficiency was low 
with these cells (<5%).  NSCs are typically understood to be ‘hard-to-label’, therefore it 
would be interesting to trial this particle with astrocytes, a highly endocytotic cell. Use of a 
magnetic particle that had these dual capabilities could offer a full combinatorial approach 
for translational application. There are however, a number of considerations. To confer 
utility for cell tracking under MRI required initial high loading of a high magnetite content 
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particle (Chapter 3 and Chapter 4). In the same manner, the extent of transgene expression 
in astrocytes was determined by particle loading, with an inverse relationship found 
between transgene expression and particle uptake (Chapter 5). Thus, there would appear to 
be two different mechanisms at play here. Therefore, to find a particle that meets these 
disparate requirements requires an initial understanding of the mechanisms by which i) 
particle:pDNA is intracellularly processed and ii) oscillating magnetic fields influence 
uptake and intracellular processing. It is needful to elucidate the characteristics of each of 
the particles. It has to be realised that the optimal parameters for particle/particle:pDNA 
uptake are specific to the cell and the particle used. Trialling any new particle with this 
cell population will require systematic adjusting of each of the parameters. 
6).     There still remains a major challenge to be addressed in extrapolating the findings 
from rodent-based research to translational application in humans, not least because of the 
difference in astrocyte characteristics. To meet this challenge, replication of the 
methodologies developed here with human astrocytes would be highly interesting and of 
considerable value to translational application. The argument for primary-derived rodent 
neural cells is pertinent to rodent-based in vitro research, as there are a number of 
considerations that would preclude the use of primary human neural cells, most notably, 
ethical considerations and supply. Human astrocyte cell lines are available, although within 
ethical consent guidelines, human neural tissue that would otherwise be discarded is one 
possibility for use, with published protocols already in place (Ridet et al., 1999; 2003).    
7).     The need to improve cell survival is a pressing one. The benefits promised through 
cell transplant are being hampered by the lack of efficacy in surgical techniques – a 
challenge that has been extensively addressed within this project. However, cell survival is 
being hampered by the hostile environment into which they are transplanted and the lack of 
growth promoting factors. Therefore, it is here that the use of a combinatorial approach 
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becomes clear. Use of the construct developed within this thesis in conjunction with the 3D 
multicellular lesion slice model (Weightman et al., 2016) has considerable developmental 
potential as a biological model to assess tissue bioengineering in the injured spinal cord. 
The 3-dimensional carrier developed here acts as a vehicle to the lesion site; promising a 
number of advantages. It can be placed in the lesion site to provide a scaffold for growth. It 
can be functionalised with growth factors, neurotrophins, inhibitory molecules, anti-
inflammatory molecules or drugs. It can transport an engineered cell transplant that can 
promote (re)myelination, growth and trophic support to the ingrowing axons. It can be 
engineered to act as a guidance channel. But, most importantly, this carrier offers two 
protective advantages. It acts as a protective delivery system for the encapsulated cell 
transplant, and continues to provide protection to the cell transplant and to the ingrowing 
axons when grafted into the hostile environment of the injured spinal cord. The findings 
from research such as this could be extrapolated to translational application. 
 
6.3 Concluding comment 
Research conducted at the bench is moving forward with an eye to translational 
application. The future direction to overcome the barriers to regeneration and recovery is 
through systematic research, and a greater understanding of the mechanisms underlying the 
non-regenerative injured spinal cord. But the most promising route of mediating repair, 
recovery and regeneration within the injured spinal cord is that of a combinatorial 
approach.  
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Click-iT® EdU (5-ethynyl-2´-deoxyuridine) cell proliferation assay 
protocol 
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Table 1. Contents and storage information.
Material C10337 C10338 C10339 C10340 Concentration Storage*
EdU (Component A) 5 mg 5 mg 5 mg 5 mg NA
• 2–6˚C
• Desiccate
• Protect from 
light
• DO NOT 
FREEZE
Alexa Fluor® azide 
(Component B)
1 vial (Alexa 
Fluor® 488)
1 vial (Alexa 
Fluor® 555)
1 vial (Alexa 
Fluor® 594)
1 vial (Alexa 
Fluor® 647)
NA
Dimethylsulfoxide 
(DMSO, Component C)
4 mL 4 mL 4 mL 4 mL NA
Click-iT® EdU reaction 
buffer (Component D)
4 mL 4 mL 4 mL 4 mL
10X solution 
containing 
Tris-buffered 
saline
CuSO4 (Component E) 1 vial 1 vial 1 vial 1 vial
100 mM 
aqueous 
solution
Click-iT® EdU buffer 
additive (Component F)
400 mg 400 mg 400 mg 400 mg NA
Hoechst 33342 
(Component G)
35 µL 35 µL 35 µL 35 µL
10 mg/mL in 
water
*These storage conditions are appropriate when storing the entire kit upon receipt. For optimal storage conditions for each 
component, see labels on the vials. When stored as directed, this kit is stable for 1 year. 
NA = Not applicable.
Number of assays: Sufficient material is supplied for 50 coverslips based on the protocol below. 
Approximate fluorescence excitation/emission maxima, in nm: Alexa Fluor® 488 azide: 495/519; Alexa Fluor® 555 azide: 555/565; 
Alexa Fluor® 594 azide: 590/615; Alexa Fluor® 647 azide: 650/670; Hoechst 33342: 350/461, bound to DNA.
Introduction
Measuring a cell’s ability to proliferate is a fundamental method for assessing cell health, 
determining genotoxicity, and evaluating anti-cancer drugs. The most accurate method 
of doing this is by directly measuring DNA synthesis. Initially this was performed by 
incorporation of radioactive nucleosides3 (for example, H-thymidine). This method was 
replaced by antibody-based detection of the nucleoside analog bromo-deoxyuridine 
(BrdU). The Click-iT® EdU Assay from Invitrogen is a novel alternative to the BrdU assay. 
EdU (5-ethynyl-2´-deoxyuridine) provided in the kit is a nucleoside analog of thymidine 
and is incorporated into DNA during active DNA synthesis.1 Detection is based on a click 
reaction,2-5 a copper-catalyzed covalent reaction between an azide and an alkyne. In this 
Search the handbook 
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application, the EdU contains the alkyne and the Alexa Fluor® dye contains the azide. The 
advantages of the Click-iT® EdU labeling are readily evident while performing the assay. The 
small size of the dye azide allows for efficient detection of the incorporated EdU using mild 
conditions. Standard aldehyde-based fixation and detergent permeabilization are sufficient 
for the Click-iT® detection reagent to gain access to the DNA. This is in contrast to BrdU 
assays that require DNA denaturation (typically using HCl or heat or digestion with DNase) 
to expose the BrdU so that it may be detected with an anti-BrdU antibody (Figure 1).
The denaturation step in the BrdU protocol can disrupt dsDNA integrity, which can affect 
nuclear counterstaining, and can also destroy cell morphology and antigen recognition 
sites. In contrast, the EdU assay kit is not only easy to use, but is fully compatible with DNA 
staining, including dyes for cell cycle analysis. The EdU assay kit can also be multiplexed with 
surface and intracellular marker detection using antibodies (see Table 2 for details). Finally, 
unlike the BrdU assay, which relies upon antibodies which can exhibit nonspecific binding, 
the Click-iT® EdU assay uses bioorthogonal (biologically unique) moieties, producing low 
backgrounds and high detection sensitivities.
The kit contains all of the components needed to label and detect the incorporated EdU 
as well as perform cell cycle analysis on samples from adherent cells (Figure 2). For cell 
cycle analysis, the kit is supplied with blue fluorescent Hoechst 33342 dye. The kit includes 
sufficient reagents for labeling 50, 18 × 18 coverslips using 500 µL of reaction buffer per test. 
For the latest information on Click-iT® EdU, visit www.lifetechnologies.com.
Figure 1. Detection of the incorporated EdU with the Alexa Fluor® azide versus incorporated BrdU with an anti-BrdU 
antibody. The small size of the Alexa Fluor® azide eliminates the need to denature the DNA for the EdU detection reagent 
to gain access to the nucleotide.
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Figure 2. Workflow diagram for the Click-iT® EdU Imaging Assay.
Plate cells 
Incubate cells with EdU and other live-cell stains
Fix and permeabilize cells
Detect EdU
Image acquisition and analysis
Optional: Sample treatment
Optional: Treat cells with antibodies and other fixed-cell stains 
(for example, cell cycle or nuclear stain)
Table 2. Click-iT® detection reagent compatibility.
Molecule Compatibility*
Qdot® nanocrystals Use Qdot® nanocrystals after the Click-iT® detection reaction.
Fluorescent proteins such as Green 
Fluorescent Protein (GFP)
Use organic dye-based reagents, such as TC-FlAsH™ or 
TC-ReAsH™ reagents, for protein expression detection or anti-
GFP rabbit or chicken antibodies before the Click-iT® detection 
reaction.
Organic dyes such as Alexa Fluor® 
dyes, fluorescein (FITC)
Completely compatible with the Click-iT® detection reaction.
TC-FlAsH™ or TC-ReAsH™ reagents
Detect the tetracysteine (TC) tag with FlAsH™ or ReAsH™ 
reagents before the Click-iT® detection reaction.
Phalloidin
Phalloidin staining is not compatible with the Click-iT® detection 
reaction. Use antibodies against other proteins, such as  
anti-α-tubulin, for visualization of the cytoskeleton.
Horseradish peroxidase (HRP) Use HRP after the Click-iT® detection reaction.
R-phycoerythrin (R-PE) and R-PE-
tandems such as Alexa Fluor® 680-R-PE
Use R-PE and R-PE tandems after the Click-iT® detection reaction.
Allophycocyanin (APC) and APC-
tandems
Completely compatible with the Click-iT® detection reaction.
*Compatibility indicates whether the fluorescent molecule itself or the detection method involves 
components that are unstable in the presence of copper catalyst used for the Click-iT® detection reaction.
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Before You Begin 
Materials required but not 
provided • Phosphate-buffered saline (PBS, pH 7.2–7.6)
• Fixative (for example, 3.7% Formaldehyde in PBS)
• Permeabilization reagent (for example, 0.5% Triton® X-100 in PBS)
• 3% Bovine serum albumin (BSA) in PBS (3% BSA in PBS), pH 7.4
• Deionized water
• 18 × 18-mm coverslips
•	 Optional: 6-well microplate
Cautions Hoechst 33342 (Component G) is a known mutagen. Use the dye with appropriate 
precautions.
DMSO (Component C), provided as a solvent in this kit, is known to facilitate the entry of 
organic molecules into tissues. Handle reagents containing DMSO using equipment and 
practices appropriate for the hazards posed by such materials. Dispose of the reagents in 
compliance with all pertaining local regulations.
Preparing the stock solutions	 	
	 1.1	 Allow the vials to warm to room temperature before opening.
	 1.2	 Prepare a 10-mM stock solution of EdU (Component A): Add 2 mL of DMSO (Component 
C) or an aqueous solution (for example, buffer, saline) to EdU (Component A), then mix well.
After use, store any remaining stock solution at ≤–20°C. When stored as directed, this stock 
solution is stable for up to 1 year. 
	 1.3	 Prepare a working solution of the Alexa Fluor® azide (Component B): Add 70 µL of DMSO 
(Component C) to Component B, then mix well.
After use, store any remaining working solution at ≤–20°C. When stored as directed, this 
working solution is stable for up to 1 year.
	 1.4	 Prepare a working solution of 1X Click-iT® EdU reaction buffer (Component D): Transfer 
all of the solution (4 mL) in the Component D bottle to 36 mL of deionized water. Rinse the 
Component D bottle with some of the diluted Click-iT™ EdU reaction buffer to ensure the 
transfer of all of the 10X concentrate. 
To make smaller amounts of 1X Click-iT® EdU reaction buffer, dilute volumes from the 
Component D bottle 1:10 with deionized water. After use, store any remaining 1X solution at 
2–6˚C. When stored as directed, this 1X solution is stable for up to 6 months.
	 1.5	 To make a 10X stock solution of the Click-iT® EdU buffer additive (Component F): Add 2 mL 
of deionized water to the vial, then mix until fully dissolved. After use, store any remaining 
stock solution at ≤–20°C. 
When stored as directed, this stock solution is stable for up to 1 year. If the solution develops 
a brown color, it has degraded and should be discarded.
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Experimental Protocols
Labeling cells with EdU The following protocol was developed with A549, HeLa, and NIH/3T3 cells with an optimized 
EdU concentration of 10 µM, but it can be adapted for any adherent cell type. Growth 
medium, cell density, cell type variations, and other factors may influence labeling. In initial 
experiments, we recommend testing a range of EdU concentrations to determine the optimal 
concentration for your cell type and experimental conditions. Although sufficient material is 
included with the kit for standard dose response, additional EdU (Cat. nos. A10044, E10187) 
is available. If you are currently using a BrdU-based assay for cell proliferation, a similar 
concentration to BrdU is a good starting concentration for EdU. 
	 2.1		Plate the cells on coverslips at the desired density, then allow them to recover overnight 
before additional treatment.
	 2.2	 Prepare a 2X working solution of EdU (Component A) in complete medium from the 10-mM 
stock solution. A suggested starting concentration is 10 µM. 
	 2.3	 Prewarm the 2X EdU solution, then add an equal volume of the 2X EdU solution to the 
volume of media containing cells to be treated to obtain a 1X EdU solution. (For example, for 
a final concentration of 10 µM, replace half of the media with fresh media containing 20 µM 
of EdU). We do not recommend replacing all of the media, because this could affect the rate 
of cell proliferation.
	 2.4	 Incubate the cells for the desired length of time under conditions optimal for the cell type. 
The time of EdU exposure to the cells allows for direct measurement of cells synthesizing 
DNA. The choice of time points and the length of time depends on the cell growth rate. Pulse 
labeling of cells by brief exposures to EdU permits studies of cell-cycle kinetics.
	 2.5		Incubate under conditions optimal for the cell type for the desired length of time. The time of 
EdU exposure to the cells allows for the direct measurement of cells synthesizing DNA. The 
choice of time points and length of time for pulsing depends on the cell growth rate. 
	 2.6		Proceed immediately to Cell	fixation	and	permeabilization (steps 3.1–3.3), followed by 
EdU	detection (steps 4.1–4.7). 
Cell fixation and 
permeabilization Note: This protocol is optimized with a fixation step using 3.7% formaldehyde in PBS, 
followed by a 0.5% Triton® X-100 permeabilization step. However, this protocol is also 
amenable to other fixation/permeabilization reagents, such as methanol and saponin.
Transfer the coverslips into a 6-well plate for convenient processing, such that each well 
contains a single coverslip.
	 3.1	 After incubation, remove the media and add 1 mL of 3.7% formaldehyde in PBS to each well 
containing the coverslips. Incubate for 15 minutes at room temperature.
	 3.2	 Remove the fixative and wash the cells in each well twice with 1 mL of 3% BSA in PBS.
	 3.3	 Remove the wash solution. Add 1 mL of 0.5% Triton® X-100 in PBS to each well, then 
incubate at room temperature for 20 minutes.
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EdU detection Note: This protocol uses 500 µL of Click-iT® reaction cocktail per coverslip. A smaller volume 
can be used as long as the remaining reaction components are maintained at the same ratios.
	 4.1	 Prepare 1X Click-iT® EdU buffer additive (see Table 3) by diluting the 10X solution (prepared 
in step 1.5) 1:10 in deionized water. Prepare this solution fresh	and use the solution on the 
same day.
	 4.2	 Prepare Click-iT® reaction cocktail according to Table 3. It is important to add the ingredients 
in the order listed in the table; otherwise, the reaction will not proceed optimally. Use the 
Click-iT® reaction cocktail within 15 minutes of preparation. 
Table 3. Click-iT® reaction cocktails. 
Reaction 
components*
Number of coverslips
1 2 4 5 10 25 50
1X Click-iT® reaction buffer 
(prepared in step 1.4)
430 µL 860 µL 1.8 mL 2.2 mL 4.3 mL 10.7 mL 21.4 mL
CuSO4 (Component E) 20 µL 40 µL 80 µL 100 µL 200 µL 500 µL 1 mL
Alexa Fluor® azide 
(prepared in step 1.3) 
1.2 µL 2.5 µL 5 µL 6 µL 12.5 µL 31 µL 62 µL
Reaction buffer additive 
(prepared in step 4.1)
50 µL 100 µL 200 µL 250 µL 500 µL 1.25 mL 2.5 mL
Total volume 500 µL 1 mL 2 mL 2.5 mL 5 mL 12.5 mL 25 mL
*Note: Add the ingredients in the order listed in the table.
	 4.3	 Remove the permeabilization buffer (step 3.3), then wash the cells in each well twice with 
1 mL of 3% BSA in PBS. Remove the wash solution.
	 4.4	 Add 0.5 mL of Click-iT® reaction cocktail to each well containing a coverslip. Rock the plate 
briefly to insure that the reaction cocktail is distributed evenly over the coverslip. 
	 4.5	 Incubate the plate for 30 minutes at room temperature, protected	from	light.
	 4.6	 Remove the reaction cocktail, then wash each well once with 1 mL of 3% BSA in PBS. Remove 
the wash solution. 
	 	 For nuclear staining, proceed to DNA	staining. If no additional staining is desired, proceed 
to Imaging	and	analysis. 
	 4.7	 Optional: Perform antibody labeling of the samples at this time, following the 
recommendations from the manufacturer of the primary and secondary antibody. It is 
important to keep the samples protected	from	light during incubations.
DNA staining
	 5.1	 Wash each well with 1 mL of PBS. Remove the wash solution.
	 5.2	 Dilute the Hoechst 33342 (Component G) solution 1:2000 in PBS to obtain a 1X Hoechst 
33342 solution (the final concentration is 5 µg/mL).
	 	 Note:	A range between 2–10 µg/mL of Hoechst 33342 has been shown to work.
	 5.3	 Add 1 mL of 1X Hoechst 33342 solution per well. Incubate for 30 minutes at room 
temperature, protected	from	light. Remove the Hoechst 33342 solution. 
	 5.4	 Wash each well twice with 1 mL of PBS. Remove the wash solution.
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Table 4. Approximate fluorescence excitation/emission maxima.
Fluorophore Excitation (nm) Emission (nm)
Alexa Fluor® 488 495 519
Alexa Fluor® 555 555 565
Alexa Fluor® 594 590 615
Alexa Fluor® 647 650 670
Hoechst 33342, bound to DNA 350 461
Imaging and analysis Click-iT® EdU cells are compatible with all methods of slide preparation, including wet 
mount or prepared mounting media. See Table 4 for the approximate fluorescence excitation/
emission maxima for Alexa Fluor® dyes and Hoechst 33342 dye bound to DNA.
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Product List Current prices may be obtained from our website or from our Customer Service Department.
Cat No. Product Name Unit Size
C10337  Click-iT® EdU Alexa Fluor® 488 Imaging Kit *for 50 coverslips*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10338  Click-iT® EdU Alexa Fluor® 555 Imaging Kit *for 50 coverslips*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10339  Click-iT® EdU Alexa Fluor® 594 Imaging Kit *for 50 coverslips*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10340  Click-iT® EdU Alexa Fluor® 647 Imaging Kit *for 50 coverslips*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
Related Products
C10289 Click-iT® AHA Alexa Fluor® 488 Protein Synthesis HCS Assay. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10327 Click-iT® RNA Alexa Fluor® 488 HCS Assay *2-plate size*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10328  Click-iT® RNA Alexa Fluor® 594 HCS Assay *2-plate size*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10329 Click-iT® RNA Alexa Fluor® 488 Imaging Kit *for 25 coverslips*. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10330 Click-iT® RNA Alexa Fluor® 594 Imaging Kit *for 25 coverslips*. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10350  Click-iT® EdU Alexa Fluor® 488 HCS Assay *2-plate size*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10351  Click-iT® EdU Alexa Fluor® 488 HCS Assay *10-plate size*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10352  Click-iT® EdU Alexa Fluor® 555 HCS Assay *2-plate size*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10353  Click-iT® EdU Alexa Fluor® 555 HCS Assay *10-plate size*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
C10354  Click-iT® EdU Alexa Fluor® 594 HCS Assay *2-plate size*  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  1 kit
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Functionalized magnetic nanoparticles (MNPs) are emerging as a major nanoplatform for re-
generative neurology, particularly as transfection agents for gene delivery. Magnetic assistive
technology, particularly the recent innovation of applied oscillating magnetic ¯elds, can signi¯-
cantly enhance MNP-mediated gene transfer to neural cells. While transfection e±ciency varies
with oscillation frequency in various neural cell types, the in°uence of oscillation amplitude has
not yet been investigated. We have addressed this issue using cortical astrocytes that were
transfected using MNPs functionalized with plasmid encoding a reporter protein. Cells were
exposed to a range of oscillation amplitudes (100–1000m), using a ¯xed oscillation frequency of
1Hz. No signi¯cant di®erences were found in the proportions of transfected cells at the ampli-
tudes tested, but GFP-related optical density measurements (indicative of reporter protein ex-
pression) were signi¯cantly enhanced at 200m. Safety data show no amplitude-dependent
toxicity. Our data suggest that the amplitude of oscillating magnetic ¯elds in°uences MNP-
mediated transfection, and a tailored combination of amplitude and frequency may further en-
hance transgene expression. Systematic testing of these parameters in di®erent neural subtypes
will enable the development of a database of neuro-magnetofection protocols — an area of
nanotechnology research where little information currently exists.
Keywords: Astrocytes; magnetic nanoparticles; magnetofection; nonviral transfection; gene
delivery.
1. Introduction
Functionalized magnetic nanoparticles (MNPs) have
high promise for regenerative neurology both as la-
beling agents for noninvasive tracking of transplant
populations1 and as transfection vectors for genetic
modi¯cation of neural cells.2 A major area of
research focus currently, is to devise strategies to
enhance the e±cacy of MNP-mediated gene transfer
to various neural cell populations. In this regard, the
major rate-limiting factor in gene delivery to cells is
thought to be the uptake of particle-gene complexes
by the cellular endocytoticmachinery.An innovative
strategy to overcome this bottleneck has been the
deployment of static magnetic ¯elds beneath cell
monolayers to promote the sedimentation of particle-
DNA complexes onto cells, thereby enhancing
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complex interaction with and subsequent uptake by
cells.3 This process of magnetically assisted gene de-
livery is known as `magnetofection'.2
A recent innovation to magnetofection has been
the use of dynamic magnetic ¯elds,4–6 including
devices that oscillate along an axis with program-
mable frequency and amplitude. Oscillating ¯elds
have yielded higher levels of transfection compared
with static ¯elds in a range of major neural trans-
plant cell types such as neural stem cells (NSCs),7
astrocytes,8 and oligodendrocyte precursor cells
(OPCs).9 The mechanisms by which oscillating
¯elds elicit greater transfection e±ciency are not
fully understood, but it is likely that lateral motion
is imparted to the MNPs, increasing the probability
of MNP-cell contact,4,8 and possibly overcoming
the accumulation biases predicted for static mag-
netic ¯elds.10 It has also been suggested that lateral
motion of unattached MNPs across the cell mem-
brane, or vibration of membrane-bound/internalized
MNPs, may mechanically stimulate endocytosis,
and/or the intracellular processing of MNPs may
be altered, for example by facilitating endosomal
escape.4,7,8,11,12
Despite the signi¯cant bene¯ts for regenerative
neurology o®ered by these systems, magnetic assis-
tive technologies are only recently being exploited
for neural transplant populations. Consequently,
there is a signi¯cant current technical knowledge
gap in respect of the parameters that govern the
e±cacy of magnetofection with neural cells. Such an
understanding can aid the development of both ro-
bust experimental protocols, and state-of-the-art
devices, to optimize the use of magnetic assistive
technology with neural transplant cells.
In this context, McBain et al. studied the corre-
lation between oscillation amplitude and e±cacy of
gene delivery to a human airway epithelial cell line,
using cell size as a comparator to select oscillation
amplitudes.4 Compared with static systems they
found improved transfection e±ciency in the pres-
ence of applied oscillating ¯elds [frequency
ðF Þ ¼ 2Hz, amplitude ¼ 200m]. Based on their
examination of a range of frequencies/amplitudes,
the authors suggest that amplitude is of greater im-
portance than frequency in enhancing gene transfer,
at least in the frequency range tested (1–4Hz).
Conversely, using a ¯xed amplitude of 200m, our
laboratory has shown frequency-dependent
enhancement of MNP-mediated gene delivery in a
range of neural cells.8 This frequency-dependent
e®ect indicates that frequency may play a greater
role in enhancing gene transfer than was previously
assumed. It is still unclear however, whether the
most e®ective identi¯ed frequency in a speci¯c
neural cell type can potentially yield better trans-
fection outcomes, when paired with an optimal
oscillation amplitude.
To address this technical issue, the goal of the
current study was to test the e®ects of systemati-
cally varying magnetic ¯eld oscillation amplitude
(while maintaining a ¯xed oscillation frequency) on
MNP-mediated gene transfer to astrocytes. The
associated safety of the protocols used was assessed
for all conditions. Astrocytes were selected as the
test cell population given their major roles in re-
generative neurology. Their expression of both re-
generation promoting and inhibiting molecules13,14
highlights astrocytes as endogenous therapeutic
targets. Their ability to migrate, integrate, and
survive post transplantation also make these cells
excellent candidates as transplant populations for
ex vivo gene delivery.15
2. Materials and Methods
The care and use of animals was in accordance with
the Animals (Scienti¯c Procedures) Act of 1986
(UK), and approved by local ethics committee.
2.1. Cell culture
Astrocytes were puri¯ed from mixed glial cultures
derived from cerebral cortices of Sprague Dawley rats
(postnatal day 1–3) using established procedures8,16
and cultured in poly-D-lysine (PDL) coated °asks
[D10 medium (DMEM with supplements: 2mM
glutaMAX-I, 1mM sodium pyruvate, 50U/ml peni-
cillin, 50g/ml streptomycin and 10% fetal bovine
serum); 95% humidi¯ed air/5% CO2; 37C] with 50%
medium changes (2–3 d). Astrocytes were trypsinized
and seeded (4 104 cells/cm2; D10) on PDL-coated
coverslips in 24-well plates (300L) and PDL-coated
96-well plates (70L).
2.2. Magnetofection device
The magnefect-nano device (nanoTherics Ltd.,
Stoke-on-Trent, UK) is composed of an array of
high gradient neodymium iron boron (NdFeB)
magnets which oscillates laterally with program-
mable amplitude and frequency beneath a culture
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plate. The ¯eld strength at the magnet face was
421 20mT and 303 5mT (24 and 96 magnet
arrays, respectively; nanoTherics, personal com-
munication). The most e®ective parameters repor-
ted for magnetofection of astrocytes were used as a
control condition (200m, 1Hz)8 within the range
of amplitudes selected for testing (all at 1Hz: 100,
200, 400, 700 and 1000m).
2.3. Magnetofection protocols
Transfection-grade MNPs were obtained from OZ
Biosciences (France) in commercially available
(NeuroMag; mean diameter 160 nm; range 140–
200 nm)8 and custom-synthesized (NeuroMag con-
jugated with the °uorophore rhodamine; termed
herein NMagRhodÞ forms. As these are proprietary
formulations, further physicochemical properties
cannot be made available. The NMagRhod MNPs
allow MNP uptake and transgene expression to be
compared within the same cells, potentially reveal-
ing relationships between oscillation amplitude,
extent of nanoparticle uptake and transgene ex-
pression. Transfection was performed as described
previously.8 Brie°y: one hour prior to transfection
(24 h post-plating) D10 medium was refreshed (24
well, 225L; 96 well, 54L). Plasmid encoding
green °uorescent protein (pmaxGFP; Amaxa Bios-
ciences, Cologne, Germany) was incubated with
MNPs in DMEM [serum-free; 20min, room tem-
perature (RT)], then added dropwise to cultures.
Quantities of pmaxGFP:DMEM:NeuroMag added
per well were 60 ng:75L:0.21L (24-well) and
12 ng:15L:0.042L (96-well); a constant MNP:
plasmid ratio was used for all experiments. Controls
were treated with plasmid in DMEM without
NeuroMag. Plates were then placed on the magne-
fect-nano (preheated within the incubator; using
24 or 96 magnet array to match culture plate) for
30min, incubated without a magnetic ¯eld for
30min, then subject to a 100% medium change. The
magnetic plate was allowed to cool for 30min be-
tween each use. At peak transgene expression (48 h
post-transfection)8 cells in 24-well plates were
washed twice (phosphate bu®ered saline, PBS),
¯xed (4% paraformaldehyde, 25min, RT) and
washed twice (PBS). Coverslips from Neuromag
experiments were immunostained, then all cover-
slips were mounted with the nuclear stain 4 0,6-
diamidino-2-phenylindole (DAPI; Vector Labora-
tories, Peterborough, UK).
2.4. Immunocytochemistry
Washed, ¯xed coverslips were blocked (5% normal
donkey serum in PBS, 0.3% Triton X-100, 30min,
RT), incubated overnight with primary antibody
(polyclonal rabbit anti-GFAP, DakoCytomation,
Ely, UK; 1:500 in blocker; 4C), washed, blocked
(30min, RT), incubated with secondary antibody
(Cy3-labeled donkey anti-rabbit IgG; 1:200 in
blocker, 2 h, RT), washed and mounted.
2.5. MTS assays
Reduction of MTS reagent to formazan was used to
assess the e®ects of transfection procedures on as-
trocyte metabolic activity (and consequently safety
of the procedures). At 48 h post-magnetofection,
medium was removed from astrocyte cultures in 96
well plates and replaced with 100L fresh D10 and
20L MTS reagent, then incubated for 3 h. Absor-
bance was measured at 490 nm (VICTOR2 Multi-
label Counter, PerkinElmer). Measurements from
cell-free wells, containing medium or medium plus
MNP–plasmid complexes as appropriate, were used
as blanks.
2.6. Microscopical analyses
Fluorescence micrographs of cultures (¯xed expo-
sure times; Axio Scope A1 °uorescence microscope,
Axio Cam ICc1 digital camera and Axiovision
software; Carl Zeiss MicroImaging, GmbH, Ger-
many) were double/triple merged as appropriate
(Photoshop CS5, Adobe, USA). For each treatment
condition, a minimum of four micrographs and 100
nuclei were analyzed. Culture purity was deter-
mined as the percentage of DAPI-stained healthy
nuclei associated with GFAP expression. Transfec-
tion e±ciency was determined as the percentage of
GFAPþ cells expressing GFP (normalized to the
control amplitude, 200m). Complementary to the
MTS assays, toxicity was assessed by determining
(i) the percentage of pyknotic nuclei (pyknotic/
pyknotic plus healthy), (ii) numbers of GFAPþ cells
per ¯eld, and (iii) proportions of type 1 and type 2
astrocytes (identi¯ed morphologically). Extent of
transgene expression was assessed by optical density
(OD) measurements. Calibration was performed
using an OD step tablet. All green (GFP) channel
images were converted to 8-bit grayscale and
inverted, then GFPþ type 1 cells (25 per condition)
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were individually delineated for OD measurement
(ImageJ software, NIH, USA). Mean OD was
reported as level of reporter protein expression. The
extent of NMagRhod uptake by astrocytes was esti-
mated based on a previously reported semi-quanti-
tative method.17
2.7. Statistical analyses
All data are presented as mean standard error of
the mean and were analyzed using one-way
ANOVA (Prism software, GraphPad, CA, USA),
with Bonferroni's multiple comparison test for post-
hoc analysis. n ¼ number of cultures, each derived
from a separate litter.
3. Results
Astrocyte cultures were of high purity as judged
by GFAP expression (99:3 0:2%; n ¼ 3). Cells
predominantly exhibited °attened, unbranched
morphologies characteristic of type 1 astrocytes
(92:6 2:7% of GFAPþ cells), with the complex,
¯nely processed branching morphologies typical
of type 2 astrocytes accounting for 7:2 2:7%
of GFAPþ cells (Fig. 1). No transfected astrocytes
were observed in plasmid-only control cultures. The
overwhelming majority of GFAPþ/GFPþ cells were
identi¯ed phenotypically as type 1 astrocytes, with
< 2% of GFAPþ/GFPþ cells exhibiting type 2
morphologies under any treatment condition
(Fig. 1). Therefore, analyses were restricted to type 1
astrocytes.
Whilst there was a tendency towards greater
transfection e±ciency at higher amplitudes
[Fig. 2(a)], no signi¯cant di®erences in astrocyte
transfection e±ciency were noted between the con-
trol amplitude (200m) and any of the `test'
amplitudes. However, GFP-related OD measure-
ments (a proxy for levels of reporter protein ex-
pression) were elevated at an amplitude of 200m
compared with amplitudes of 100m and 400m
[Figs. 2(b) and 2(c)]. No di®erences were noted be-
tween treatment conditions with respect to cell
counts [Fig. 2(d)], percentage of pyknotic nuclei
(< 1%), or the relative proportions of type 1 and
type 2 astrocyte subtypes (data not shown). These
¯ndings were corroborated by MTS assays, where
no alterations to metabolic function were detected
for any treatment conditions [Fig. 2(e)].
Fluorescently labeled NeuroMag particles were
employed to explore a correlation between extent of
amplitude, MNP uptake and levels of transgene
expression. Approximately 90% of GFAPþ cells
exhibited NMagRhod-labeling, with  40% of these
being GFPþ. However, no systematic relationship
was apparent between extent of NMagRhod accu-
mulation and either success of transfection or levels
of transgene expression for individual cells (Fig. 3).
4. Discussion
Here we have studied the in°uence of varying am-
plitude of oscillation (at a frequency previously
identi¯ed as optimal for astrocyte transfection) on
MNP-mediated gene delivery to a major transplant
population — the astrocytes. To the best of our
knowledge, our work is the ¯rst to systematically
address the signi¯cant knowledge gap regarding
optimal parameters for magnetofection of the di-
verse cells of the nervous system, particularly in the
context of cells of primary origin.
Our methods allow for both proportions of
transfected cells and extent of protein expression,
extrapolated from quantitative imaging, to be sep-
arately quanti¯ed, unlike previous studies using
bioluminescence measures of transgene expression.
Our ¯ndings demonstrate for the ¯rst time that
whilst amplitude of oscillation does not in°uence
proportions of transfected cells, it nevertheless
Fig. 1. MNPs mediate delivery of gfp plasmid to both type 1
and type 2 astrocytes. Fluorescence micrograph depicting the
di®erent morphologies of type 1 (arrow) and type 2 (arrowhead)
astrocytes. GFP expression was predominantly observed in
type 1 astrocytes. Small numbers of GFPþ type 2 astrocytes
were noted (inset shows counterpart micrographs).
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modulates levels of transgene expression within a
cell. Our protocols showed high safety and we con-
sider these ¯ndings have signi¯cant implications for
tissue engineering and transplant mediated delivery
of therapeutic biomolecules. As an example, for
clinical applications enhanced transgene expression
would produce greater quantities of therapeutic
biomolecules intended to promote neuror-
egenerative processes; for example, growth factors
such as BDNF and FGF2 to promote nerve ¯ber
regeneration and blood vessel growth, respectively.
These ¯ndings emphasize the importance of identi-
fying the most e®ective combinations of frequency
and amplitude, for use in magnetofection protocols
to optimize gene transfer to neural cell populations.
McBain et al. measured levels of transgene ex-
pression at three frequencies combined with four
(a) (b) (c)
(d) (e)
Fig. 2. Extent of transgene expression is in°uenced by amplitude of oscillation without acute cytotoxicity. Bar graphs show (a) No
signi¯cant di®erences in transfection e±ciency between amplitudes, although a tendency towards increased e±ciency at the greater
amplitudes is noted. (b) Greater levels of GFP expression (optical density) at 200m amplitude compared to 100m and 400m
(Bonferroni's post-hoc tests; p < 0:05). (c) Representative °uorescence micrographs showing di®erences in GFP expression between
the 200m amplitude condition (main image) and 400m (inset), arrows showing cells with high levels of expression. (d) No
di®erences in the average nuclei per microscopic ¯eld under any treatment conditions. (e) No di®erences in metabolic activity
between treatment groups (MTS assay). n ¼ 3 for all experiments.
Fig. 3. Lack of correlation between MNP uptake and gfp
transgene expression. This lack of consistency is illustrated by
(i) high levels of GFP expression (arrow head) in cells exhi-
biting moderate levels of particle uptake, (ii) lack of GFP ex-
pression (red arrows) despite extensive particle uptake, and (iii)
extensive particle uptake coupled with high levels of GFP ex-
pression (inset, white arrows).
In°uence of Amplitude of Oscillating Magnetic Fields on MNP-Mediated Gene Transfer
1450006-5
amplitudes, and concluded that \perhaps the am-
plitude is more important than frequency"4; an ob-
servation broadly in accordance with the enhanced
levels of transgene expression reported here. How-
ever, it should be noted that this study used a biolu-
minescence assay, and could not discriminate between
higher proportions of transfected cells versus individ-
ual cells expressing higher transgene levels. Therefore,
based on our ¯ndings, we can propose a scheme
wherein oscillation frequency determines transfection
e±ciency8whereas amplitudedetermines the extentof
transgene expression in individual cells, at least in
astrocytes.
By using multimodal MNPs with both transfec-
tion and imaging capabilities, we were able to ex-
amine the relationship between MNP uptake and
gene delivery. No relationship could be discerned
between the extent of particle accumulation in cells
and transgene expression, therefore we were unable
to establish if enhanced protein expression at the
200m amplitude is due to increased MNP uptake.
Our results further suggest that particle uptake
alone is not su±cient for successful transfection. It is
not clear what accounts for these observations, but
it may involve di®erences in intracellular processing
of MNP–plasmid complexes. Cultures derived from
primary sources often exhibit heterogeneous be-
havior, and these di®erences may be related to in-
dividual cells (i) being at di®erent stages of the cell
cycle (mitosis-associated breakdown of the nuclear
envelope being known to facilitate plasmid entry
into the nucleus) or (ii) belonging to subpopulations
with di®ering intracellular processing character-
istics. For example, it is feasible that cells lacking
transfection despite extensive particle uptake se-
quester the particles within intracellular vacuoles or
subject the plasmid to degradative processes. Fur-
ther detailed analyses of these processes using elec-
tron microscopy, lysotracker analyses and plasmid-
tagging are warranted to elucidate the cellular
mechanisms that contribute to successful transfec-
tion in neural cells. Our studies indicate that
achieving MNP-labeling of cells, for example for
imaging applications, is relatively simple compared
with achieving e±cient transfection, which shows a
more complex relationship with MNP uptake. This
emphasizes the need for advanced research at the
interface between biological tra±cking mechanisms,
nanoparticle handling and gene delivery to facilitate
the development of next generation transfection-
grade particles.
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Aim: To achieve high and sustained magnetic particle loading in a proliferative and 
endocytotically active neural transplant population (astrocytes) through tailored 
magnetite content in polymeric iron oxide particles. Materials & methods: MPs of 
varying magnetite content were applied to primary-derived rat cortical astrocytes 
± static/oscillating magnetic fields to assess labeling efficiency and safety. Results: 
Higher magnetite content particles display high but safe accumulation in astrocytes, 
with longer-term label retention versus lower/no magnetite content particles. 
Magnetic fields enhanced loading extent. Dynamic live cell imaging of dividing 
labeled astrocytes demonstrated that particle distribution into daughter cells is 
predominantly ‘asymmetric’. Conclusion: These findings could inform protocols to 
achieve efficient MP loading into neural transplant cells, with significant implications 
for post-transplantation tracking/localization.
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Published online: 20 January 2016
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Deploying magnetic particles (MPs) with 
cell therapies for magnetic cell localization 
and imaging applications is paving the way 
for safe and efficient delivery of cell trans-
plant populations to sites of pathology, and 
allowing for noninvasive monitoring of 
grafts [1–4]. A major emergent area for such 
applications, given the limited regenerative 
capacity of the central nervous system, is in 
neural cell transplantation for the repair of 
neurological injury and disease. Labeling 
cells prior to transplantation requires a cell–
particle combination that results in rapid 
and safe particle uptake by the majority of 
(ideally all) cells. However, the regenerative 
capacity of most transplant populations relies 
partially on their proliferative capacity which 
results in rapid dilution of intracellular parti-
cle accumulations in labeled cells [5]. Particle 
loss can also occur via exocytosis, potentially 
compromising magnetic cell localization 
and imaging success [6]. Therefore, a further 
requirement for transplant cell labeling is 
long-term retention of sufficient particles per 
cell to confer utility, despite the proliferative 
nature of the cell, which could be achieved by 
high initial loading of label into graft cells.
In order to achieve this goal, we require 
a clear understanding of both the physico-
chemical and biological parameters that 
govern particle loading in transplant popu-
lations. However, there is a major knowledge 
gap regarding the factors that contribute to 
successful ‘magnetolabeling’ and label reten-
tion in neural cells. These issues are compli-
cated by the complexity of the architecture 
of the nervous system wherein multiple cell 
types are present possessing distinct biologi-
cal properties. These cell types vary greatly 
in terms of proliferative and endocytotic 
capacity, cell-specific modes of intracel-
lular particle processing and susceptibility 
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to particle induced toxicity, requiring detailed char-
acterizations on a cell-by-cell basis for neurological 
applications [7].
We recently proved that systematic tailored increases 
in the magnetite content of polymeric particles could 
significantly enhance cell labeling (>95% cells labeled) 
in the typically ‘hard-to-label’ transplant population 
of neural stem cells (NSCs) [8]. However, this study 
did not evaluate the longer-term retention of particles 
of different magnetite content by the labeled cells, or 
establish the pattern of ‘inheritance’ of particles by 
daughter NSCs post-proliferation. Furthermore, it is 
well established that uptake of nanoparticles is medi-
ated via a range of endocytotic mechanisms [9–12]. In 
this context, it should be noted that NSCs have rela-
tively small cell bodies, elaborate limited amounts of 
cell membrane and appear in ultrastructural obser-
vations to possess comparatively quiescent mem-
branes [13]. How neural transplant cell populations 
with greater levels of endocytotic activity handle such 
high magnetite content MPs is unclear, but it can be 
postulated that such cell/MP combinations can result 
in greater enhancement of cell labeling for neural 
transplant applications.
In order to address these issues, we have applied 
particles with differing magnetite content to corti-
cal astrocytes of primary origin. The astrocytes offer 
major promise as a transplant population [14–16] and 
also play key roles in lesion sites post-injury [17]; as 
such these are of great interest as a target cell popu-
lation for nanotechnology studies. Astrocytes have 
major homeostatic functions in the CNS, for exam-
ple in the maintenance of normal ionic concentra-
tions and neurotransmitter levels in the extracellular 
space [18,19]. Consistent with these roles, astrocytes 
display high levels of membrane activity and can 
mediate nanoparticle uptake via a broad range of 
endocytotic mechanisms [19,20]. Indeed, in a recent 
ultrastructural study using an advanced and high-
resolution scanning electron microscopy technique, 
we showed that astrocytes are the dominant neuro-
epithelial population in terms of particle uptake, dis-
playing extensive membrane ruffling with numerous 
filopodia/membrane pits in line with greater particle 
uptake/transfection, relative to other major neural cell 
types such as neurons and oligodendrocytes [21]; MPs 
appear to be relatively stable (not degraded) within 
these cells [7]. Of relevance to the current study, these 
cells also have a relatively short cell cycle time (ca. 
20 h) making these ideal for capture of cell division 
events and dynamic imaging studies of particle inher-
itance [22,23]. Polymeric particles with different lev-
els of magnetite content deployed in this study were 
formulated using biocompatible and biodegradable 
components highlighting their translational potential 
and justifying their use in this study [8]. The main 
study goals were to investigate the influence of tai-
lored particle magnetite content on astrocyte loading 
and particle retention, while evaluating the safety of 
the methods and to investigate the profiles of particle 
inheritance in the daughter cells of labeled astrocytes 
using dynamic time-lapse imaging.
Materials & methods
The care and use of animals were in accordance with 
the Animals (Scientific Procedures) Act of 1986 (UK), 
and approved by the local ethics committee.
Astrocyte cell culture
Disaggregated cerebral cortices from Sprague- Dawley 
rats (post-natal day 1–3) were used to establish 
mixed glial cultures. Following 7 days’ culture in 
D10 medium (Dulbecco’s modified Eagle’s medium, 
2 mM glutaMAX-I, 1 mM sodium pyruvate, 50 U/ml 
penicillin, 50 μg/ml streptomycin and 10% fetal 
bovine serum), sequential overnight shakes facilitated 
astrocyte purification [24]. Astrocytes were enzymati-
cally detached (TrypLE synthetic trypsin, Life Tech-
nologies), plated on poly-D-lysine (PDL)-coated T75 
flasks and maintained in D10 medium, as previously 
described [25]. Subconfluent cultures were enzymati-
cally detached by addition of TrypLE and orbital 
shaking at 100 rpm, <5 min. Following centrifuga-
tion (1000 rpm; 4 min) and phosphate buffered saline 
(PBS) wash (800 μl), cells were resuspended in D10 
for plating.
Magnetic particle characterization
Superparamagnetic, poly(lactic acid)/poly(vinyl alco-
hol) (PLA/PVA)-coated particles, with a fluorescent 
BODIPY® 564/570–PLA coating and of differing 
relative magnetite matrix loading, termed MP-0x 
(nonmagnetite), MP-1x and MP-5x, were prepared by 
the Boris Polyak Laboratory, Drexel University, Phila-
delphia, using published procedures [26]. These were 
formulated using biocompatible and biodegradable 
components (PLA, PVA, magnetite and oleic acid). 
Extensive characterization of these MPs has previously 
been undertaken [8,27]. In brief, the average sizes are 
similar for each particle type (hydrodynamic diameter 
262–278 nm) with a slightly negative surface charge 
(-9.5 to -14.4 mV) The differing magnetite content 
of these particles alters magnetic responsiveness and 
weight ratio of the MPs, but not particle size or surface 
charge. Fourier transform IR spectroscopy confirmed 
similar organic composition of each particle type, with 
no alteration due to increased magnetite loading [8] 
(Table 1).
www.futuremedicine.com 347future science group
Endocytotic potential governs magnetic particle loading in dividing neural cells    Research Article
Magnetic particle labeling utilizing the 
magnefect-nano device
The MPs were evaluated for cellular labeling efficiency 
and extent of cellular accumulation over time. For par-
ticle uptake experiments, astrocytes were seeded onto 
PDL-coated glass coverslips in 24-well plates (0.4 × 
105 cells/cm2), and allowed to adhere for 24 h prior to 
addition of MPs, followed immediately by exposure to 
a magnetic field. Lyophilized MPs were resuspended 
in sterile water and added to D10 at a concentration of 
13 μg (MP-0x), 15 μg (MP-1x) and 26.5 μg (MP-5x) 
per ml of fresh D10 medium; each corresponding to 
an identical concentration (particles per ml), as MP 
density increases with greater magnetite content [8].
Particles were added to cultures (0.3 ml per culture 
well), with control cultures receiving D10 without 
MPs. To enhance particle/cell interactions, a magne-
fect-nano device was used (high gradient neodymium 
iron boron [NdFeB] magnets with lateral oscillation 
capability and programmable frequency/amplitude; 
field strength at magnet face 421 ± 20 mT [24-mag-
net array] and 303 ± 5 mT [96-magnet array]; nano-
Therics Ltd., Stoke-on-Trent, UK). The superpara-
magnetic nature of the particles allows for magnetic 
responsiveness only when particles are exposed to a 
magnetic field and field gradient. Therefore, deploy-
ing a magnetic field and field gradient (permanent 
NdFeB magnets in this study) beneath the culture 
plate attracts the particles down to the cell mono-
layer, while the application of an oscillating field/
gradient (termed later as a magnetic field condition 
for simplicity) theoretically causes particles to move 
horizontally along the magnet’s surface enhancing the 
likelihood of contact with cells, and/or oscillate in 
situ when attached to cell membrane, thus stimulat-
ing endocytotic mechanisms and enhancing cellular 
MP uptake [20,28–30]. Culture plates were exposed to a 
static magnetic field (frequency, F = 0 Hz), an oscil-
lating field (F = 1 Hz; 200 μm amplitude) or no mag-
netic field (NF) for the first 30 min of the MP incu-
bation period (either 4 or 24 h; 37°C, 5% CO
2
/95% 
humidified air throughout). Then cells were washed 
twice with PBS to remove any particles not internal-
ized by cells, and fixed with 4% paraformaldehyde 
(25 min at room temperature, RT).
Long-term particle retention
Particle retention, that is, percentage of cells labeled 
and the extent of MP accumulation were monitored 
over a 21 day period, together with assessment of parti-
cle safety. For these experiments, astrocytes were incu-
bated with particles for 24 h, with exposure to magnetic 
field conditions for the first 30 min, as detailed above, 
followed by PBS washes (×2) to remove noninternal-
ized particles, then fresh D10 medium was added. To 
facilitate continued proliferation of astrocytes over the 
long term, coverslips containing MP-loaded cells were 
transferred to PDL-coated 6-well plates at 96 h, cul-
tured up to day 7 with the coverslip containing cells 
then transferred to a fresh well at 14 days and culti-
vated up to 21 days. Cells were maintained in D10 
medium with 50% refresh every 2–3 days, with some 
cultures fixed (PBS wash x2; 4% paraformaldehyde, 
25 min, RT) at day 1 and every 4 days thereafter up to 
day 21 (six time points in total).
Immunostaining
Cells were immunostained for GFAP to enable assess-
ment of culture purity, morphological characteris-
tics and intracellular localization of particles. Cells 
were incubated in blocker (5% normal donkey serum 
and 0.3% Triton X-100; 30 min at RT) followed by 
overnight incubation at 4°C in primary antibody, 
polyclonal rabbit anti-GFAP (Z0334; DakoCytoma-
tion, Ely, UK; 1:500 in blocker). Following two PBS 
washes (15 min/wash at RT), cells were incubated in 
blocker (30 min at RT) prior to incubation with sec-
ondary antibody (FITC-labeled donkey antirabbit, 
IgG; Jackson Laboratories, USA; 1:200 in blocker; 
2–3 h at RT). Coverslips were washed with PBS (3 × 
5 min) then mounted with the nuclear stain DAPI 
(4′,6-diamidino-2-phenylindole; Vector Laboratories, 
Peterborough, UK).
Fluorescence imaging
MP-labeling efficiency, extent of particle accumula-
tion and MP intracellular localization, together with 
culture characteristics and safety assessment, were 
assessed using fluorescence micrographs. These con-
sisted of four images – fluorescent channels (BODIPY 
564/570-PLA MPs; FITC-GFAP+ astrocytes; DAPI 
Table 1. Physical characterization of magnetic particles.
Magnetic particle Magnetite content (w/w) Hydrodynamic diameter 
(nm)
ζ-potential (mV)
MP-0x Nonmagnetite 267 ± 0.65 -8.98 ± 0.16
MP-1x 11.5 ± 0.98 262 ± 9.56 -9.46 ± 0.14
MP-5x 46.0 ± 1.08 278 ± 1.62 -14.4 ± 0.34
Data taken from [8,26].
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stained nuclei) and phase image (Axio Scope A1 fluo-
rescence microscope, AxioCam ICc1 digital camera 
and Axiovision software; Carl Zeiss MicroImaging, 
GmbH, Germany). A standardized exposure time was 
used for density quantification of BODIPY 564/570-
PLA MPs. For each of the experimental conditions, at 
least four micrographs, encompassing a minimum of 
100 nuclei, were quantified for statistical analyses.
Particle inheritance-dynamic time-lapse 
imaging
Dynamic time-lapse imaging allowed determination of 
the pattern of particle inheritance in daughter cells of 
dividing astrocytes (Axio Zoom V16 with AxioCam 
ICm1 camera and ZEN software [Blue Ed., v.1.1.1.0]; 
Carl Zeiss GmbH, Germany). Time-lapse images 
were acquired from transmitted light and BODIPY 
564/570-relevant fluorescence channels for 48 h, post-
addition of MPs. Visual observation of time-lapse imag-
ing videos provided counts of symmetrical/nonsymmet-
rical particle inheritance events. A total of 30 mitotic 
events were recorded (60 daughter cells) and each was 
classified as ‘symmetric’ or ‘asymmetric’. The total area 
occupied by MPs was determined for both daughters, 
and events were classed as symmetrical inheritance when 
each daughter cell contained 40–60% of this area, with 
nonsymmetrical defined as >60% in one daughter cell.
Histological analyses of culture properties
Fluorescence micrographs were triple-merged (Pho-
toshop CS5 Extended, Version 12 x32; Adobe, CA, 
USA) and viewed using ImageJ (NIH USA) to allow 
quantification of culture and particle uptake character-
istics and safety assessments across each experimental 
condition. Culture purity was determined as the per-
centage of DAPI-stained nuclei which were GFAP+, 
with average cell counts determined from the number 
of nuclei per micrograph. To quantify astrocyte phe-
notype ratios, each astrocyte was classified based on 
morphological characteristics (Type 1 [flat, membra-
nous, unbranched] or Type 2 [highly branched, com-
plex cells]). For each experimental condition, average 
cell count, distribution of astrocyte phenotype and 
percentage of pyknotic nuclei (defined as shrunken, 
fragmenting nuclei) were quantified from fluorescence 
micrographs.
Integrated density-based technique for 
unbiased quantification of extent of cellular 
MP uptake
In terms of quantification of cellular particle uptake, tak-
ing average measures of fluorescence (using plate readers) 
across cultures or assessing iron uptake by quantitative 
(culture wide) iron assays, assumes an even particle dis-
tribution between cells, and while arguably appropriate 
for cell lines (which behave in a relatively homogenous 
and clonal manner in respect of particle uptake), this 
approach is not suitable for evaluating MP uptake in the 
astrocyte cultures used in our studies which are derived 
from primary cortical tissue and show extensive hetero-
geneity in uptake. Moreover, fluorescence measurements 
typically include substantial extracellular (membrane-
bound) particles (notably, up to 50% of the signal for 
astrocytes [31]). In this context, a flow cytometry approach 
was also considered but rejected as particles adherent to 
the plasma membrane lead to ‘false-positives’. Moreover, 
enzymatically detached cells provide few morphologi-
cal features for analysis, features pertinent to the assess-
ment of uptake and toxicity in specific astrocyte classes. 
MP-labeling efficiency (% labeled cells) and the extent 
of particle accumulation within cells, were quantified 
using triple-merges of DAPI, GFAP and particle images/
channels. The dense accumulation of internalized par-
ticles prevented exact particle counts per cell, therefore 
particle accumulation per cell was quantified using inte-
grated density (ID – a measure of pixel intensity) val-
ues (ImageJ software, NIH USA). Merged fluorescence 
micrographs were scaled and, for each MP-labeled astro-
cyte, the total area per cell occupied by intracellular MPs 
was outlined, with this outline then being transferred to 
the unmerged particle channel from which a raw cellu-
lar ID measure was obtained. Five background measures 
were taken from the same unmerged particle channel. 
The cellular ID values are presented as a corrected total 
cell fluorescence (CTCF) measure, where:
CTCF = ID - (area of selected cell × mean fluorescence 
of background readings)
Therefore, the resulting CTCF value represents the 
fluorescence intensity of the internalized particles (hav-
ing corrected for any background fluorescence) and as 
such provides a quantifiable and unbiased measure of 
particle accumulation within the cell.
Statistical analyses
Data were analyzed by one-way ANOVA, with Bon-
ferroni’s post hoc multiple comparison test (Prism soft-
ware, version 6.03; GraphPad, CA, USA). All data are 
expressed as mean ± standard error of the mean with 
‘n’ referring to the number of different cultures, each 
derived from a different rat litter.
Results
Astrocyte uptake characteristics for particles 
with differing proportions of magnetite
Astrocyte cultures used in our study were of high 
purity as judged by expression of the astrocyte marker 
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GFAP (99.4 ± 0.2% of cells were GFAP+, n = 6). Cells 
displayed healthy morphologies typical of Type 1 and 
Type 2 astrocytes (Figure 1A), with Type 1 cells domi-
nating (92.4 ± 1.0% of GFAP+ cells). Both perinuclear 
and cytoplasmic distributions of MPs were observed 
post-labeling (Figure 1A–C). Visual analysis showed 
widespread cellular uptake throughout cultures for all 
three particle types, and revealed cellular heterogeneity 
in terms of relative particle accumulation showing low, 
medium or high uptake (Figure 1A–C).
Particle uptake was rapid, and for magnetite-loaded 
cells a substantial proportion (ca. 50%) of cells were 
MP-labeled at 4 h post-particle exposure; MP-5x par-
ticles showed significantly increased labeling efficiency 
versus the other particle types, and in turn, MP-1x 
showed significantly increased MP-labeling versus 
MP-0x (Figure 1D). By contrast, magnetic field applica-
tion had no effect on labeling efficiency with MP-0x 
or MP-1x particles at 4 h. Further, magnetic fields had 
no effect on the proportion of cells labeled with the 
MP-5x particles, which was very high (>90%) even 
under the no magnetic field condition. With regard to 
the extent of particle accumulation at 4 h, cells labeled 
with MP-5x particles showed significantly higher par-
ticle accumulation compared with MP-0x and MP-1x 
particles for both magnetic field conditions (Figure 1E); 
fields also resulted in significantly greater accumula-
tion of MP-5x particles versus the no field condition 
(Figure 1E).
At 24 h, a greater proportion of cells were MP-
labeled versus 4 h for all particle types (compare 
Figure 1D & F). Notably, for MP-1x and MP-5x par-
ticles, virtually all (>98%) astrocytes were MP-labeled 
(Figure 1F); magnetic field application at both frequen-
cies was without effect at this time point. The extent 
of particle accumulation was also much greater at 24 h 
compared with 4 h for all magnetite containing par-
ticles (compare Figure 1E & G; please note scale dif-
ference of y-axes), with particle accumulation signifi-
cantly higher versus MP-0x (Figure 1G). Further, for 
MP-5x particles magnetic field application promoted 
particle accumulation (Figure 1G) but the effect was 
not observed for MP-1x.
Long-term particle retention analysis
Long-term particle retention was studied for magne-
tite containing particles with applied oscillating fields, 
which yield optimal MP loading using our protocols. 
For both MP-1x and MP-5x, substantial label retention 
(>50%) was evident over 21 days. For MP-1x particles, 
approximately 92% of cells were labeled at day 1 and 
this value declined significantly by day 17 to ca. 51% 
of cells (Figure 2A). For MP-5x particles, in contrast, 
a greater labeling efficiency (ca. 99% of cells) was 
obtained at day 1, which declined significantly by day 
21, albeit with >78% of cells remaining labeled at this 
time point (Figure 2B). A steady reduction in particle 
retention was noted over the 21-day time period, with 
considerable heterogeneity observed over cells in terms 
of extent of particle retention. Visual observations over 
time for MP-1x showed a clear transition from perinu-
clear clustering of particles (Figure 2C, inset) to a more 
cytoplasmic distribution (Figure 2C, main image) sug-
gesting reverse trafficking of particles. While a similar 
pattern was seen overall with MP-5x (Figure 2D, inset), 
it was noticeable that a subpopulation of astrocytes 
retained large particle accumulations clustered around 
the nucleus even at 21 days (Figure 2D, main image). 
Extent of particle retention was lower for MP-1x than 
MP-5x particles (compare Figure 2E & F: please note 
scale difference of y-axes).
Safety assessment of long-term particle retention
Long-term retention of the particles did not impair 
the proliferative capacity of astrocytes, with average 
cell numbers showing a significant increase by day 
9 for both MP-1x and MP-5x particles and for both 
magnetic field conditions, with no significant differ-
ences compared with untreated controls at 21 days 
(Figure 3A & B). Culture purity remained at >99% 
over the 21 days (Figure 3C & D). There was no effect 
of either particles or magnetic field condition on 
astrocyte phenotype distribution (84.6 ± 0.7% Type 
1 compared with 15.4 ± 0.7% Type 2, average across 
all conditions; Figure 3E & F). A small proportion 
(<2%) of nuclei were pyknotic across all time points; 
pyknosis was associated with aberrant intense GFAP 
staining indicative of membrane detaching from the 
substrate (Figure 4A & B). By contrast, using histologi-
cal analyses, the majority of labeled cells showed no 
obvious aberrations in GFAP staining or in astrocyte 
morphologies compared with controls.
Live cell imaging of particle inheritance in 
dividing astrocytes
To gain further insight into the pattern of particle 
distribution into daughter cells, astrocytes labeled 
with MP-5x particles were studied using dynamic 
time-lapse imaging of proliferating cells (Figure 5; see 
Supplementary Video). This revealed that daughter 
cells exhibited a predominantly asymmetric profile of 
particle inheritance (from 30 mitotic events, 21 were 
asymmetric compared with 9 showing symmetri-
cal inheritance; Figure 5A). Distribution of particles 
within the parent cell prior to division (Figure 5B & F) 
was predictive of the inheritance profile in daughter 
cells. Parent cells exhibiting a symmetric perinuclear 
distribution of particles (Figure 5B–D) gave rise to 
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Figure 1. Magnetic particle labeling of astrocytes at 4 h and 24 h post-particle exposure, with and without 
magnetic field application. (A–C) Representative triple-merged images of MP-5x uptake in Type 1 and Type 2 
([A] , inset) astrocytes (24 h). Arrows indicate (A) ‘low’, (B) ’medium’ and (C) ’high’ levels of intracellular particle 
accumulation. ([B] , inset) Z-stack micrograph demonstrating intracellular localization of particles. (D) Bar chart 
displaying MP-labeling efficiency in astrocytes at 4 h. (E) Bar chart showing extent of particle accumulation 
across magnetic fields at 4 h. (F) Bar chart showing MP-labeling efficiency at 24 h. (G) Bar chart showing extent 
of particle accumulation across magnetic fields at 24 h. Differences are indicated in terms of magnetic field 
(†††p < 0.001) and particle (*p < 0.05; **p < 0.01; ***p < 0.001). All graphs: n = 6. 
MP: Magnetic particle.
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daughter cells with symmetric inheritance of particles 
(Figure 5E), and mitosis of parent cells with asym-
metrically distributed particles resulted in asymmetric 
inheritance (Figure 5I).
Discussion
Here, we have investigated the interaction between 
the physicochemical properties (specifically, magnetite 
content) of polymeric iron oxide particles and a highly 
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Figure 2. Long-term particle retention following 30-min application of an oscillating magnetic field. Bar charts 
showing proportions of labeled cells post-exposure to (A) MP-1x and (B) MP-5x particles (***p < 0.001).  
(C & D) Representative triple-merged images showing differences in levels of particle accumulation seen at day 
1 (insets) and day 21 (main images) post-labeling with (C) MP-1x and (D) MP-5x particles. Arrows indicate ‘high’ 
levels of perinuclear labeling at day 21 with MP-5x particles. Bar charts displaying levels of (E) MP-1x and (F) MP-5x 
particle accumulation over 21 days following exposure to oscillating magnetic field. Within each particle condition 
versus day 1 (*p < 0.05; **p < 0.01; ***p < 0.001). All graphs: n = 3. 
MP: Magnetic particle.
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Figure 3. Safety assessment of long-term particle retention. Bar charts displaying astrocyte number per 
microscopic field post-labeling under (A) static and (B) oscillating magnetic field conditions (*p < 0.05;  
***p < 0.001 vs day 1). Bar charts displaying proportions of GFAP+ cells post-labeling under (C) static field and 
(D) oscillating field conditions. Bar charts showing the distribution of astrocyte phenotypes post-labeling under 
(E) static field and (F) oscillating field conditions. All graphs: n = 3.
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endocytotic neural cell (the astrocyte). When trying to 
achieve intracellular particle uptake by transplant pop-
ulations, two delivery routes can be considered. Either 
intrinsic ‘engulfing’ behaviors of cells can be exploited 
or the membrane can be temporarily disrupted (e.g., by 
electroporation or ultrasound bubble stimulation [32]). 
As the former approach relies on natural biological 
mechanisms, it can be argued that this offers a safer 
and more attractive labeling approach, particularly 
when long-term safety (e.g., post-transplantation into 
host tissue) is a critical consideration [33,34]. Generally 
speaking however, the relative endocytotic behaviors of 
major neural transplant populations have been poorly 
documented. In turn, the combinatorial interactions 
of such engulfing mechanisms with the physicochemi-
cal properties of particles have received little attention, 
but remain an important issue when developing neural 
transplant labeling methods. It can be predicted that 
the effectiveness of different labeling approaches may 
vary depending on the cell type and particle deployed, 
and protocols will need to be tailored for individual 
cell/particle combinations.
As far as we are aware, the integrated density-
based approach that we have utilized has never been 
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Figure 4. Identification of pyknotic cells in astrocyte cultures. (A) The viability of astrocyte cultures was assessed 
by identifying cells with fragmenting and condensing nuclei, frequently associated with aberrant glial fibrillary 
acidic protein staining and evidence of membrane detachment from the substrate, all features indicative of 
pyknosis (red arrows indicate same pyknotic cell in main image and inset). Healthy nuclei were associated with 
adherent cells and normal GFAP staining (white arrows indicate same cells in main image and inset). (B) The 
percentage of pyknotic nuclei did not vary across conditions or time points (p > 0.05). All graphs: n = 3.
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applied for quantification of nanoparticle uptake in 
cells, providing an unbiased, objective approach at 
the single-cell level while allowing for simultaneous 
evaluation of cellular morphological features and 
subcellular particle localization. We demonstrate that 
enhanced magnetite concentration in particles leads 
to greater particle loading in highly endocytotically 
active cells. This is associated with longer particle 
retention (≥21 days) versus cells loaded with particles 
of lower/no magnetite content. Greater labeling effi-
ciency with high magnetite particles within a short 
time frame is likely attributable to accelerated gravi-
tational particle sedimentation onto cells (due to the 
increased particle density), similar to the mechanism 
by which applied magnetic fields enhance transfec-
tion-grade MP-mediated gene transfer to target cells 
(‘magnetofection’). This technique is now an estab-
lished experimental procedure, used widely in labo-
ratories in genetic modification protocols [35], but the 
compatibility of this approach with a wider range 
of MPs (e.g., clinical contrast agents or polymeric 
particles for drug delivery/magnetic cell targeting) 
is still relatively unexplored. With the MPs studied 
here, application of static or oscillating fields did not 
influence the proportions of cells labeled, but signifi-
cantly enhanced the extent of intracellular particle 
accumulation. Together, our data suggest that a tai-
lored combination of magnetic field application, high 
magnetite content particles and longer particle expo-
sure times operate synergistically allowing for greater 
labeling efficiencies to be achieved. The prolonged 
retention of higher magnetite content particles is of 
high relevance for translational applications, where 
proliferative dilution/exocytosis and label loss are 
known to be major challenges [5,36]. It is possible that 
the longer retention is simply related to higher ini-
tial loading into cells, but we cannot rule out effects 
such as slower exocytosis of higher magnetite content 
particles. The combination of high survival of our 
transplant populations post-labeling in conjunction 
with such slower excretion, may serve to reduce the 
instance of ‘false-positive’ signals, due to second-
ary uptake by cell populations such as the resident 
astrocytes and microglial cells in host tissue.
The overall trend in labeling was similar to that seen 
in NSCs, although magnetic field application did sig-
nificantly enhance labeling efficiency with low mag-
netite content particles in the latter [8]. We can spec-
ulate that the higher levels of endocytotic activity in 
astrocytes result in rapid particle uptake and outweigh 
the benefits of field application, particularly for higher 
magnetite content particles with more rapid sedimen-
tary profiles. Further, microscopic observations reveal 
that for a given condition, the intracellular label per cell 
is greater in astrocytes versus NSCs. The reasons for 
this may be related to the morphological features and 
relative endocytotic profiles of the cells. For example, 
scanning electron micrographs show broad, flattened 
morphologies for astrocytes with elaboration of large 
amounts of cell membrane, and surface features sug-
gestive of high cellular membrane activity (Figure 6A). 
By contrast, NSCs are bipolar cells with smaller cell 
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Figure 5. Particle inheritance in labeled astrocytes. (A) Pie chart displaying quantification of particle inheritance 
profiles in MP-labeled astrocytes. (B–I) Representative sequential still images from dynamic time-lapse imaging 
(Supplementary Data) of dividing astrocytes post-labeling with MP-5x particles without a magnetic field, showing 
examples of (B–E) symmetric and (F–I) asymmetric particle inheritance between daughter cells (arrows). 
MP: Magnetic particle.
Particle inheritance
between daughter cells of 
dividing astrocytes
Total = 30
Symmetrical
Asymmetrical
Particle inheritance
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bodies, relatively quiescent membranes and less surface 
area available for particle uptake (Figure 6B); addition-
ally label loss appeared to occur rapidly from NSCs 
(within 1 week, unpublished observations). Taken 
together, our findings highlight the importance of 
studying the interactions of neural cell type and endo-
cytotic behaviors in conjunction with particle tailoring 
strategies.
They also indicate the potential benefits of ‘endo-
cytosis prestimulation’ strategies in enhancing particle 
uptake, although such strategies are not routinely used 
currently in labeling protocols. These could include 
serum starvation [37], growth factor stimulation [38] or 
mechanical stimulation (as deforming or shear forces 
may stimulate endocytosis [28]). A less obvious point to 
note here is the importance of controlling cell densities 
for such work; in some populations containing actively 
dividing cells, there is a density-dependent inhibition 
of endocytosis which could negatively impact particle 
uptake processes [39]. The majority of neural transplant 
populations are highly proliferative and are usually 
propagated under growth factor drive, so the optimal 
cell densities for each cell type must be established 
and cellular confluence carefully monitored prior to 
particle addition in labeling protocols for biomedical 
applications.
The safety of the procedures utilized here was of 
paramount concern, given the combined variation 
of multiple parameters (particle properties, magnetic 
field application and duration of particle exposure). 
The procedures did not result in acute or long-term 
alterations in magnetolabeled cells, as determined by a 
spectrum of safety assays assessing survival, prolifera-
tive capacity and cell phenotype. This finding paral-
lels our previous observations in NSCs, highlighting 
the neurocompatibility of the particles used [8]. The 
safety profile of these MPs could be attributable to 
the slow degradation profile of the PLA matrix com-
ponent (limiting the rate at which iron leaches from 
degrading particles; rapid leaching is a major corre-
late of MP toxicity [40,41]), and is also consistent with 
the observed stability of intracellular MPs in astro-
cytes [7]. We have used histological analyses to evalu-
ate particle safety, however astrocytes participate in 
complex signaling pathways and secrete several bio-
molecules needed for homeostatic function [16,18,19]. 
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Figure 6. Cellular membrane activity features. Scanning electron micrographs of (A) an astrocyte, and (B) a neural stem cell, for 
comparison of typical morphological characteristics. Note the differences between the two cell types in terms of both quantity of 
membrane available for particle interactions, and the quantity of specific membraneous features associated with endocytotic activity, 
such as processes, filopodia and ruffles. Electron microscopy and neural stem cell culture methods published previously [21].
Figure 7. Factors influencing cellular particle uptake. Schematic diagram showing factors that influence cell 
loading with particles, illustrating the combined dynamics of the physicochemical characteristics of magnetic 
particles and the biological function of the cell. Micrograph shows MP-5x labeled astrocytes. 
MP: Magnetic particle.
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More detailed readouts of safety will require com-
bined proteomic and bioinformatic pathway analyses 
of potential dysregulated processes in magnetolabeled 
astrocytes, to establish if particular secretory mecha-
nisms or individual proteins involved in regenerative 
processes or signaling pathways are perturbed by the 
labeling procedures.
As far as we are aware, our study is the first to use a 
dynamic, live cell imaging approach to study the distri-
bution (inheritance) of MPs into the progeny of neural 
cells derived from primary cultures. Our observations 
that particle inheritance is largely asymmetric (in that 
particle distributions are uneven between daughter 
cells, post-proliferation) are consistent with previ-
356 Nanomedicine (Lond.) (2016) 11(4) future science group
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ous observations in cell lines wherein particle uptake 
and redistribution to daughter cells after mitosis, is a 
‘random’ and asymmetric process [5,36,42,43]. The rea-
sons for this uneven inheritance are unclear, but may 
relate to nonuniform distribution of MPs around the 
nuclear poles, which we consistently observed in the 
majority (ca. 75%) of labeled astrocytes. In turn, 
the reasons for this polarized initial distribution are 
unknown. Nonetheless, we consider that our findings 
do have significant implications for the use of the MP 
platform for biomedical applications involving astro-
cytes, and indeed other proliferative neural transplant 
populations. Label loss with cell division contributes 
to reduced efficacy of particle labeling for imaging/
targeting applications; however our results indicate 
that not all transplant cells would be affected similarly 
in this regard. Unequal inheritance would imply that 
with each division, the utility of the intracellular MP 
label would exponentially diminish for a subpopula-
tion of daughter cells. On the other hand, useful lev-
els of labeling would persist in a larger subpopulation 
for a longer period of time (than would be predicted 
with symmetric inheritance) resulting in the ability to 
track overall biodistribution of the cellular graft, even 
if some cells are lost to the imaging process. Conse-
quently, we believe that an understanding/character-
ization of the specific modes of particle inheritance 
in the progeny of a given labeled transplant popula-
tion is an important parameter contributing to par-
ticle detection and must be taken into consideration 
in studies aiming to optimize MP labeling for neural 
cell therapies. In summary, a wide range of biologi-
cal and chemical parameters exert an influence on the 
utility of the MP platform for neural transplantation 
therapies (Figure 7) but require systematic investiga-
tion. A detailed understanding of the relative impor-
tance of each of these parameters will allow for the 
tailored development of optimal labeling protocols for 
translational applications.
Conclusion 
We show that initial greater MP cell loading achieved 
using high-magnetite-content polymeric particles in 
highly endocytotic neural cells, leads to enhanced 
cellular particle retention. The inheritance of par-
ticles into daughter cells, studied using dynamic live 
cell imaging, is predominantly asymmetric/unequal 
which we consider will have significant implications 
for tracking of labeled cells in imaging applications.
Supplementary data
To view the supplementary data that accompany this paper, 
please visit the journal website at: www.futuremedicine.com/
doi/full/10.2217/NNM.15.202
Supporting information available: Video 1
Time-lapse micrographs of astrocyte culture 8 h post-addi-
tion of MP-5x particles. Arrows indicate two mitotic events, 
with examples of both asymmetric (red arrow, upper half, 
occurring at time point ∼01:50; 70:30 inheritance split) and 
symmetric (white arrow, lower half, occurring at time point 
∼01:32; 50:50 inheritance split) MP inheritance.
Executive summary
Effective tracking of neural transplant populations using magnetic particles requires efficient cell 
labeling
•	 This involves high initial cellular loading and effective particle retention for clinically relevant periods in 
labeled populations.
•	 The synergistic interactions of biological properties such as cellular endocytotic capacity and physicochemical 
properties such as particle magnetite content in neural cells are not known.
Tailored nanoparticle & protocol design can increase the efficacy of transplant cell labeling
•	 Rapid and efficient particle uptake is achieved using particles with high magnetite content versus those with 
low/no magnetite.
•	 Higher magnetite particles are also associated with longer-term particle retention in cells.
•	 Applied magnetic fields/gradients did not affect cell labeling efficiency, but did increase extent of cell loading 
for higher magnetite particles.
Most neural transplant populations are proliferative & cell division dilutes particle label limiting tracking 
capacity
•	 Few studies have investigated the pattern of particle ‘inheritance’ into daughter cells post-division.
•	 Mitosis typically results in asymmetric particle distribution: daughter cells do not inherit equal proportions of 
particles.
•	 The implications for such unequal particle distribution remain to be established with complementary MRI 
studies.
Conclusion
•	 Our data can provide valuable information to transplantation biologists and materials chemists to develop 
effective protocols for labeling cell transplant populations.
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